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Already 100 years ago, the importance of ion channels for nerve cell conduction was 
described. Subsequently, an expression und function of ion channels outside of the nervous 
system was discovered. Approximately 20 years ago, ion channels were found to be involved in 
diseases, termed channelopathies. Within the Kv10 family of voltage-gated potassium 
channels, a functional role of Kv10.1 in cancer and cell proliferation has been demonstrated. 
Up to date, not much is known about Kv10.2, the second member of the Kv10 family.  
Therefore, the aim of this PhD thesis was to characterize the distribution of Kv10.2 in 
mouse tissues and specifically in the brain. We generated and evaluated a novel anti-Kv10.2 
antibody, which recognized both human and murine Kv10.2 and did not cross-react with 
Kv10.1. Using this antibody, we found a broad expression of the Kv10.2 protein in various 
mouse tissues and an enrichment of Kv10.2 in certain brain areas, such as the olfactory bulb, 
thalamus, amygdala and globus pallidus. Within the central nervous system, Kv10.2 was shown 
to be mainly localized to neurons. 
We found Kv10.2 expressed during early brain development as well as in other 
embryonic tissues. While knockout of Kv10.1 resulted only in a mild phenotype, genetic 
ablation of Kv10.2 effected embryonic survival. This may indicate a function of the channel 
during embryonic development. With our newly generated antibody we provide a valuable 
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All prokaryotic and eukaryotic cells are surrounded by a lipid layer, the cell membrane. 
In eukaryotic cells various cellular compartments are further separated by membranes, such as 
the nucleus or the Golgi apparatus. In order to transport ions across these membrane barriers 
cells rely on two mechanisms: facilitated diffusion or active transport. The facilitated diffusion 
is mainly carried out by transmembrane proteins through which ions can diffuse according to 
their concentration gradient without energy consumption (Stein and Lieb, 1986). Alternatively, 
ions can be forced to move against their concentration gradient during the process of active 
transport. For this purpose, the cell employs proteins embedded in the membrane, which use 
the energy of adenosine-5'-triphosphate (ATP). These reestablish the concentration 
differences of the ions on opposite sides of the cell membrane. The difference in ion 
concentration on both sides of the membrane leads to a difference in charge, thereby 
generating an electrical potential difference known as the membrane potential. The unaltered 
membrane potential in excitatory and non-excitatory cells is termed the resting potential. 
Modulation of the resting potential in cells, due to ion channel opening, can lead to an electric 
current. In simplified terms, once this momentary change of the electric membrane potential 
surpasses a certain threshold, an action potential is generated (Egri and Ruben, 2012). 
Amongst others, the physiological roles of ion channels include cell volume regulation by 
governing ion flux control and controlling signal cascades, in which especially calcium (Ca2+) 
conducting channels are involved (Dolmetsch et al., 2001, Okada, 2004). Ion channels have a 
pivotal role in the stabilization of the membrane potential, as well as in the modulation of 
action potentials. The protein group of ion channels is very heterogeneous and classifications 
are typically based on the type of ion for which they are specific, such as sodium (Na+), Ca2+ or 
potassium (K+) channels. Subclassifications within these groups are diverse, for instance by 
gating behavior, i.e. ion channels that are voltage-gated or ligand-gated, or based on the 







1.1 K+ channels  
 
K+ channels are essential for setting of the membrane potential as well as for the 
modulation of the resting potential in excitatory and non-excitatory cells. Furthermore, in 
excitatory cells such as neurons and muscle cells they participate in the generation and 
modulation of action potentials (Coetzee and Rudy, 2006, Egri and Ruben, 2012). Moreover, K+ 
channels are involved in proliferation and differentiation (DeCoursey et al., 1984, Bruggemann 
et al., 1997). Expression of genes encoding K+ channels is regulated in an ontogenetic,  cell or 
tissue dependent manner, thereby generating the most diverse group of ion channels (Rudy, 
1988, Hille, 2001). The translation of a K+ channel gene leads to the synthesis of an α-subunit 
of the K+ channel (Figure 1A). A conductance pore is assembled by multiple α-subunits (Figure 
1B). This further enhances the diversification of K+ channels by not only forming homomeric 
ion channels, but also heteromeric channels, based on their α-subunits. Moreover, K+ channels 
are often effector proteins of second messenger cascades modulating channel activity, 
including kinases and phosphatases (Covarrubias et al., 1994, Drain et al., 1994, Jonas and 
Kaczmarek, 1996), Ca2+ (Stansfeld et al., 1996) or G-proteins (Huang et al., 1993). These 
attributes make K+ channels an interesting and important target for research, also in context of 




Figure 1: Overview of Kv protein channel structure  
A: A schematic representation of an α-subunit of the Eag potassium ion channel family. It contains six 
transmembrane (TM) domains (S1-S6), a pore (P) forming domain, a N-terminal Per-Arnt-Sim (PAS) 
domain and a C-terminal cyclic nucleotide binding domain (cNBD). The S4 TM domain functions as the 
voltage sensor. B: Proposed structure of a functional ion channel by tetramerization of α-subunits. A,B: 





K+ channels are not only present in the plasma membrane but also in other cell 
organelle membranes, e.g. the nuclear (Mazzanti et al., 1990, Maruyama et al., 1995, Chen et 
















Figure 2: Classification of K
+
 ion channels by gating behavior  
K
+
 channels can be divided into subgroups according to their gating behavior. There are Ca
2+
-activated 
channels, membrane voltage-activated channels and channels that are inward-rectifying. Furthermore, 
K
+
 channels exist that are not gated, resulting in “leak” K
+





 channels. Figure modified from Coetzee (Coetzee and Rudy, 2006). 
More than 100 different K+ channel proteins have been identified, either by cloning from 
different organisms (Capel, 1974, Jan and Jan, 1997, Kim and Hoffman, 2008), by genome 
projects (Wei et al., 1996) or through in silico analysis (Salkoff and Jegla, 1995). K+ channels can 
be grouped into five main classes according to their function (Coetzee and Rudy, 2006) (Figure 
2): 
1. Voltage-gated K+ channels, activation occurs by membrane depolarization.  
2. Ca2+-activated K+ channels, activation depends on the intracellular Ca2+ concentration.  
3. Inward-rectifying K+ channels which allow efflux of K+ ions. 
4. “Leak” K+ channels which do not show specific control of K+ flux.  
5. Na+-activated K+ channels, gating properties depend on the intracellular Na+ ion 


















Figure 3: Overview of the mammalian Kv10 family 
Schematic representation of the Eag family which belongs to the voltage-gated K
+
 channels and includes 
three subfamilies: Kv10 (eag), Kv11 (erg) and Kv12 (elk). Figure was modified from Bauer (Bauer and 
Schwarz, 2001). 
The Eag family belongs to the group of voltage-gated potassium channels (Warmke et 
al., 1991) (Figure 3). These channels have a higher selectivity for K+ ions than for Na+ or Ca2+ 
ions in mammals (Hille, 2001). 
1.2 Eag family of ion channels 
Shaker (Sh, mammalian nomenclature: Kv1.1) was discovered by investigation of a 
Drosophila melanogaster mutant which showed a phenotype of abnormal motor behavior 
under ether narcosis (Kaplan and Trout, 1969). Mutations resulting in this motor behavior 
were traced to the gene locus of Sh which was the first K+ channel encoding gene to be 
genetically investigated (Kamb et al., 1987, Papazian et al., 1987, Papazian et al., 1988, Pongs 
et al., 1988) together with ether-à-gogo (Eag; mammalian nomenclature: Kv10.1) (Kaplan and 
Trout, 1969). Sequence analysis of Eag revealed that this protein contains similarities with the 
Shaker K+ channel. The highest homology was reported in the voltage sensor (S4 domain) and 




Further genetic investigations in Drosophila melanogaster resulted in the discovery of 
aditional K+ channels expanding Shaker, Eag and other potassium channels to whole gene 
families. The Shaker family was expanded by the finding of Shab, Shaw and Shal (Butler et al., 
1989, Butler et al., 1990). Eag (mammalian nomenclature: Kv10, Kv11, Kv12) (Warmke et al., 
1991, Bruggemann et al., 1997) became a family by the discovery of ether-à-gogo -like 
potassium channel (elk, mammalian nomenclature: Kv12) (Warmke and Ganetzky, 1994) and 
ether-à-gogo -related gene potassium channel (erg, mammalian nomenclature: Kv11) (Titus et 
al., 1997) subfamilies. 
In mammals, eight genes belonging to the Eag family have been reported: KCNH1 
(Kv10.1), KCNH5 (Kv10.2), KCNH2 (Kv11.1), KCNH6 (Kv11.2), KCNH7 (Kv11.3), KCNH8 (Kv12.1), 
KCNH3 (Kv12.2), KCNH4 (Kv12.3) (Packer et al., 2000, Bauer and Schwarz, 2001) (Figure 3). The 
nomenclature of these channels has been standardized by the International Union of Basic and 
Clinical Pharmacology (IUPHAR) (Gutman et al., 2005). For a better overview, a table with the 
new and outdated names according to the IUPHAR is shown in the appendix section 
(Appendix, Table 1). Characterization of the Eag family of ion channels lead to the observation 
that they all share a common constitution of four α-subunits assembling one functional ion 
channel (Figure 1Figure 1B). Besides the general structure, the α-subunits have a common 
structure of six hydrophobic membrane-spanning domains (S1-S6), a hydrophobic pore 
segment (P) and an intracellular amino- (N-) and carboxy- (C-) terminal domain (Yellen, 2002, 
Wray, 2004) (Figure 1A).  
Being the founding member of the Eag family, Kv10.1 had novel features revealed by 
sequence analysis. Most notable and divergent from known members of the Kv1 family was the 
cyclic nucleotide-binding domain (cNBD) in the cytoplasmic C-terminus of Kv10.1 (Guy et al., 
1991). The fourth transmembrane domain (S4) contains the voltage sensor, which senses the 
depolarization of the membrane (Papazian et al., 1991, Logothetis et al., 1992) (Figure 1A). 
Assembly or tetramerization of a functional Kv ion channel is based on protein domains located 
in the cytoplasmic C-terminus of the α-subunits (Li et al., 1992, Shen et al., 1993). For all three 
human Kv11 channels it has been shown that the α-subunits can tetramerize to form a 
heteromultimeric channel when expressed in Chinese hamster ovary (CHO) cells (Wimmers et 
al., 2001, Wimmers et al., 2002). Moreover, this has been described in vivo by 





The conserved domains of the Eag family include a Per-Arnt-Sim (PAS) domain at the 
N-terminal cytoplasmic region and at the C-terminus a cNBD and a domain required for 
assembly (Ludwig et al., 1997, Cui et al., 2001). Furthermore, the ion channels within one 
family share a high homology of the DNA and amino acid sequence. For example, the human 
Kv10.1 protein is 73 % identical to Kv10.2 (Ju and Wray, 2002). 
In terms of electrophysiology the Kv10 family is characterized by outward rectification 
without inactivation. Furthermore, the activation kinetics depend on the holding potential as 
well as on the extracellular magnesium concentration (Ludwig et al., 1994, Stansfeld et al., 
1996, Terlau et al., 1996, Saganich et al., 1999, Bauer and Schwarz, 2001).  
1.3 Expression of members of the Kv10 subfamily of the Eag family  
The Kv10 subfamily of the Eag family consists of two members, Kv10.1 and Kv10.2. As 
well as the understanding of the structure of an ion channel based on its domains and 
electrophysiological studies, which indicate its possible physiological function in vivo, it is 
pivotal to localize its expression. Since the Kv10 family of ion channels was discovered in 
Drosophila melanogaster neurons, a neuronal localization of Kv10.1 in the mammalian brain 
was speculated. In contrast to Kv10.1 for which specific expression analyses have been 
reported at the RNA and protein level in different mammalian samples, protein analysis data 
for the Kv10.2 channel is limited since distribution studies have mainly been performed at the 
RNA level.   
1.3.1 Expression pattern of KCNH1 (Kv10.1)  
In humans and the rat, Kcnh1 expression is limited to the brain and testes (Ludwig et 
al., 1994, Pardo et al., 1999). As detected by in situ hybridization (ISH) , Kcnh1 has the highest 
mRNA expression in the olfactory bulb (ob), cerebral cortex (Cx), hippocampus (Hipp) and 
cerebellum (Cer) of adult rats (Ludwig et al., 2000, Saganich et al., 2001) (Figure 4A,B). Martin 
and co-workers performed further mRNA analysis of Kcnh1 of regions of the rat brain by qRT-
PCR (Martin et al., 2008). This study revealed a low expression of Kcnh1 in the thalamus. In this 
brain region the ISH by Saganich (Saganich et al., 2001) and Ludwig (Ludwig et al., 2000) were 
negative for Kcnh1. Additionally, the distribution of this ion channel was assessed on the 




4C), which revealed a ubiquitious protein distribution. Comparison of the mRNA distribution 
detected by ISH by Ludwig (Ludwig et al., 2000) and Saganich (Saganich et al., 2001) with the 
protein distribution by Martin et al. (Martin et al., 2008) leads to further inconsistencies of 
Kcnh1 protein and mRNA localization in the adult rat brain. Discordances in expression pattern 
for this gene were found, for example, in different nuclei of the thalamus, amygdale and 
brainstem. Furthermore, in all layers of the cortex, Kv10.1 was equally distributed (Martin et 
al., 2008), while mRNA was found abundantly in layers IV and VI (Saganich et al., 2001). In the 
cerebellum the Kv10.1 protein and mRNA of Kcnh1 detected showed no correlation. In this 
brain region, mRNA levels detected were highest in the granular layer and lowest in the 
Purkinje  layer (Ludwig et al., 2000, Saganich et al., 2001) Protein levels were vice versa, high in 
the Purkinje layer and low in the granular layer (Martin et al., 2008). Within the same study the 
expression of Kv10.1 in rat brain was compared to the expression of Kv10.1 in selected human 
brain regions (Martin et al., 2008). In humans the frontal cortex, the hippocampus and the 
cerebellum were positive for Kv10.1 as observed in the rat brain (Martin et al., 2008). 
Additionally, the authors claimed positive staining of the human thalamus and brainstem but 
did not show the data in their publication.  
Furthermore, the distribution of Kv10.1 and Kv10.2 was investigated in rat retina (Jow 
and Jeng, 2008). Kv10.1 was ascertained in the outer and inner segments of photoreceptor 
cells, in the outer plexiform layer, in the inner nuclear layer and the ganglion cell layer. The 
strongest staining and therefore the highest Kv10.1 protein level was observed in the inner 
plexiform layer (Jow and Jeng, 2008). This protein was not found in the outer nuclear layer. In 
contrast, Kv10.2, the second Kv10 family member, was not present in the inner plexiform layer, 
while the outer nuclear layer was positive for Kv10.2. Strong signals were observed in the outer 
and inner segments of photoreceptor cells, the outer plexiform layer and the inner nuclear 















Figure 4: Expression of Kv10 ion channels mRNA determined by two In Situ hybridization approaches 
and IHC for Kv10.1 on adult rat brain sections 
A: Kcnh1 (left) and Kcnh5 (right) mRNA distribution in adult rat brain sections with non radioactive ISH. 
Abbreviations used are according to FigureA. Kcnh1 is localized to the olfactory bulb (ob), olfactory 
tubercle (Tu), hippocampus (Hipp) and cerebellum (Cer). The caudate putamen and several nuclei of the 
amygdala were also Kcnh1 mRNA positive. Kcnh5 was localized to the ob, Tu, cortex, inferior colliculus 
(IC) and thalamus (Th). Furthermore, low expression was detected in the intercalated nucleus of the 
amygdala and in some nuclei of the brainstem. Cryo frozen sections obtained at 40 µm. Figure from 
Saganich et al. (Saganich et al., 2001). B: Kcnh1 (left) and Kcnh5 (right) mRNA distribution in adult rat 
brain sections with radioactive ISH. Kcnh1 transcripts were detected in the olfactory bulb, hippocampus, 
all cortical layers, and some nuclei of the amygdala, hypothalamus, caudate putamen and cerebellum. 
Kcnh5 was detected in the olfactory bulb, hippocampus, cortical layers III and IV, some nuclei of the 
amygdala, hypothalamus, thalamus, inferior colliculus, superior colliculus, lateral lemniscus and nuclei of 
the lower brainstem. Cryo frozen sections were obtained at 10 to 16 µm. Scale bars represent 3000 µm. 
Figure from Ludwig et al. (Ludwig et al., 2000). C: Overview of an IHC for Kv10.1 on adult rat sagittal 




commissure (ac), nucleus accumbens (Acb), anterior olfactory nucleus (AO), genu of corpus callosum 
(gcc), gigantocellular reticular nucleus (Gi), inferior colliculus (IC),  optic chiasm (ox), periaqueductal gray 
(PAG), pontine nuclei (Pn), superior colliculus (Sc), 3
rd
 ventricle (3V),  4
th
 ventricle (4V). Scale bar 
represents 500 µm. Figure from Martin et al. (Martin et al., 2008). 
1.3.2 Expression pattern of KCNH5 (Kv10.2) 
Although first evidence linking Kv10.2 to certain diseases is available, data on protein 
expression pattern are very limited. With the exception of the rat retina study, the knowledge 
regarding distribution of Kcnh5 mRNA has been studied in the brain of rat and partially in 
mouse and ferret by ISH. The Kcnh5 transcript has been consistently found in the olfactory 
bulb, cortex, thalamus and amygdala of rats (Saganich et al., 1999, Ludwig et al., 2000, 
Saganich et al., 2001) (Figure 4A,B). At the regional level, differences of Kcnh5 mRNA 
distribution were found in the hippocampus and cerebellum. Data acquired by Saganich and 
co-workers (Saganich et al., 2001) concerning Kcnh5 mRNA distribution in adult rat brain are 
partially inconsistent with the data he presented earlier (Saganich et al., 1999). In his earlier 
work, Kcnh5 expression is shown to be strongest in the cortical layer IV, while no Kcnh5 
expression was found in layers II and III; in these layers the staining was estimated to be at the 
background level. More recent work by Saganich (Saganich et al., 2001) shows abundant Kcnh5 
expression in layer III and to a lesser degree in layer II of the rat cortex. In contrast to 
Saganich’s (Saganich et al., 2001) findings, Ludwig (Ludwig et al., 2000) detected Kcnh5 
expression by ISH on rat brain in cortical layer VI. Further comparison of the ISH by Ludwig 
(Ludwig et al., 2000) and Saganich (Saganich et al., 2001) revealed discrepancies in Kcnh5 
distribution, for example in the nucleus accumbens of the basal ganglia, periglomerular cell 
layer of the olfactory bulb and the spinal trigeminal nucleus. Additional analysis of Kcnh5 
expression was performed with PCR by Saganich (Saganich et al., 1999). Expression of Kcnh5 
was virtually limited to the brain in the rat model organism, with the exception of the testes 
(Saganich et al., 1999), while heart, skeletal muscle, spleen, lung, kidney and liver were 
negative for Kcnh5. 
Northern blot analysis of rat tissue revealed a shorter transcript of 3 kb compared to 
the 12 kb transcript of Kcnh5 found in the brain. It was postulated by the authors that this 
might be an alternatively processed Kcnh5 transcript (Saganich et al., 1999). Interestingly, in 
humans Ju and co-worker found Kv10.2 protein that was truncated in the C-terminal cNBD 
domain (Ju and Wray, 2002). This protein was only 611 amino acids long, compared to the 988 
amino acids of the full length human Kv10.2. Within the same publication, KCNH5 mRNA 




size of 6.8 kb. Moreover, Ju and colleague (Ju and Wray, 2002) found a transcript of 1.4 kb in 
size in heart and skeletal muscle, further underlining the possible existence of alternative 
KCNH5 spliced transcripts.  
Additionally, RNA distribution analysis was done by Rowell and co-workers in the 
neocortex of the ferret and mouse by ISH (Rowell et al., 2010). Although the ferret is more 
distantly related to rodents, the data gained indicate a possibly conserved gene expression 
profile of the Kcnh5 channel between mammalian species. Similar to the expression pattern of 
Kcnh5 in the rat brain, Kcnh5 is found in the ferret brain in the cortical layers II – V and in the 
upper layer VI, with the strongest signal obtained in layer IV (Rowell et al., 2010). Strikingly, 
within the visual cortex, the layer IV can be separated in a Kcnh5 positive upper and a Kcnh5 
negative lower layer. The ISH performed on the mouse visual cortex revealed expression in 
layer V neurons and a stringent labeling of layer IV, with no sub lamination as seen in the ferret 
brain (Rowell et al., 2010). Concerning its distribution in the cerebellum, Huang and co-worker 
detected Kcnh5 expression in the granular layer, molecular and the Purkinje cell layer by ISH 
(Huang et al., 2012). This is in accordance with results from Western blot analysis performed 
by the same group that detected Kv10.2 protein in total cerebellar lysate.  
1.4 Channelopathies of K+ channels 
Interest in ion channel research increased considerably once it was discovered that 
they are in fact the cause of a number of pathological conditions or disorders in man. Diseases 
caused by dysfunctional ion channels are termed channelopathies (Griggs and Nutt, 1995) and 
have been reported for some genes encoding K+ channels (Sanguinetti and Spector, 1997, 
Kullmann, 2002). Different genes of the Eag family also have been described to be involved in 
diseases, for example Kv10.1 in carcinogenesis (Asher et al., 2010). Due to the conserved 
domains and the high homology within the Eag family, the published diseases of this ion 
channel family might indicate further relevance of Kv10.2 in the context of channelopathies.  
Besides their involvement in channelopathies, research of ion channels participating in 
cell cycle propagation has been conducted (Blackiston et al., 2009). Uncontrolled cell cycle 
progression often results in carcinogenesis. An example of an ion channel involved in diseases 
is KCNH2. The human KCNH2 (Kv11.1) gene encodes the α-subunit of a K
+ channel that is 
involved in mediating the rapid delayed rectifying potassium currents of the heart (Trudeau et 




KCNH2 has been reported to be involved in the Long QT2 syndrome (Larsen et al., 
2001, Sugiyama et al., 2011). Missense mutations and intragenic deletions of KCNH2 result in 
alteration of repolarisation in the cardiac ventricles. The deceleration of repolarisation is linked 
to the long QT2 syndrome (LQT2S, Romano-Ward-syndrome), where the excitation and 
repolarization of the heart are desynchronized, leading to arrhythmia (Torsade de pointes) 
(Keating and Sanguinetti, 1996, Sanguinetti, 2010). Until December 2010, 291 mutations of 
KCNH2 leading to LQT2S had been reported according to the inherited arrhythmias database 
(http://www.fsm.it/cardmoc/).  
In human cancer cell lines enhanced expression of KCNH2 has been reported, while its 
expression is also found in primary tumors of the endometrium and colon (Bianchi et al., 1998, 
Arcangeli et al., 1999, Cherubini et al., 2000, Lastraioli et al., 2004).  
Other ion channels, which have been reported to be involvement in cancer, are the 
members of the Kv10 family. Although in humans and rodents the expression of KCNH1 is 
limited to the brain (Pardo et al., 1999, Ludwig et al., 2000, Saganich et al., 2001), Pardo and 
co-workers found protein of this ion channel expressed in human cancer (Pardo et al., 1999, 
Pardo et al., 2005). In non-CNS cancerous tissue derived from patients, Kv10.1 expression is 
found in >75% of all samples investigated (Hemmerlein et al., 2006). Its oncogenic potential is 
further supported by the fact, that CHO transfected cells expressing human KCNH1 resulted in 
increased proliferation in vitro (Pardo et al., 1999) and injection of these cells into immune-
suppressed mice resulted in tumor formation in vivo (Pardo et al., 1999).  
In the context of cancer, the involvement of KCNH5 is controversial because of the 
following reasons. In non-small cell lung cancer KCNH5 was found to be highly methylated in 
comparison to controls (Feng et al., 2008), indicating a downregulation of gene expression. 
Recent findings indicate a role of Kv10.2 in facilitating medulloblastoma (MB) growth (Huang et 
al., 2012), by the fact that overexpression of Kv10.2 was found in MB subgroups of mouse and 
human while knockdown of Kcnh5 resulted in late G2 phase arrest. Concerning diseases of the 
CNS, Kcnh5 expression was significantly downregulated in the brain of adult rats on the 7th day 
after transient global brain ischemia in rats (de Oliveira et al., 2012), indicating a role of Kcnh5 
in stroke recovery. Furthermore, Martin and co-workers analyzed Kcnh5 expression in isolated 
reared rats (Martin et al., 2010). Kcnh5 was found to be downregulated in all brain regions 
except the cerebellum in isolated reared rats compared to controls. This is indicative of a 
possible role of Kcnh5 in psychological disorders. So far, Kcnh5-caused channelopathies were 




protein level may give insights of Kv10.2 function and may lead to further discoveries of the 
involvement of this ion channel in diseases.  
1.5 Primary cilium 
Cilia are membrane-bounded cell organelles that derive from the centrioles of cells, 
which can be separated into two groups based on their structure (Murray and Larson, 2010). 
Both types of cilia consist of a cytoskeleton that is formed by microtubule projections 
(axoneme). The first group, the motile cilia, consists of nine microtubule doublets which 
surround a central pair of singlet microtubules (9 + 2 axoneme) (Sorokin, 1962). These cilia can 
generate a physical flow (Guirao and Joanny, 2007). However, few examples of immotile 9 + 2 
cilia have been reported (Menco, 1994). The second group of cilia contains of nodal and 
primary cilia (Figure 5A). These cilia also contain the outer ring of microtubule doublets but not 
the central pair of singlet microtubules (9 + 0 axoneme) (Figure 5B). Nodal cilia are motile and 
present on the mouse embryonic node (Sulik et al., 1994). The primary cilium is an immotile, 
solitary cellular protrusion that is present on virtually all vertebrate cell types 
  
 
Figure 5: Overview of the structure and the appearance of the primary cilium 
A: Electron micrograph of the primary cilium of a canary brain radial glia. Scale bar represents 10 µm. B: 
Schematic representation of the primary cilium and its basal body. The basal body, derived from a 
centriole, contains triplet microtubules. The 9 + 0 axoneme is extended into the cilium. Figure from 





(http://www.bowserlab.org/primarycilia/cilialist.html). Ciliogenesis of the primary cilium is co-
ordinately regulated with the cell cycle (Quarmby and Parker, 2005). Briefly, the formation of 
cilium starts in the interphase of the cell cycle (Yoshimura et al., 2011) is present during the G1 
or G0 phase and reabsorbed when the cell re-enters the cell cycle (Kim and Tsiokas, 2011). At 
the cytoplasmatic end of the primary cilium lays the basal body, from which it originates. The 
basal body itself is derived from a centriole, yet, this process is reversible (Hoyer-Fender, 
2010). Due to the role of centrioles in cell cycle progression (Doxsey et al., 2005), it remains 
unclear, if the formation and resumption of the primary cilium controls the cell cycle 
progression or vice versa.  
The role of the primary cilium is diverse. Besides others, it is involved in signaling 
pathways, such as Hedgehog (Rohatgi and Scott, 2008, Kim et al., 2009), Wnt (Corbit et al., 
2008, Lienkamp et al., 2012), platelet-derived growth factor-αα (Christensen et al., 2008, 
Schneider et al., 2010) as well as mechano sensing (Praetorius and Spring, 2001, 2003).  
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2 Aim of the study 
The major goal of this thesis was to explore the Kv10.2 distribution in the whole mouse 
organism, since investigations on the protein level are virtually missing and the function of 
Kv10.2 is still unknown. Kv10.2 could be localized in neurons on mRNA level; however, 
expression on protein level is virtually missing. One reason is probably a lack of specific 
antibodies that can distinguish between Kv10.2 and the highly related channel Kv10.1. 
Therefore, we aimed to: 
1) Obtain an antibody that specifically recognizes Kv10.2 
Kv10.2 and Kv10.1 are highly similar proteins, therefore we need an antibody that can 
specifically distinguish both channels. To fulfill this aim, various commercially antibodies will be 
evaluated. If none of the antibodies is specific, we will generate a novel antibody.   
2) Investigate the expression of Kv10.2 in mouse tissues 
Using the antibody obtained from aim 1, we will study the expression of Kv10.2 in 
different tissues of the mouse. Since Kv10.2 is known to be expressed in the brain, we further 
want to determine the localization in different brain regions. These experiments will be 
complemented with an expression analysis on an mRNA level. Kv10.1 knockout mouse exhibits 
only a mild phenotype. A possible explanation would be an upregulation of Kv10.2 in these 
animals. Therefore the aim is to study the expression of Kv10.2 in Kv10.1 total knockout mouse. 
3) Get first insights into the physiological role of Kv10.2  
To investigate its physiological function in vivo, we wanted to analyze a conditional 
Kv10.2 knockout mouse. As an alternative approach, we planned knockdown experiments in 
cell cultures. 
Materials and Methods 
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3 Materials and Methods 
Unless stated otherwise, standard protocols were followed (Green and Sambrook, 2012). 
Likewise, standard buffers and solutions were prepared and used as described (Green and 
Sambrook, 2012). 
3.1 Instrument and equipment 
Instrument      Producer 
Agarose gel documentation Duo Store Intas, Goettingen  
Analytical balance, Competence CP64 Sartorius, Goettingen 
Apparatus for tissue processing, TP 1020 Leica, Bensheim 
Autoclave Vakulab S3000 Systec, Giessen 
Axiocam Color Carl Zeiss, Goettingen 
Barcode printer Ebar II Ventana (Roche), Mannheim 
Centrifuge Biofuge 28RS  Heraeus Laboratory products, Hanau 
Chemi-Doc luminescence detection system Bio-Rad, Munich 
Centrifuge 5424 Eppendorf, Hamburg 
Centrifuge 5402 Eppendorf, Hamburg 
Centrifuge 5804R Eppendorf, Hamburg 
Desinfector G7736 Miele, Gütersloh 
Digital monochrome printer P93D INTAS, Goettingen 
Electro-Luter 422 BioRad, Munich 
Heating plate 14801 Medax, Regensburg  
Hybridization incubator OV 3 Biometra, Goettingen 
Incubator B5042 E  Heraeus Laboratory products, Hanau 
Incubator BB6220  Heraeus Laboratory products, Hanau 
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Incubater shaker, Innova 4330 New Brunswick scientific (Eppendorf), 
Hamburg 
Incubator UT 6060 (200°C)  Heraeus Laboratory products, Hanau 
LaminAir TL 2472 cell culture hood  Heraeus Laboratory products, Hanau 
LaminAir HBB 2472 cell culture hood  Heraeus Laboratory products, Hanau 
Light microscope, Telaval 31 Carl Zeiss, Goettingen  
LightCycler 480  Roche, Mannheim 
Light microscope, Axioscope 2  Carl Zeiss, Goettingen  
Magnetic stirrer/heater, IKAMAG RCT Janke und Kunkel, Staufen i. Br. 
Microwave R-937 Sharp, Hamburg 
Microscope Stemi SV6 Carl Zeiss, Goettingen 
Microtome RM2255 Leica, Bensheim 
Nano photometer, Pearl Implen, Munich 
Neubauer chamber  Schütt Labortechnik, Goettingen 
NuPAGE Bis-Tris Electrophoresis System BioRad, Munich 
PCR cycler, labcycler Sensoquest, Goettingen 
Perfusor Compact S Braun, Melsungen 
pH-meter, SevenEasy Mettler-Toledo, Giessen 
Pipetting robot epMotion 5075 Eppendorf, Hamburg 
Power Pack P25 Biometra, Goettingen 
Purewater Arium 611 Sartorius, Goettingen 
Rollmixer Fröbel Labortechnik, Lindau 
SP5 confocal laser scanning microscope Leica, Mannheim 
Steamer, MultiGourmet Braun, Kronberg 
Thermomixer 5436 Eppendorf, Hamburg 
Thermomixer compact Eppendorf, Hamburg 
Tissue lyzer Qiagen, Hilden 
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Ultrasonic Desintigrator Sonopuls GM70/UW70 Janke und Kunkel, Staufen i. Br. 
UV Stratalinker 1800 Stratagene (Agilent), Waldbronn 
UV-table 3-3102 Fotodyne, New Berlin (USA) 
Ventana Discovery XT Ventana (Roche), Mannheim 
Vibratome VT1000S Leica, Bensheim 
Vortexer, Vortex Genie 2  Bender & Hobein,Zurich, Switzerland 
Wallac 1420 Victor 2 multilabel counter American Instrument Exchange,  
 Haverhill, MA, USA 
Waterbath 25900 Medax, Regensburg 
3.2 Chemicals and reagents 
Chemicals      Producer 
100 bp DNA Ladder  Invitrogen, Darmstadt 
1 Kb DNA Ladder  Invitrogen, Darmstadt 
ABTS single solution (2,2'-Azinobis  Invitrogen, Darmstadt 
[3-ethylbenzothiazoline- 6-sulfonic acid]- 
diammonium salt)      
Acetic acid Merck, Darmstadt 
Acrolein Sigma-Aldrich, Seelze 
Agar  Gibco (Invitrogen), Darmstadt 
Agarose  Gibco (Invitrogen), Darmstadt 
Aminopterin Sigma-Aldrich, Seelze 
Ampicillin  Roche, Mannheim 
Antibody diluent Roche, Mannheim 
B-27 supplement Gibco (Invitrogen), Darmstadt 
Bacto-Trypton  Carl Roth GmbH, Karlsruhe 
Boric acid Merck, Darmstadt 
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Chemiluminescent HRP substrate  Millipore, Billerica, MA, USA 
Chloroform Merck, Darmstadt 
Coomassie Brilliant Blue R250  Biomol, Hamburg 
Cytoseal 60 Roche, Mannheim 
Dimethylsulfoxid (DMSO)  Carl Roth GmbH, Karlsruhe 
Dithiothreitol (DTT)  Biomol, Hamburg 
dNTPs (deoxyribonucleotide triphosphates) (100 mM)  New England Biolabs, Frankfurt am 
Main 
DEPC (diethylpyrocarbonate) Sigma-Aldrich, Seelze 
DIG (digoxigenin) RNA labelig mix Roche, Mannheim 
DMEM (Dulbecco's Modified Eagle's Medium) Gibco (Invitrogen), Darmstadt 
DMSO (Dimethyl sulfoxide) Sigma-Aldrich, Seelze 
DPBS (Dulbecco's Phosphate-Buffered Saline) Gibco (Invitrogen), Darmstadt 
Ethidiumbromid  Sigma-Aldrich, Seelze 
Ethylendiamin-tetraacetat (EDTA)  Sigma-Aldrich, Seelze 
Ethanol  Merck, Darmstadt  
Ethidiumbromide  Sigma-Aldrich, Seelze 
Ficoll 400 Sigma-Aldrich, Seelze 
FCS (Fetal Calf Serum) PAN Systems, Aidenbach 
Formaldehyde Merck, Darmstadt 
Formamid Sigma-Aldrich, Seelze 
Geniticin (G418)  Invitrogen, Darmstadt 
Gentamycin Invitrogen, Darmstadt 
Glutamax Gibco (Invitrogen), Darmstadt 
Guanidine Hydrochlorate Sigma-Aldrich, Seelze 
Haematoxylin  Merck, Darmstadt 
HEPES (4-(2-hydroxyethyl)-1- Carl Roth, Karlsruhe 




Hydrochloric acid, 37% Merck, Darmstadt 
Hydrogen peroxid Sigma-Aldrich, Seelze 
Hypoxanthine Sigma-Aldrich, Seelze 
Imidazol  Fluka (Sigma-Aldrich), Seelze 
Insulin- Transferin- Selenium- A 100x Invitrogen, Darmstadt 
Isopropyl-â-D-thiogalactopyranosid (IPTG)  Biomol, Hamburg 
Isopropanol  Merck, Darmstadt 
Ketamine 10% Medistar, Holzwickede 
L-Thyroxine Sigma-Aldrich, Seelze 
LDS (lithium dodecyl sulfate) sample buffer Invitrogen, Darmstadt 
Luria Broth  Invitrogen, Darmstadt 
β-Mercaptoethanol  Fluka (Sigma-Aldrich), Seelze 
Methanol Merck, Darmstadt 
Monopotassium phosphate (KH2PO4) Merck, Darmstadt  
Ni-NTA (nickel(II)-nitrilotriacetic acid) agarose  Qiagen, Hilden 
Nitro blue tetrazolium (NBT)/  Roche, Mannheim 
5-bromo-4-chloro-3-indolyl phosphate (BCIP)  
NuPAGE MES Running buffer (20x) Invitrogen, Karlsruhe 
NuPAGE LDS Sample buffer (4x)  Invitrogen, Karlsruhe 
NuPAGE Antioxidant Invitrogen, Darmstadt 
OligoFectamine Invitrogen, Karlsruhe 
Orange-G  Sigma-Aldrich, Deisenhofen 
Paraffin (melting temperature: 60 °C) Leica, Bensheim 
Paraformaldehyde (PFA) Serva, Heidelberg 
PBS tablets Gibco, Invitrogen, Darmstadt 
Permount Fischer Scientific, Schwerte 
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Penicillin/Streptamycin Gibco, Invitrogen 
Phenylmethanesulfonyl fluoride (PMSF) Sigma-Aldrich, Deisenhofen 
PMSF (phenylmethanesulfonylfluoride) Sigma-Aldrich, Deisenhofen 
Poly-L-lysine (PLL) Sigma-Aldrich, Seelze 
Potassium chloride (KCl) Invitrogen, Darmstadt  
Precision Plus protein standard 7710  Bio-Rad, Munich 
ProLong Gold antifade reagent with DAPI Invitrogen, Darmstadt 
Putrescine Sigma-Aldrich, Seelze 
QIAzol lysis reagent Qiagen, Hilden 
Reducing agent  Invitrogen, Darmstadt 
Sodium azide (NaN3) Merck, Darmstadt 
Sodium chloride (NaCl) Sigma-Aldrich, Seelze 
Sodium citrate (C6H6Na2O7) Sigma-Aldrich, Seelze 
Sodium dihydrogen phosphate (NaH2PO4) Merck, Darmstadt 
Sodium dodecylsulfat (SDS) Sigma-Aldrich, Seelze 
Sodium flouride (NaF) Sigma-Aldrich, Seelze 
Sodium hydroxide (NaOH) Merck, Darmstadt 
Sodium pyrophosphate dibasic (Na2H2P2O7) Sigma-Aldrich, Seelze 
Sodium orthovanadate (Na3VO4) Sigma-Aldrich, Seelze 
Dynabeads MyOne Streptavidin T1 Invitrogen, Darmstadt 
Thymidine Sigma-Aldrich, Seelze 
Tris-Base  Sigma-Aldrich, Seelze  
Tris-HCL  Merck, Darmstadt 
Tris-acetate SDS running buffer Invitrogen, Darmstadt 
Tri-Iodo-Thyrodine (TIT) Fluka (Sigma-Aldrich), Seelze 
Triton X-100 Sigma-Aldrich, Seelze 
Tween-20 Sigma-Aldrich, Seelze  
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Urea MP Biomedicals, Ohio, USA 
Western blot stripping buffer Thermo Scientific, Bonn 
Whatman filter paper  GE Healthcare, Munich 
Xylazine 2% Riemser, Greifswald 
Xylol  Merck, Darmstadt 
Zeocin Invitrogen, Darmstadt 
3.3 Biochemical solutions und Enzymes 
Biochemicals Producer 
Biotherm polymerase  Genecraft, Cologne 
Bovine serum albumin (BSA) Sigma-Aldrich, Seelze   
Casein  Roche, Mannheim 
DNase (anti-Deoxyribonuclease) I   Qiagen, Hilden 
Fetal calb serum (FCS) PAN, Aidenbach 
Goat serum Gibco (Invitrogen), Darmstadt 
Ni-NTA Agarose Qiagen, Hilde 
Progesteron Sigma-Aldrich, Seelze 
Protease 3 Roche, Mannheim 
Protease inhibitor cocktail  Roche, Mannheim 
Proteinase K Carl Roth GmbH, Karlsruhe 
RNase H Invitrogen, Darmstadt 
Reverse Transkriptase SuperScript II  Invitrogen, Karlsruhe 
T7 RNA polymerase Roche, Mannheim 
Trypsine-EDTA (0.25 %) PAA Laboratories, Pasching, Austria  
Uracil-DNA-glycosylase New England BioLabs, Frankfurt 
 am Main 
Yeast extract Carl Roth GmbH, Karlsruhe 
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3.4 Commercial kits 
Kits        Producer 
A/B Block      Roche, Mannheim 
Antibody diulent     Roche, Mannheim 
BCA protein assay kit     Thermo Scientific, Bonn 
BlueMap Kit Roche, Mannheim 
CC1 Roche, Mannheim 
CC2 Roche, Mannheim 
DAB Map Kit Roche, Mannheim 
EndoFree Plasmid Maxi Kit  Qiagen, Hilden 
ECL Developing Kit Millipore (Merck), Darmstadt 
FastStart High Fidelity PCR System Roche, Mannheim 
NucleoSpin Plasmid Kit Macherey-Nagel, Düren 
NucleoSpin Spin Kit  Macherey-Nagel, Düren 
NFR Roche, Mannheim 
OneStep RT-PCR-Kit      Qiagen, Hilden 
Pellet Paint Novagen, Darmstadt 
RiboFix Kit Roche, Mannheim 
Ready-to-use hot-start PCR master mix   Roche, Mannheim 
RNase-free DNase set     Qiagen, Hilden 
RNeasy mini kit      Qiagen, Hilden 
SuperScript first-strand synthesis system   Invitrogen, Darmstadt 
 for RT-PCR 
TaqMan PCR Reagent Kit  Applied Biosystems, Darmstadt 
Tri-Reagent       Sigma-Aldrich, Deisenhofen 




Commonly used solutions were prepared after Sambrook (Green and Sambrook, 2012) and are 
listed below. Depending on their usage, chemicals were dissolved in double distilled or 1% 
(v/v) DEPC treated water and autoclaved or sterile filtered. Application specific solutions are 
listed in the appropriate sections. 
 
 Phosphate buffered saline (PBS)  
  1 PBS tablet dissolved in 500 ml ddH2O 
 
 Saline-sodium citrate buffer (SSC) 20x 
  3 M NaCl 
  0.3 M Sodiumcitrate 
  adjust to pH 7.0 mit NaOH 
 
 Tris-buffered saline (TBS) 10x 
  1.37 M NaCl 
  100 mM Tris-HCl, pH 7.6 
  add ddH2O to 1000 ml 
 
 Tris-EDTA buffer 
  10 mM Tris-HCl, pH 8.0 
  1 mM EDTA 
  dissolved in ddH2O 
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3.6 Media, antibiotics and agar plates 
3.6.1 Media for bacteria 
 LB (Luria-Bertani)-Medium   
  1%  (w/v) Trypton 
   0,5% (w/v) Yeast extract 
   1 % (w/v) NaCl 
   adjust to pH 7.0 
 
Media for cultivation of bacteria were dissolved in ddH2O, autoclaved and stored at 4°C. 
According to the required resistance, ampicillin (final concentration: 100 μg/ml) or kanamycin 
(final concentration: 50 μg/ml) was added. 
3.6.2 Agar plates 
LB- medium was supplemented with 1.5 % (w/v) agar prior to autoclaving. After autoclaving, 
solution was cooled to 55°C, supplemented with ampicillin (final concentration: 50 μg/ml) and 
poured into petri dishes. After solidification, agar plates were stored at 4°C. 
3.6.3 Media for eukaryotic cell culture 
The culture media composition with all additives are listed below. FCS was inactivated at 56°C 
for 30 min. Media additives sterility was assured by manufactorers or achieved by sterile 
filtration if possible. Genectin (G418) or Zeocin was added to the media for selection of 
transgenic cell lines.  
 Medium for HEK293 cells 
500 ml Dulbecco's Modified Eagle's Medium (DMEM, 4.5 g/l glucose and L-
glutamine) 
 10 % (v/v) fetal calf serum (FCS)  
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 Medium for 108CC05 and 108CC15 cells  
 900 ml DMEM (4.5g Glucose/l)  
 10% (v/v) FCS 
 10 ml 10 mM hypoxanthine in approx. 0.1 mM NaOH 
 2 ml 0.5 mM aminopterin in ddH20 
 1 ml 16 mM thymidine in ddH20 
 
 Medium for Oli-Neu cells  
96 ml DMEM (4.5g Glucose/L) 
1 ml Insulin- Transferin- Selenium- A 100x 
1 ml Horse Serum 
1 ml 10 mM Putrecine in ddH20 
100 µl 500 µM Tri-iodo-Thyrodine (TiT) 
50 µl Gentamycin Solution 
13 µl 4mM L-Thyroxin 
10 µl 2mM Progersteron in Ethanol 
3.7 Sterilisation of consumable supplies, solutions and media 
Consumable supplies, solutions and media for cultures were autoclaved overnight at 121°C 
and 1.5 bar or sterilized at 220°C overnight. Solutions sensitive to heat were sterile filtered. 
Aqueous solutions for RNA preparation or analysis were treated with 1% (v/v) DEPC, incubated 
for 12 – 24 h at RT und autoclaved. 
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3.8 Biological material 
3.8.1 Bacterial strains 
For cloning procedures and plasmid preparation the chemo-competent Escherichia coli DH5α 
(Hanahan, 1983) (Invitrogen, Darmstadt) with the following genotype was used:  
 
E. Coli strain Genotype 
DH5α 80lacZΔM15, recA1, endA1, gyrA96, thi-1, hsdR17 (rK-,mK+), 
supE44, relA1, deoR, Δ(lacZYA-argF)U169 
BL21 E.coli B, F-, dcm, ompT, hsdS(rB- mB-), galλ (DE3) 
3.9.2 Eukaryotic cell lines 
If not stated otherwise, cell lines were obtained from ATCC and LGC (LGC Standards GmbH, 
Wesel) and listed below:  
Name    Description 
HEK293 Human embryonic kidney cells. Established from a human 
primary embryonal kidney transformed by adenovirus type 5; 
from ATCC. 
Neuro-2a (N2a) Established from a neuroblastoma of a strain A albino mouse; 
gift from Sebastian Schmidt (Max Planck Institute of 
Experimental Medicine, Goettingen). 
Oli-neu Established from mouse oligodendrocyte precursor cells 
transformed by retroviral transfection with neu tyrosine 
kinase; gift from Dr. Celia Kassmann (Max Planck Institute of 
Experimental Medicine, Goettingen). 
108CC05 & 108CC15 Fused neuroblastoma cells (N18TG2) with gliomacells (C6-BU-
1); gift from Prof. Hamprecht (University of Tübingen, 
Tübingen).  




Strain C57BL6/N, animal house of the Max Planck Institute of Experimental Medicine, 
Goettingen. 
Kv10.1 deficient mice, strain C57BL6/N: Kv10.1 deficient mice were generated by homologous 
recombination in embryonic stem (ES) cells to disrupt part of the Kv10.1 gene. The “3 Lox P 
strategy” was used to generate total and conditional knockout mice. In order to produce non-
functional Kv10.1 proteins, Exon 7, which encodes the voltage sensors and pore regions of 
Kv10.1 protein, was deleted. This work was done previous in our department. Mice were 
described in Ufartes et al. (2013). 
Kv10.2 deficient mice, strain C57BL6/N: Kv10.2 deficient mice were generated by homologous 
recombination in embryonic stem (ES) cells to disrupt part of the Kv10.2 gene. The “3 Lox P 
strategy” was used to generate total and conditional knockout mice. In order to produce non-
functional Kv10.2 proteins, exon 7, which encodes the voltage sensors and pore regions of 
Kv10.2 protein, was deleted. This work was done previous in our department. 
TYFF (Thy1-EYFP, yellow neurons), strain FVB/N, mice were described in Hirrlinger et al. 
(Hirrlinger et al., 2005). 
GFEA (GFAP-EGFP, green Bergmann glia/astrocytes), strain FVB/N, mice were described in 
Nolte et al. (Nolte et al., 2001). 
CXCR1 (CX3CR1-EGFP, green microglia), strain C57BL6/N mice were described in Jung et al. 
(Jung et al., 2000). 
EMX1-Cre mice, strain C57BL6/N were gifted from the Cortical Development Group (Max 
Planck Institute of Experimental Medicine) and were described in Gorski et al. (Gorski et al., 
2002). 
Wistar rats, animal house of the Max Planck Institute of Experimental Medicine, Goettingen. 
Mice were housed in a 12 h light-dark cycle facility with free access to food and water. 
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3.9 Synthetic oligonucleotides 
3.9.1 Synthetic oligonucleotides for In Situ hybridization 
Oligonucleotides were obtained from Metabion (Martinsried, Germany), underlined sequences 
are the T7 RNA polymerase promoter for In vitro transcription. 
Oligonucleotide name Sequence 5’ – 3’ 
Kcnh5 exon 7 ISH forward GCT CTAC CAG TTG GCC TTG A 
Kcnh5 exon 7 ISH reversed TAC AAT ACG AGT GCA GGG ATC TG 
Kcnh1 exon 7 ISH forward GCT CTA CCA ACT GGC ATT GG 
Kcnh1 exon 7 ISH reversed GGG TCT GGT TCA GGG AAG TG 
Kcnh5 exon 7 T7 ISH forward  TAA TAC GAC TCA CTA TAG GGG CTC 
TAC CAG TTG GCC TTG A 
Kcnh5 exon 7 T7 ISH reversed TAA TAC GAC TCA CTA TAG GGC AGA 
TCC CTG CAC TCG TAT TGT A 
Kcnh1 Exon7 T7 ISH forward TAA TAC GAC TCA CTA TAG GGG CTC 
TAC CAA CTG GCA TTG G 
Kcnh1 exon 7 T7 ISH reversed TAA TAC GAC TCA CTA TAG GGC ACT 
TCC CTG AAC CAG ACC C 
Kcnh1 exon 7 forward GCATCAGCAGCCTGTTCAGT 
Kcnh1 exon 7 reversed ATCTTCGCAGTGGCCATCAT 
Kcnh5 exon 7 forward GGAATCAGCAGTCTCTTCAGC 
Kcnh5 exon 7 reversed AGATGTTCTCAGTGGCCATGA 
Calbindin forward ATC AGG ATG GCA ACG GAT AC 
Calbindin reversed TGG CCT AAG CAT GGT CTT TC 
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Kcnh5 exon 6-8 forward CAGCTGGGATCAGACATCCT 
Kcnh5 exon 6-8 reversed TAACGGTTGGTGTTGGCATA 
HPRT forward GAC CGG TCC CGT CAT GCC GA 
HPRT reversed GGC ATA ATG ATT AGG TAT AC 
3.9.2 Synthetic oligonucleotides for genotyping of mouse strains 
Kcnh1 (Kv10.1) total knockout mice 
Oligonucleotide name Sequence 5’ – 3’ 
5’F forward TGC GTA CAT GGT GCT TGA TTT C 
NeoR reversed CGC GAA GGG GCC ACC AAA G 
ExF forward CAT GAT GAT TGG CTG TGA GTA TG 
3’R reversed CCC TCT TTC CAC TAA CAG CAT C 
 
Kcnh5 (Kv10.2) conditional and total knockout mice 
Oligonucleotide name Sequence 5’ – 3’ 
E2-KO-geno-BamH forward ACAGGGTCCCCTACCAGAGA 
E2-KO-geno-Ex forward CACCATGACGAGCCTTACAAC 
E2-Null reversed TCCCCACACACAGTTTTTCA 
E2-LoxP1 forward GGAATTGCTCCTCTTCAAACAC 
E2-LoxP1 reversed TCAGGAGACAACTCAGCCTACA 
 
 




Oligonucleotide name Sequence 5’ – 3’ 
Cre forward TCG ATG CAA CGA GTG ATG AG 
Cre reversed TTC GGC TAT ACG TAA CAG 
 
TYFF mice 
Oligonucleotide name Sequence 5’ – 3’ 
TYFF forward CGC TGA ACT TGT GGC CGT TTA CG 
TYFF reversed TCT GAG TGG CAA AGG ACC TTA GG 
 
GFEA mice 
Oligonucleotide name Sequence 5’ – 3’ 
GFEA forward CAGGTTGGAGAGGAGACGCATCA 
GFEA reversed CCAGCTTGTGCCCCAGGATGT 
 
Wildtype control for TYFF and GFEA mice 
Oligonucleotide name Sequence 5’ – 3’ 
Wildtype control forward GAGGCACTTGGCTAGGCTCTGAGGA 








Oligonucleotide name Sequence 5’ – 3’ 
CXCR forward TCAGTGTTTTCTCCCGCTTGC 
CXCR wt reversed CAGTGATGCTCTTGGGCTTCC 
CXCR ki reversed GTAGTGGTTGTCGGGCAGCAG 
3.9.3 Synthetic oligonucleotides for quantitative real-time PCR 
UPL synthetic oligonucleotides obtained from Roche Diagnostics and Taqman synthetic 
oligonucleotides obtained from Sigma-Aldrich for samples analysis by Lightcycler 480. 
Oligonucleotide name Sequence 5’ – 3’ 
hKcnh1 forward TCT GTC CTG TTT GCC ATA TGA TGT 
hKcnh1 reversed  CGG AGC AGC CGG ACA A 
hKcnh1 Taq (6-FAM) AAC GTG GAT GAG GGC ATC 
AGC AGC CT (6-Tamra) 
hKcnh5 forward CCC TCT GCT TTG TGG TGT CAG 
hKcnh5 reversed CGG ACG TTC GCA CAT GC  
hKcnh5 Taq (6-FAM) CCC TTC CCT AAA ATA GCC 
ACC ACC TCA (6-Tamra) 
hTfR forward GAC TTT GGA TCG GTT GGT GC 
hTfR reversed CCA AGA ACC GCT TTA TCC AGA T 
hTfR Taq (JOE) TGA ATG GCT AGA GGG ATA CCT 
TTC GTC CC (6-Tamra) 
mKcnh5 forward TTG TCT CAA CAT GGT CAA TGT CA 
mKcnh5 reversed CGG TTC AGA TGA ACA CAG ATG TC 
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mKcnh5 TaqMan probe # 3158 (6-FAM) AGA TGG AGA GGA CCT TCT 
CTG TGT CG (6-Tamra) 
mKcnh1 forward TCT GTC CTG TTT GCC GTA TGA CG 
mKcnh1 reversed GAG ACG GAG CAG CCG CAC 
TaqMan Probe  (6-FAM) AAC AGG CTG CTG ATG CCC 
TCA TCC AC (6-Tamra) 
3.10 Antibodies 
Description Supplier 
Mouse anti-tetra-His antibody, IgG Qiagen, Hilden 
Rabbit anti-goat IgG, HRP-labeled: 172-1034 Bio-Rad Laboratories, Munich 
Anti-digoxigenin fab fragment, AP-labeled Roche, Mannheim 
αBungerotoxin, biotin-labeled Invitrogen, Darmstadt 
Rabbit anti-Kv10.2: APC-053 Alomone Labs, Jerusalem, Israel 
Donkey anti-rabbit IgG, HRP-labeled: NA934 GE Healthcare, Munich 
Mouse anti-Tubulin IgG: T 6074 Sigma, Seelze 
Goat anti-rat IgG, HRP labeled: AP136P Merck, Millipore, Schwalbach 
Rabbit anti-Kv10.2 (C-20) IgG: sc-69290 Santa Cruz Biotechnology, Heidelberg 
Rabbit anti-Kv10.2 N-terminal IgG: ab32975 Abcam, Cambridge, UK 
Rabbit anti-Kv10.2 C-terminal IgG: ab86216 Abcam, Cambridge, UK 
Rabbit anti-Kv10.2 IgG: HPA030487 Sigma, Seelze 
Rabbit anti-adenylyl cyclase III (C-20) IgG: sc-588 Santa Cruz Biotechnology, Seelze 
Goat anti-actin IgG, (C-11): sc-1615 Santa Cruz Biotechnology, Seelze 
Mouse anti-acetylated tubulin IgG2b: 6-11B-1 Sigma, Seelze 
Goat anti-rabbit IgG, Alexa-633 labeled (A-21071) Invitrogen, Darmstadt 
Rabbit anti-Kv10.2 IgG Aldevron/own work 
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3.11 Plasmids and constructs 
Plasmid Supplier 
pET16b Novagen, Darmstadt 
pTracer Invitrogen, Karlsruhe 
pCDNA3.1 Invitrogen, Karlsruhe 
 
Construct 
Kv10.1-BBS in pTracer  
A minimal bungarotoxin binding site (BBS) was inserted at the extracellular loop between 
transmembrane segments 3 and 4 of full length human Kv10.1 (Figure 6). This location was 
chosen because there exists a natural splice variant with additional 27 amino acid residues at 
this location that shows no functional differences with the major form; detailed 
characterization of this construct did not detect functional differences with the wild type 




Figure 6: schematic representation of BBS insertion in human Kv10.1 





 transmembrane domain. Figure from Kohl et al. (Kohl et al., 2011). 
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Kv10.2-BBS in pcDNA3 
A minimal bungarotoxin binding site (BBS) was inserted at the extracellular loop between 








The peptide H1X consists of two amino acid chains, the sequence of the pore region and C-
terminal part of Kv10.1, linked by a peptide linker containing a 6xHis-tag. This was previous 
work of the department. 






The peptide hKv10.2 consists of the C-terminal cytoplasmatic domain of the human Kv10.2 





The peptide UBC-H5 consists of a sequence of the human ubiquitin-conjugating enzyme E2D 1, 
with a C-terminal 6xHis-tag linked by a peptide linker. This peptide was gifted by Dr. Hiroshi 
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Kawabe (Department of Molecular Neurobiology, Max Planck Institute of Experimental 
Medicine). 
3.13 Isolation of nucleic acids 
3.13.1 Plasmid mini preparation  
For plasmid mini preparations the MACHEREY-NAGEL NucleoSpin Plasmid Kit was used. One 
E.coli colony was picked and inoculated in 5 ml LB medium containing the appropriate 
antibiotic. Incubation was performed for 10-16 h at 37°C with 225 rpms agitation. Cultures 
were harvested by centrifugation for 5 min at 5000xg and the pellet was treated according to 
manufacturer’s instructions. DNA was eluted with 50 μl of ddH2O. 
 P1 buffer (minipreparation of plasmid DNA)  
  50 mM Tris- HCl pH 8.0 
  10 mM EDTA 
  100 μg/ml RNase A 
 
 P2 buffer (minipreparation of plasmid DNA) 
  200 mM NaOH, 
  1% (w/v) SDS 
 
 P3 buffer (minipreparation of plasmid DNA)  
  3 M potassiumacetat pH 5.5 
  10x PBS 1.37 M NaCl 
  81 mM Na2HPO4 
  27 mM KCl 
  14.7 mM KH2PO4 
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3.13.2 Plasmid endotoxin free Maxi preperation 
For transfection of HEK293 cells endotoxin free DNA was prepared with EndoFree Plasmid 
Maxi Kit according to manufacturer’s instructions (Qiagen, Hilden). For this purpose 5 ml LB- 
medium containing the appropriate antibiotic was inoculated with a single colony of 
transformed BL21 bacterial strain and incubated overnight at 37°C with 225rpms agitaion. The 
preculture was inoculated in 100 ml LB- medium containing the appropriate antibiotic and 
incubated overnight as described previously.  
3.13.3 DNA isolation from mouse tails 
To isolate genomic DNA from mouse tails, tail samples were incubated at 56°C with 1000 rpms 
on a heating block between 2 h and overnight in lysis buffer II followed by isopropanol 
precipitation. The DNA was precipitated by centrifugation, washed with 70% ethanol and 
resuspended with 80-100 μl of ddH2O.  
 Lysis buffer II (mouse tail) 
 100 mM Tris pH 8.5 
 5 mM EDTA pH 8.0     
 200 mM NaCl      
 0.2% (w/v) SDS 
 0.1 mg/ml proteinase K 
  dissolved in ddH20 
3.13.4 Ethanol precipitation of DNA 
Prior to in vitro transcription, template DNA was ethanol precipitated in order purify DNA. 
Ethanol precipitation was performed with the Novagen Pellet Paint co-precipitant according to 
manufacturers manual. Briefly, 2 µl Pellet Paint and 0.1% (v/v) 3 M natrium acetate were 
added to the sample and vortexed. 2 volumes of ethanol was added and incubated for 2 min. 
The sample was centrifuged at 16,000 x g for 5 min. Precipitated DNA together with the Pellet 
Paint formed a pink pellet. The supernatant was discarded, the pellet rinsed twice with 700 µl 
70% ethanol diluted in DEPC-water and centrifuged. After a final wash step with 100% ethanol 
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the supernatant was removed. Residual ethanol was removed by air drying. Pellet was 
resuspended in 30 µl DEPC-water until the pellet paint was in solution. Afterwards the 
concentration was determined.  
3.13.5 Purification of RNA from cells 
RNA from cells was extracted via the QiaShredder columns prior to the Qiagen RNeasy mini kit. 
Cells (2-3 x 106) were disrupted in 600 μl RLT Buffer supplemented with 1% (v/v) ß-
mercaptoethanol and filtered through QiaShredder columns by centrifuging for 2 min at 
14000xg. Ethanol was added to the lysates, vortexed, loaded on a Qiagen RNeasy mini column 
and manufacturer’s instructions were followed. To eliminate genomic DNA, DNAse treatment 
was performed according to manufacturer’s instructions. RNA was eluted in 30 µl RNase-free 
DEPC treated ddH2O. 
3.13.6 Purification of RNA from tissue 
RNA from tissue was extracted via phenol-chloroform extraction followed by the use of Qiagen 
RNeasy mini kit. Tissue (< 100 mg) was homogenized in 1 ml QIA-zol lysis reagent with a tissue 
lyzer. 200 µl chloroform was supplemented to the samples, vortexed and incubated for 5 min 
at room temperature (RT). Samples were centrifuged for 15 min at 12000xg at 4°C. The 
aqueous phase was transferred to a new cup, 600 µl 70% ethanol was added and vortexed. 
The suspension was transferred to a RNeasy mini spin column and treated according to 
manufacturer’s instructions. DNAse treatment and elution of RNA was performed as described 
above. 
3.13.7 Concentration determination of DNA and RNA 
DNA concentration as well as DNA purity was measured spectrometrically by NanoDrop at 
260nm. The quotient of extinction at 260nm and 280nm determines purity and should have a 
value between 1.8 and 2.  
For Pellet Paint precipitated samples, the manufacturer’s protocol (Novagen) was followed.  
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3.14 Agarose gel electrophoresis  
Agarose gel electrophoresis was used to separate DNA or RNA fragments obtained by PCR or In 
Vitro transcription. 1x Turbo buffer cotaining 1 – 4 % (w/v) agarose was heated in a microwave 
until the agarose was completely dissolved. After cooling to 60°C, Ethidium bromide (5 μl/100 
ml) was added and poured in a horizontal gel chamber. After solidification of the gel it was 
placed in an electrophoresis chamber filled with 1x Turbo buffer. The PCR product was mixed 
with Stop-Mix I, applied on the gel and run at 200 Volt for 20 to 45 min. Ethidium bromide 
labeled DNA was visualized by UV light. 
 20x Turbo-Puffer 
  0.2 M NaOH 
 Adjust to pH 8.0 with Boric acid 
 in ddH2O 
 
 Stop-Mix I 
  15% Ficoll 400 
 200 mM EDTA 
 0.1% (w/v) Orange G 
 Dissolved in ddH2O and DEPC treated 
3.15 Transformation of bacteria  
 
Chemically competent bacteria are able to uptake plasmids after a heat shock at 42°C. 
Competent bacteria was thawed on ice and incubated with up to 100 ng plasmid DNA or 10 μl 
ligation reaction. Cells were incubated on ice for 30 min and permeabilized with a heat shock 
at 42°C for 45 sec followed by 2 min incubation on ice. 500 μl LB-medium was added and 
incubated for 45 min at 37°C with gentle agitation. Transformed bacteria were plated on LB-
agar plates containing the appropriate antibiotics and grown overnight at 37°C. 
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3.16 Polymerase chain reaction (PCR) 
3.16.1 PCR from genomic DNA or plasmid 
The polymerase chain reaction (PCR) is a molecular technique to specifically amplify DNA 
fragments with specific oligonucleotides (primer). A PCR reaction consists of denaturation, 
annealing and elongation steps. These steps are repeated for 20-40 cycles. For a PCR reaction 
the following compounds are required: template DNA, specific primers, desoxynucleoside 
triphosphates (dNTPs), divalent ions (MgCl2), and a heat-stable DNA polymerase. PCRs were 
performed in 25 μl - 50 μl reactions in the following composition: 
 10-100 ng cDNA 
 2.5 - 5 μl 10xPCR buffer with MgCl2 to a final concentration of 1x  
 10 pmol forward primer 
 10 pmol reverse primer 
 1 μl nucleotide mix (200 μM of each dNTP) 
 1 unit DNA polymerase/25 µl reaction 
 add ddH2O to a final volume of 25 µl or 50 µl 
Initial denaturation was achieved by incubating 5 min at 98°C followed by 30-40 cycles. PCR 
reaction had the following steps: 
 Temperature Time Cycles 
 98°C 5 min 1 
 98°C 30 sec 30 – 40 
 50°C – 60°C 30 sec 30 – 40 
 68°C – 72°C 30 sec – 120 sec 30 – 40 
 68°C – 72°C 10 min 1 
A last elongation step was performed for 10 min at 72°C and afterwards the sample was 
maintained a 4°C. 
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Genotyping of Kv10.1 and Kv10.2 deficient mice 
For genotyping of Kv10.1 and Kv10.2 deficient mice a touchdown cycle was applied before the 
above mentioned PCR protocol: 
5 × Touchdown cycle 
 Temperature Time Cycles 
 95°C 30 sec 5 
 64°C – 60°C 30 sec 5 
 (decreasing each cycle by 1°C) 
 72°C 30 sec 5 
 
Genotyping of Emx-Cre mice  
 Temperature Time Cycles 
 95°C 3 min 1 
 95°C 10 sec 30 
 55°C 30 sec 30 
 72°C 30 sec 30 
 72°C 5 min 1 
 
 
Genotyping of TYFF, CXCR and GFEA mice  
 Temperature Time Cycles 
 94°C 3 min 1 
 94°C 30 sec 35 
 60°C 30 sec 35 
 72°C 1 min 35 
 72°C 10 min 1 
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Amplification of In Situ hybridization templates 
For amplification of DNA template for In Situ hybridization probes, one primer, either forward 
or reversed, directly linked to the T7 promoter, in combination with a non-linked primer was 
used. Amplification was performed with the FastStart High Fidelity PCR System (Roche) in 50 
µL reaction with the following composition:  
 100 ng cDNA 
 5 μl 10xFastStart High Fidelity reaction buffer with 18 mM MgCl2  
 10 pmol forward primer 
 10 pmol reverse primer 
 1 μl nucleotide mix (200 μM of each dNTP) 
 2.5 units FastStart High Fidelity Enzyme Blend (5 U/µL) 
 add DEPC-treated ddH2O to a final volume of 50 µl 
 
Amplification of In Situ hybridization probes  
 Temperature Time Cycles 
 94°C 3 min 1 
 94°C 40 sec 50 
 62°C 30 sec 50 
 72°C 30 sec 50 
 72°C 5 min 1 
3.16.2 Reverse transcriptase PCR 
cDNA synthesis for reverse transcriptase-polymerase chain reaction (RT-PCR)  was performed 
with the SuperScript first-strand synthesis system. For synthesis of cDNA 2.5 μg or 5 μg total 
RNA was used. For each reaction a negative sample was used, to validate qRT-PCR for genomic 
DNA contamination. Into each sample 0.5 μg oligo (dT) was added and DEPC-water to achieve 
a 12 μl volume. After each step the samples were mixed by vortexing and centrifuged. Samples 
were incubated at 70°C for 10 min and rapidly cooled on ice for 1 min. 7 µl reaction buffer was 
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added to the reaction mixture and incubated at 42°C for 5 min. Samples were supplemented 
with 1 μl reverse transcriptase enzyme (200 units), while to negative control samples 1 μl 
DEPC-water was added. Reaction mixtures were incubated for 50 min at 42°C. Subsequently 
reverse transcriptase enzyme was inactivated by heating the samples at 70°C for 15 min. To 
digest RNA in the samples, 2 units of RNAse H was added and incubated for 20 min at 37°C. 
Finally, reaction volume was adjusted with DEPC- water to a cDNA concentration of 0.1 μg/μl. 
 Reaction buffer 
  2 μl 10x reverse transcriptase buffer 
  2 μl MgCl2 25 mM 
 6 μl of dNTPs 10 mM 
2 μl of dithiothreitol (DTT) 0.1 M 
3.16.3 In vitro transcription 
For in vitro transcription of digoxigenin labeled RNA In Situ hybridization (ISH) probes 100 ng 
template was used. The template was amplified as described in 3.16.1 and ethanol 
precipitated with Pellet Paint (Novagen) as described in 3.13.4. The reaction was set up with 
labeling mix I and incubated for 90 min at 37°C. To increase the reaction efficiency 10 µl 
labeling mix II was added and incubated for 60 min at 37°C. To remove cDNA from the 
reaction, 4 µl RDD buffer, 2 µl DNase and 4 µl DEPC-water was added and incubated for 8 min 
at 37°C. 10 µl stop buffer was added. The sample was loaded on a Microspin column and 
centrifuged for 1 min at 500xg. The elution was loaded on a second Microspin column and 
centrifuged for 2 min at 500xg. 2 µl of the elution was loaded on a 3.5% agarose gel and run at 
200 Volt for 45 min. The reaction was adjusted to 100 µl with DEPC-ddH20, 100 µl formamid 
was added, aliquoted and stored at -80°C. 
Labeling mix I 
 2 µl 10x DIG RNA labeling mix 
 2 µl 10x transcription buffer 
 2 µl 100mM DTT 
 1 µl T7 RNA polymerase 
 X µl DNA template (100 ng) 
 add DEPC-ddH20 to a final volume of 20 µl 
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 Labeling mix II 
1 µl 10x DIG RNA labeling mix 
1 µl 10x transcription buffer 
1 µl 100mM DTT 
1 µl T7 RNA polymerase 
6 µl DEPC-ddH20 
 
 Stop buffer 
  1% (w/v) SDS 
  0.1 M Tris- HCl pH 8.0 
  10 mM EDTA pH 8.0 
  Dissolved in ddH2O and DEPC treated 
3.16.4 Quantitative real-time PCR 
Quantitative real-time PCR (qRT-PCR) was performed utilizing the TaqMan system in the 
LightCycler 480 (Roche). Primers and probes were chosen from the Universal Probe Library 
(UPL) from Roche or designed with Primer3 software. TaqMan probes are labeled at the 5’ end 
of the probe with the reporter dye 6-carboxyfluorescein (FAM) or 2,7,-dimethoxy-4,5- 
dichloro-6-carboxyfluorescein (JOE) and a Dark Quencher Dye (Tamra) at the 3’ end of the 
probe. During PCR, exonuclease activity of the DNA polymerase cleaves the reporter and 
quencher dye of the probe. When separated, the reporter emits a fluorescence signal detected 
by the LightCycler 480.  
For analyzing the mRNA expression of the desired target gene, qRT-PCR with housekeeping 
gene TaqMan primers and probes on the same template was used to control for RNA integrity 
and quantification.  
Real-time PCR was performed with 100 ng cDNA, 200 nM forward and reverse primer, 100 nM 
TaqMan probe, 0.2 units Uracil-DNA-glycosylase, and a ready-to-use hot-start PCR mix 
containing Taq DNA polymerase, dNTP mix, as well as buffer and MgCl2.  
PCR conditions were:  
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 Temperature Time Cycles 
 50°C 2 min 1 
 95°C 10 min 1 
 95°C 10 sec 45 
 60°C 30 sec 45 
 40°C 10 sec 45 
Afterwards the sample was maintained at 4°C. 
The relative mRNA expression was determined by the number of PCR cycles to reach the cycle 
threshold (Ct). The results were standardized to the amount of the housekeeping gene in the 
respective probe and to the amount of mRNA expression in the calibrator (mouse brain RNA or 
human brain RNA).  
For this purpose the ΔΔCt-Method as described in Livak et al. (Livak and Schmittgen, 2001) was 
applied:  
Normalized ratio: 2 ΔCt1 / 2 ΔCt2 
ΔCt1 = Ct target (calibrator) – Ct target (sample) 
ΔCt2 = Ct housekeeping gene (calibrator) – Ct housekeeping gene (sample) 
3.17 DNA sequencing analysis 
16 μl of DNA (100 ng/μl) diluted in ddH2O was submitted to the sequence facility (AGCT Lab) of 
the Max Planck Institute of Experimental Medicine. The obtained sequencing data was 
analyzed using DNAStar (SeqManII) software package. Sequences were also verified on public 
domain databases such as ENSEMBL (http://www.ensembl.org) and BLAST at 'National Centre 
for Biotechnology Information' (NCBI). If not stated otherwise, standard primers of the 
sequencing facility were used.  
Oligonucleotide name Sequence 5’ – 3’ 
 C-Terminus hKv10.2 forward TAATACGACTCACTATAGGG 
 C-Terminus hKv10.2 reversed GACCCGTTTAGAGGCCCCAAGG 
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3.18 RNA assays 
3.18.1 Dot blot assay 
PCR amplified target sequences of the digoxigenin labeled RNA antisense probes were diluted 
1:1, 1:10, 1:100 and 1:1000. PCR amplifications of Kcnh1 and Kcnh5 target sequences, total 
brain cDNA and calbindin PCR product were dropped on a nylon membrane. Total brain cDNA 
served as a positive sample, while calbindin DNA served as a negative sample. Membranes 
were air dried, crosslinked in a UV-oven (stratalink) and rehydrated with TBS.  Blocking of 
membranes was performed in 3% (w/v) BSA in TBST for 30 min. 3 µl Antisense probe was 
diluted in 100 µl 3% (w/v) BSA in TBST and denaturated at 70°C for 10 min. The membrane was 
hybridized with the digoxigenin labeled RNA antisense probes. Hybridization temperature was 
51°C for the antisense probe targeted against Kcnh1 and 55°C for the antisense probe targeted 
against Kcnh5. The incubation time was 30 min for both probes. Membrane was washed at 
47°C in 2x SSC for 15 min, 0.1% SDS in 2x SSC for 15 min, 0.2x SSC for 15 min and in TBS. 
Membrane was blocked in 3% BSA in TBST for 30 min at RT. Anti-digoxigenin antibody in 0.1% 
Casein in TBST was incubated for 30 min at RT. Membrane was washed in TBS and AP-buffer at 
RT. Enzymatic reaction was performed in 20 ml substrate buffer (0.02% NBT/BCIP in AP-
buffer). Rinsing of membrane with water stopped the reaction. 
 Alkaline phosphatase staining solution  
  100 µl NBT/BCIP 
  dissolved in 5 ml AP-Puffer 
 
 Alkaline phosphatase buffer (AP)  
  100 mM NaCl 
  50 mM MgCl2 
  100 mM Tris- HCl pH 9.5 
3.18.2 In Situ Hybridization 
In Situ Hybridization was performed on a Ventana Discovery XT with the Research ISH Blue 
Map XT procedure according to manufacturer’s instructions. The BlueMap Kit utilizes the nitro 
blue tetrazolium (NBT) and 5-Bromo-4-chloro-3-indolyl phosphate (BCIP) chemicals. In 
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combination with an alkaline phosphatase (AP) labeled antibody, the NBT serves as an oxidant 
and the BCIP as the AP substrate, resulting in a blue staining. Briefly, paraffin embedded 
mouse sections were deparaffinized and incubated for 12 min in Riboclear solution (Ribo Fix 
Kit). Tissue was conditioned in mild CC2 (Citrat Buffer pH 6) setting and for 4 min incubated 
with Protease 3 (0.02 units/ml alkaline protease) at 37°C. 2.5 µl antisense probe and 2.5 µl 
sense probe were each diluted in 100µl RiboHybe buffer and titrated on the slide. The slides 
were incubated at 70°C for 8 min for RNA denaturation. Hybridization was performed at 50°C 
for 6 h. Washing steps were performed with 0.1% SSC at 55°C. Post fixation was performed 
with RiboFix solution for 20 min. HRP-labeled anti-digoxegenin antibody diluted 1:500 in 
antibody diluent was titrated on the slide and incubated for 32 min. BlueMap detection 
solution was incubated for 6 h on the slide. Slide cleaning was performed.  
For the Kcnh5 probe, different condititions were applied in order to gain specificity of the ISH 
probe: Increased temperature of hybridization and washing steps to 57°C, shortened 
hybridization time (3 h) and titration of probe (0.5 µl, 1 µl, 1.5 µl and 2 µl).  
3.19 Biochemistry 
3.19.1 Protein extraction from cells 
Cell lysates were derived from cells treated as described in 3.16. Cells were transferred to a 
reaction cup and washed twice with PBS, followed by centrifugation. Lysis was performed by 
adding 300 µl lysis buffer I and homogenized using an Insulin Needle. Lysat was incubated for 
30 min at RT. Subsequently the sample was centrifuged for 15 min at 18,000xg at 4°C to 
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 Lysis buffer I (cell and tissue protein)  
  25 mM Tris- HCl pH 7.4 
  150 mM NaCl 
  2.5 mM EDTA 
  0.5% Triton X-100 
  2.5 mM Na2- Pyrophosphate 
  0.25 mM Na- Orthovanadate 
  0.25 mM PMSF 
  0.25 mM DTT 
  5 mM NaF 
  Protease inhibitor cocktail  
3.19.2 Protein extraction from tissue 
Extracted organs were supplemented with 100 µl – 1 ml lysis buffer I (see 3.20.1) and 
homogenized with the tissue lyser (Qiagen). Sample was centrifuged at 18,000xg at 4°C for 30 
min to remove cell debris. Supernatant containing total protein extract was transferred to a 
new reaction cup and centrifuged again. Supernatant was removed and stored at -80°C. 
3.19.3 BCA protein assay 
To determine protein concentration the bicinchoninic acid (BCA) protein assay kit was used. To 
quantify protein concentration in the sample bovine serum-albumin (BSA) in different 
concentrations served as a standard curve. The samples along with the BSA standard were 
treated in triplicates and were incubated in a 96-well plate in a volume of 25 μl together with 
the BCA reagent. BCA reagent was composed by solution A (sodium carbonate, sodium 
bicarbonate, bicinchoninic acid and sodium tartrate in 0.1 M sodium hydroxide) and solution B 
(4 % cupric sulfate) in a ratio of 50:1. Following incubation for 30 min at 37°C the absorbance 
was measured in Victor Wallac plate reader at 550 nm. 
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3.19.4 SDS-PAGE  
30 µg (cells) or 50 µg (tissues) of total protein extract per sample were diluted with Running 
Buffer and heated for 10 min at 70°C. Sample was loaded and separated on a gradient 3-8% 
TRIS-acetate SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) NuPAGE 
Novex gel. SDS-gels were either used for Western blot analysis or stained with Comassie for 
protein detection and quantification. 
Running buffer (10 µl) 
 2.5 µl 4x LDS 
 1 µl 10x Reducing agent 
 X µl protein extract 
 add ddH20 to 10 µl 
3.19.5 Western blot analysis 
For Western blot (WB) analysis proteins were transferred from a SDS-gel to nitrocellulose 
hybridization membranes. Subsequently membranes were blocked for 1 h with 0.1% (w/v) 
casein diluted in TBST. Primary antibody was incubated overnight at 4°C diluted in 0.1% (w/v) 
casein TBST. Membrane was washed with 1000 ml deionized water for 7 times and incubated 
in TBST for 5min. Secondary antibody coupled to horseradish peroxidase (HRP) was incubated 
for 1 h followed by washing with 1000 ml deionized water for 7 times. To detect bound 
antibody chemiluminescent HRP substrate was used and signals visualized in a Chemi-Doc 
luminescence detection system using no illumination for chemilumiscence acquisition and epi-
white light for acquisition of protein molecular weight standard. Afterwards membranes were 
stripped by incubation in stripping solution for 20 min at 37°C. To verify proper loading of 
samples and to control equal amounts of protein loaded in each sample, membranes were 
stained with an anti-α-tubulin antibody. The procedure is described above.  
Aquired images were processed using Quantity One (Biorad) software to linear brightness and 
contrast adjusting. Images obtained from chemilumiscence and epi-white acquisition were 
superimposed. Protein standart was replaced with drawn bars to indicate the migration 
distance of the molecular weight standard. Furthermore, images of Western blots were 
cropped to the required molecular weight range.   
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 50x Transferbuffer 
  0.5 M NaHCO3 
  0.15 M Na2CO3 
  in ddH2O 
 Transferbuffer 
  20 ml 50x Transferbuffer 
  20% (v/v) Methanol  
  0.01% (v/v) SDS 
  add ddH2O to 1000 ml 
 
 TBST 
  10%  (v/v) 10x TBS 
  0.05% (v/v) Tween-20 
  89.95% (v/v) ddH2O 
 
 Blocking buffer (Western Blot) 
  TBST 
  0.1% (w/v) casein  
 
Antibody   Dilution    
Anti-α-tubulin   1:10000 
Anti-actin  1:400  
Anti-Eag2 (Aldevron/own work)  1:400 
Anti-Eag2-Abcam-N-terminal  1:1000 
Anti-Eag2-Abcam-C-Terminal  1:300  
Anti-Eag2-Alomone-Biolabs  1:200 
Anti-Eag2-Sigma-Aldrich  1:500  
Anti-Eag2-St.Cruz-Biotechnology  1:200 
Anti-Eag1-9391  1:1500 
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Anti-goat-HRP  1:8000 
Anti-mouse-HRP  1:8000 
Anti-rabbit-HRP  1:8000 
Anti-tetra-His  1:800 
3.19.6 Protein Staining with Coomassie 
Besides visualization of proteins separated by SDS-PAGE by SybroRuby, Coomassie staining was 
used. SDS-gels were stained in 10 ml Coomassie staining solution for 5 min und washed 
overnight in ddH2O to remove excess of Coomassie. Coomassie stained SDS-gels were 
documented by light in a Chemi-Doc luminescence detection system. 
 Coomassie staining solution  
  30% (v/v) Methanol 
  10% (v/v) acetic acid 
  0.05% (w/v) Coomassie Brilliant Blue R250 
  in DEPC ddH20 
3.19.7 Densitometrical calculation 
Densitometrical calculation was performed with Quantitiy One software (BioRad) verifying for 
non-saturation. Values are expressed as the integrals (area * mean density) of each band and 
normalized to α-tubulin. 
3.19.8 Purification of BBS-tagged Kv10.1 and Kv10.2 
For purification of BBS-tagged Kv10.1 and Kv10.2 full-length proteins, 800µg protein lysate from 
HEK293 wildtype, HEK293 Kv10.1-BBS and HEK293 Kv10.2-BBS overexpressing cells was used. 
The volume of each sample was adjusted to 500 µl with protein lysis buffer III. 15 µl BTX-Biotin 
(11.5 µM) was added and sample was incubated on ice with occasional vortexing. 20 µl T1-
dynabeads were washed in a reaction cup with PBS to remove any detergents. Dynabeads 
were recovered by magnetic separation on a magnetic rack. Protein lysates were added to the 
Dynabeads and rotated at 4°C for 60 min. The protein BTX-biotin complex was recovered by 
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magnetic separation. Supernatant was removed and pellet was washed with 500 µl lysis buffer 
for 10 minutes at 4°C rotating 3 times. Following magnatic separation, pellet was washed with 
500 µl TBS at 4°C rotating. After magnetic separation, the beads were eluted in following 
buffers: 
 SDS-PAGE buffer 
16.25 µl TBS 
6.25 µl 4x Novex-LDS-buffer 
2.5 µl 10x reducing agent 
3.20 Generation of novel anti-Kv10.2 antibody 
3.20.1 Heterologous protein expression  
A colony of E.coli BL21 cells containing the plasmid Kv10.2-pET16b was picked and inoculated 
in 50 ml LB- Amp medium and incubated overnight on an orbital shaker at 37°C. 5 ml of 
overnight culture was inoculated in 6 x 2 liter flasks filled with 500 ml LB-Amp medium. 
Cultures were incubated at 37°C with 180rpms until the OD 600 of 0.6. Each flask was treated 
with IPTG to a final concentration of 0.7 mM. The cultures were incubated for 5 h at 37°C and 
180rpms. Cells were harvested by centrifugation and resuspended in 7 ml resuspension buffer. 
Cells were lysed by sonification (80% power, 10% cycle) and centrifuged at 10.000xg for 30 min 
at 4°C. Soluble fraction was transferred to a new tube and pellet was resuspended in 50ml lysis 
buffer III. 5 ml Ni-NTA agarose was added and incubated overnight under constant agitation. 
After centrifugation for 10 min at 500xg at 4°C, beads were washed with wash buffer I. The 
same step was applied with wash buffer II. Bound protein was eluted from the Ni-NTA agarose 
with elution buffer or elution buffer urea under constant agitation at 4°C. The solution was 
transferred to a dialysis column (1 kDa MWCO) and dialyzed starting with either dialyses 
solution I till dialysis solution III or by dialysis solution Urea I till dialysis solution Urea IV by 
changing solutions every 12 h. After dialysis, the expressed C-terminus of Kv10.2 preparation 
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 Resuspension buffer 
 50 mM Tris- HCl 
 200 mM NaCl 
  pH 8 
  
 Lysis buffer III  
  6M Guanidiniumhydrochloride 
  20 mM NaH2PO4*H20 
  500 mM NaCl 
  adjust to pH 7.8 
 Wash buffer I 
  8 M Urea 
  20 mM NaH2PO4*H20 
  500 mM NaCl 
  in PBS 
  pH 7.8  
 Wash buffer II 
  8 M Urea 
  20 mM NaH2PO4*H20 
  500 mM NaCl 
  in PBS 
  pH 6.9 
 Elution buffer 
  6 M Guanidiniumhydrochloride 
  20 mM NaH2PO4*H20 
  500 mM NaCl 
  500 mM Imidazol 
  adjust to pH 4.0 
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 Elution buffer urea 
  8 M Urea 
  20 mM NaH2PO4*H20 
  500 mM NaCl 
  500 mM Imidazol 
  adjust to pH 6.8  
 Dialysis solution I 
  6 M Guanidiniumhydrochloride 
  50mM Tris- HCl pH 8.0 
  200mM NaCl 
  pH 8.0 
 Dialysis solution II 
  4 M Guanidiniumhydrochloride 
  50 mM Tris- HCl pH 8.0 
  200 mM NaCl 
  pH 8.0 
 Dialysis solution III 
  2 M Guanidiniumhydrochloride 
  50 mM Tris- HCl pH 8.0 
  200 mM NaCl 
  pH 8.0 
 Dialysis solution Urea I 
  8 M Urea 
  50mM Tris- HCl pH 8.0 
  200mM NaCl 
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 Dialysis solution Urea II 
  6 M Urea 
  50 mM Tris- HCl pH 8.0 
  200 mM NaCl 
  pH 8.0 
 Dialysis solution Urea III 
  4 M Urea 
  50 mM Tris- HCl pH 8.0 
  200 mM NaCl 
  pH 8.0 
 Dialysis solution Urea IV 
  2 M Urea 
  50 mM Tris- HCl pH 8.0 
  200 mM NaCl 
  pH 8.0 
3.20.2 Generating of novel Kv10.2 antibody 
The C-terminus of Kv10.2 expressed as described in 3.20.1 was sent to Aldevron (Freiburg, 
Germany) for vaccination of two rabbits and antibody generation. ELISA was performed by 
Aldevron to indicate antibody specificity. Antibody was delivered in PBS in a final 
concentration of 8.7 mg/ml.  
The anti-Kv10.2 antibody was aliquoted and frozen at -80°C. Working dilutions were adjusted 
to 1 mg/ml with PBS and stored at 4°C.  
3.20.3 Indirect ELISA  
The enzyme-linked immunoabsorbant assay (ELISA) is a biochemical method used to detect an 
antigen in a sample. 96-well plate was coated with 500 ng protein in 100 μl TBS buffer and 
incubated at 4°C overnight. Unspecific binding sites were blocked with 3% (w/v) BSA in TBS for 
1 h at RT. Antibody diluted in 3% (w/v) BSA in TBS was added and incubated for 2 h at RT. 
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Subsequently the well was washed 3 times and the appropriate HRP conjugated secondary 
antibody was added and incubated for 1 h at RT. Well plates were washed 3 times with TBS 
and 100 μl ABTS substrate was added. The developed reaction was measured in the Victor 
Wallac plate reader at 405 nm and 490 nm.  
3.21 Cell culture methods 
3.21.1 Cell culture of commercial cell lines  
HEK293 cells were cultivated under standard cell culture conditions at 37°C in a humidified 
atmosphere with 5% CO2 in an incubator. 
108CC05 and 108CC15 cells were propagated as described in Hamprecht et al. (Hamprecht et 
al., 1985). Cells were cultivated at 37°C in a humidified atmosphere with 10% CO2 in an 
incubator. 
Oli-Neu cells were propagated as described in Jung et al. (Jung et al., 1995). Cells were 
cultivated at 37°C in a humidified atmosphere with 10% CO2 in an incubator. 
3.21.2 Sub-cultivation of cell lines 
For sub-cultivation of eukaryotic cells medium was removed and cells washed twice with 
Dulbecco’s Phosphate Buffered Saline (DPBS). 0.05% trypsine- ethylene-diamine-tetraacetic 
acid (EDTA) solution was added to the cells and incubated for 5 min at 37°C. 10% FCS 
containing medium was added to stop the enzymatic reaction. Cells were resuspended, if 
necessary counted in a Neubauer chamber and plated in desired cell numbers. 
3.21.3 Cryoconservation 
To cryoconserve eukaryotic cells were detached as described. 1-5 x 106 cells per ml were 
resuspended in cryoconservation medium and transferred to storage vials. Vials were frozen in 
an insulated box at -80°C overnight and stored in liquid nitrogen. 
  





10% (v/v) dimethyl sulfoxide (DMSO) 
3.21.4 Revitalization 
Cryconserved cells were removed from liquid nitrogen and were thawed quickly at 37°C in a 
water bath. Pre-warmed supplemented medium was added and suspension was centrifuged 
for 2 min at 300xg. Supernatant was discarded and the pellet resuspended in the appropriate 
medium. Cells were transferred to a new cell culture flask and medium changed after 24 h. The 
revitalization procedure was performed as quickly as possible to reduce toxic side effects of 
DSMO. 
3.21.5 Stable transfection of HEK293 cells transfection 
HEK293 cells were transfected with pTracer-Kv10.1-BBS as described in Kohl et al. (Kohl et al., 
2011). The same protocol was applied for transfection with pcDNA3-Kv10.2-BBS. Cells were 
transfected by Lipofectamine 2000 according to the manufacturer’s description. Briefly, cells 
were seeded in a 6 well plate. After incubation of 6 µg DNA with Lipofectamine 2000 400 µl 
transfection solution was added to the cells, incubated for 18 h and replaced with fresh 
medium. To produce stable cell lines Zeocin (300 μg/ml) or G418 (500 μg/ml) was added after 
48 h to the culture medium for selection. The minimal working concentration was estimated in 
kill curve assays. 
3.21.6 Preparation of glass coverslips and PLL- coating 
Glass coverslips were washed with subsequently with acetone, ethanol and 70% ethanol and 
sterilized in an oven for 4 h at 200°C.   
Sterilized glass coverslips were placed in the appropriate well-plates and coated with 0.01% 
PLL overnight. Before use coverslips were washed with PBS.  
T75 cell culture flasks were coated with 10 ml PLL solution (0.01% PLL in PBS). 
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3.22 Histological procedures 
3.22.1 Fixation of cells 
For immunocytochemistry cells grown on cover slides were washed twice with ice cold PBS 
and fixed in 4% (v/v) PFA in PBS for 20 min at RT. Fixed cells were washed twice with PBS and 
cover slides were glued on a Superfrost Plus slide for staining.  
3.22.2 Fixation of organs 
For dissection of organs mice were anesthetized using ketamine (75 mg/kg) and xylazine (15 
mg/kg) and were consequently transcardially perfused with: 
Paraformaldehyd fixation: PBS followed immediately by 4% (v/v) paraformaldehyd and 
processed as described.  
Paraformaldehyd- acrolein fixation: 2% (w/v) sodium nitrate in PBS followed by acrolein 
solution and processed as described.  
Acrolein solution 
  4% paraformaldehyde pH 6.8 
  2.5% acrolein 
  In 0.1 M PBS 
3.22.3 Generation of paraffin sections from tissue 
Paraformaldehyde fixed tissue was placed in Tissue Tek cassettes, rinsed with water for 30 min 
and dehydrated in a graded ethanol series and paraffinized in the apparatus for tissue 
processing as follows: 
 Applied substance time cycles 
 75% ethanol 1 h three 
 96% ethanol 1 h 30 min two 
 100% ethanol 1 h 15 min three 
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 xylol 2 h two 
 paraffin 1 h two 
 
Acrolein fixed mouse brains were placed in Tissue Tek cassettes and dehydrated in a graded 
ethanol series and paraffin embedded as follows: 
 Applied substance time cycles  
 50% ethanol 1 h one 
 70% ethanol 2 h twice 
 96% ethanol 1 h twice 
 100% ethanol 1 h twice 
 isopropanol 1 h once 
 xylol 2 h twice 
 paraffin 2 h twice 
  
Paraffin embedded tissue was cut on a microtome in 5 µm sections, transferred on a Super 
Frost Plus slide and baked for 2 h at 60°C in an incubator. 
3.22.4 Generation of vibratome sections from tissue 
Paraformaldehyd fixed mouse brains were mounted in 5 % (w/v) agarose and cut into 25 µm 
sections on a vibratome. Sections were stored in PBS containing 0.04 % (w/v) NaN3 until 
processing.  
Vibratome cut mouse brain sections were mounted on a Superfrost Plus slide and air- dried 
until adherence. 
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3.23 Immunological protein detection 
3.23.1 Immunocytochemistry 
Immunocytochemistry with cells fixed as described 3.22.1 on Superfrost Plus slides was 
performed in the Ventana Discovery XT staining robot. DAB Map XT procedure, which utilizes 
3,3'-Diaminobenzidine (DAB) as substrate in combination with a HRP-coupled antibody, was 
used. The HRP oxidizes DAB resulting in a brown staining.  
The samples were covered with Reaction buffer and incubated with avidin and biotin (A/B 
block) for 4 min each to block endogenous biotin. The Kv10.2 antibody was diluted 1:100 in 
antibody diluent and 100 µl titrated on the slide. Incubation was performed at 37°C for 60 min. 
After washing steps, the biotinylated secondary antibody was dissolved 1:500 in antibody 
diluent and incubated on the tissue at 37°C for 32 min. Following washing steps the DAB 
substrate was dispensed on the slide and incubated for 8 min. Finally, slide cleaning was 
performed. 
Antibody  Dilution    
Anti-Kv10.2 (Aldevron/ own work) 1:100 
Anti-rabbit-HRP 1:500 
3.23.2 Immunohistochemistry on paraffin tissue sections 
Immunohistochemistry on sectioned paraffin embedded tissue was performed with the 
Research IHC BlueMap XT procedure in the Ventana Discovery XT staining robot. The BlueMap 
procedure utilizes nitro blue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl phosphate 
(BCIP) together with alkaline phosphatase resulting in a blue staining. Tissue was conditioned 
in CC1 buffer (EDTA Buffer pH 9) with mild settings and A/B block was applied for 4 min each. 
The anti-Kv10.2 antibody was incubated as described above. After washing steps, the 
biotinylated secondary antibody was dissolved 1:500 in antibody diluent and incubated on the 
tissue at 37°C for 28 min. Following washing steps the BlueMap substrate was dispensed on 
the slide and incubated for 48 min. Finally slide cleaning was performed.  
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Antibody  Dilution    
Anti-Kv10.2 (Aldevron/ own work) 1:100 
 Anti-adenylyl cyclase III 1:200 
 anti-acetylated tubulin 1:2000 
Anti-mouse-Biotin 1:400 
Anti-rabbit-Biotin 1:400 
3.23.3 Immunohistochemistry on vibratome tissue sections 
Vibratom cut sections were washed with Buffer A for 5 minutes three times and incubated 
with the primary antibody in Buffer A overnight at 4 °C with constant agitation. Afterwards 
sections were washed for 5 minutes three times with Buffer A. Subsequentally the secondary 
antibody was applied in Buffer A for 2 h at RT. Sections were washed with PBS containing 
0.15% (v/v) Triton-X100 for 5 min three times. The stained sections were placed on Super frost 
plus glass slides by using Montage solution, left to dry and cover-slipped in Prolong antifade 
with DAPI for microscopic observations. 
 Buffer A 
  2% (w/v) BSA 
  1% (v/v) goat serum 
  0.15% (v/v) Triton X-100 
  dissolved in PBS 
 
 Montage solution 
  0.2 % gelatin 
  0.15 % Triton X-100 
  dissolved in PBS 
(heat 100 ml with gelatin in microwave, then fill up with 392.5 ml PBS and add 7.5 
ml 10 % Triton X-100)  
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 Antibody Dilution 
 Anti-Kv10.2 (Aldevron/own work) 1:100 
 Goat anti-rabbit Alexa-633 conjugated 1:400 
3.23.3 Embedding of samples 
Microscope slides stained as described in 3.22.5 were subsequently dehydrated in a graded 
ethanol series. Following settings were used: 
 Applied substance time   
 50% ethanol 5 min  
 70% ethanol 5 min  
 90% ethanol 5 min  
 96% ethanol 5 min  
 100% ethanol 5 min  
 xylol 10 min  
 xylol 10 min  
Finally, cover glass was mounted on microscope slides with Permount mounting solution. 
3.24 Image acquisition and processing 
Images of fluorescently stained samples were acquired with a Leica SP5 (Leica, Mannheim) 
confocal laser scanning microscope (CLSM) equipped with hybrid detectors that were used in 
"photon-counting mode" in order to acquire low-noise fluorescence from representative 
fields-of-view with a 40x (1.25NA) oil immersion objective. Depending on sample labeling, 
eGFP, eYFP and Alexa Fluor (c)-633 were excited sequentially with either 488, 514 or 633nm 
wavelengths, respectively. The emission maximum for each flourophore was collected. Optical 
section was 1 µm.  
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Chromogenic images were acquired using the Zeiss (Jena) Axiovert microscope together with 
the Zeiss (Jena) Axiocam using standard brightfield settings. Shading correction was performed 
prior to image acquisition. 
All image processing was limited to linear brightness and contrast adjusting using FIJI 
(Schindelin et al., 2012). 
3.25 Statistical analysis 
Statistical analyses were performed using unpaired, two-tailed Student’s T-test. 
Variance is expressed as standard error of the mean. 
For evaluation of indirect ELISA, one-way analysis of variance (one way ANOVA) with posthoc 
test of Tamhame was performed. 
3.26 Application specific computer programs 
Program:      Used for: 
AxioVision Rel.4.6     Axiovert 200M fluorescence   
       microscope 
LAS AF 2.6.0  Leica SP5 confocal laser scanning 
microscope 
LightCycler 480 Software 1.5    LightCycler 480 
Quantity One 4.6.2     Chemi-doc luminescence detection  
       system 
Wallac 1420 Manager, Version 2.0   Victor 2 multilabel counter  
INTAS GDS Version 3.34.04.02.2011   Agarose gel documentation 
NexEX Version 10.4 Ventana Discovery XT device software 
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3.27 Computer programs 
Program:      Used for: 
DNA Lasergene 9 suite Sequence analysis 
BLAST (NCBI) Sequence analysis 
Primer3  Primer design, Reference: Rozen and 
Skaletsky (Rozen and Skaletsky, 2000) 
Microsoft Excel 2003 ELISA und qRT-PCR evaluation 
EndNote X Bibliography/ Citatition Manager 
SPSS Statistical analysis 
Biorad Quantity One  Western blot analysis and 
densitometric calculation 
Fiji Image analysis, Reference: Schindelin 









4.1 Commercially available antibodies are not sensitive or specific to 
detect Kv10.2 in Western blot analysis 
For our aim to assess the protein distribution of Kv10.2 in mouse, we first evaluated 
five commercially available antibodies for their sensitivity and specificity to recognize Kv10.2 in 
lysates of human embryonic kidney cells (HEK293) Wild type (Wt), HEK293 BBS-Kv10.1 and 
HEK293 BBS-Kv10.2 by Western blot analysis. HEK293 cells overexpressing full-length human 
Kv10.1 or Kv10.2 fused to a α-bungarotoxin binding site (BBS), as well as mouse brain lysates 
and HEK293 Wt cells were used as positive and negative controls, respectively. Before 
analyzing the overexpressing cells by Western blot, we evaluated the expression levels of 
KCNH1 and KCNH5 in the different HEK293 cells in comparison to endogenous Kv10.1 and 
Kv10.2 mRNA levels of HEK293 Wt cells by qRT-PCR (Figure 7A).  
We detected no transcripts of KCNH1 and KCNH5 in HEK293 Wt cells. HEK293 BBS-
Kv10.1 cells had an approximately 260 fold higher mRNA expression of KCNH1 as compared to 
the human total brain calibrator, and were negative for KCNH5. HEK293 BBS-Kv10.2 cells were 
negative for KCNH1 and had an approximately 310 fold higher KCNH5 mRNA expression in 
comparison to the total human brain calibrator. Furthermore, as shown in Figure 7B, the 
presence of Kv10.1 protein was confirmed by a pull-down assay with a biotin-conjugated α-
bungarotoxin antibody and subsequent Western blot analysis using the anti-Kv10.1 antibody 
9391. This antibody has already been shown to specifically detect Kv10.1 (Chen et al., 2011). 
The use of the anti-Kv10.1 antibody detected a protein band of approximately 115 kDa, the 
predicted molecular weight of BBS-Kv10.1. The expected molecular weight of the full-length 
channel is 111 kDa; the BBS-tag, inserted into the second extracellular loop of the channels, 
increases the molecular weight by approximately 4 kDa. The same applies to Kv10.2, which has 
the predicted molecular weight of 112 kDa. The inserted BBS-tag increases the molecular 
weight to 116 kDa. 
We verified by qRT-PCR and Western blot analysis that HEK293 BBS-Kv10.1 cells 




cells and expected that similar to HEK293 BBS-Kv10.1, HEK293 BBS-Kv10.2 cells also synthesize 








































Figure 7: Validation of KCNH1 and KCNH5 RNA expression in HEK293 cells determined by qRT-PCR and 
of protein translation by pull-down assay and Western blot analysis 
A: In HEK293 Wt cells no KCNH1 (black columns) and KCNH5 (grey columns) transcripts were detected. 
HEK293 BBS-Kv10.1 cells were only positive for KCNH1. HEK293 BBS-Kv10.2 cells only expressed KCNH5. 
All values were normalized to the human total brain calibrator (expression =1, data not shown). B: 
Validation of protein synthesis of BBS-Kv10.1 in HEK293 BBS-Kv10.1 overexpressing cells. Pull-down with 
biotin conjugated α-bungarotoxin was performed and subsequently analyzed by Western blot with 
polyclonal anti-Kv10.1 9391 antibody. Detection of an approximately 115 KDa protein, representing 
Kv10.1, was shown in the Kv10.1 overexpressing cells only. 
 
To evaluate the commercially available antibodies directed against Kv10.2, whole 
protein lysates from HEK293 Wt, HEK293 cells overexpressing BBS-Kv10.1, HEK293 cells 
overexpressing BBS-Kv10.2 and mouse total brain lysates were used in Western blot analysis. 
Detection of a protein of approximately 116 kDa in the lysates of BBS-Kv10.2 overexpressing 
HEK293 cells and a protein of approximately 112 kDa in mouse brain by the use of the Kv10.2 
antibody would indicate specificity to Kv10.2, whereas, a band of approximately 115 kDa in 
HEK293 BBS-Kv10.1 overexpressing cells would indicate cross-reactivity with Kv10.1. In control 
cells, the amino-terminal (N-terminal) anti-Kv10.2 antibody from Abcam did not react with any 
protein at the molecular weight of 115 kDA representing either Kv10.1 or Kv10.2 (Figure 8A). 
Therefore, this antibody did not show sensitivity towards Kv10.2. Instead, a protein of lower 
molecular weight, approximately 105 kDa, was detected in all samples derived from HEK293 
cells. No protein of the predicted molecular weight of Kv10.2 was recognized in the whole brain 
lysate. Protein loading determined by anti-α-tubulin antibody of the HEK293 Wt and HEK293 



























































Figure 8: Evaluation of 5 commercially available anti-Kv10.2 antibodies by Western blot analysis 
Immunoblotting of cell lysates of HEK293 Wt, HEK293 BBS-Kv10.1, HEK293 BBS-Kv10.2 and mouse total 
brain performed with commercially available anti-Kv10.2 antibodies. A: N-terminal anti-Kv10.2 antibody, 
Abcam: No protein was detected at the molecular weight of 116 kDa of BBS-Kv10.2 in HEK293 BBS-




was detected in the HEK293 BBS-Kv10.2.  In HEK293 BBS-Kv10.1. cell lysates, indicating cross-reactivity. 
C: Anti-Kv10.2 antibody, Sigma-Aldrich: The antibody detected Kv10.2 in HEK293 BBS-Kv10.2 cell lysate. 
Due to a non-specific band at approximately 116 kDa, an analysis of Kv10.2 protein level in total brain 
lysate was not possible. D: C-terminal anti-Kv10.2 antibody, Abcam: No specific protein was detected in 
the HEK293 BBS-Kv10.2 cell lysate. At approximately 116 kDa a protein was detected in all three HEK293 
cell samples, even in those negative for Kv10.2. E: Anti-Kv10.2 antibody, Alomone Biolabs: A protein of 
the molecular weight of Kv10.2 was detected in HEK293 BBS-Kv10.2 overexpressing cells. A protein of the 
molecular weight of Kv10.1 was detected in HEK293 BBS-Kv10.1 overexpressing cells. A-E: Equal protein 
loading was determined by anti-α-tubulin (arrows). Arrows indicate the predicted molecular weight of 
BBS-Kv10.2 (=116 kDa).  
more HEK293 BBS-Kv10.2 protein was loaded, the antibody did not bind to Kv10.2. Therefore, 
we can conclude that the antibody is not sensitive enough for Kv10.2 recognition in Western 
blot analysis. 
The Santa Cruz Biotechnology anti-Kv10.2 antibody, directed against the human 
carboxyl-terminus (C-terminus), recognized in Western Blot analysis a protein with a size 
compatible to the molecular weight of BBS-Kv10.1 in lysates of BBS-Kv10.1 overexpressing 
HEK293 cells (Figure 8B). It also interacted, to a lesser extent, with a protein of higher 
molecular weight (116 kDa) in the sample of the BBS-Kv10.2 overexpressing cells. In total 
mouse brain protein lysate, only weak signals were obtained in the molecular weight range of 
100 - 130 kDa. This rendered the protein recognized by this antibody indistinguishable of being 
Kv10.1 or Kv10.2. These results show that the Santa Cruz Biotechnology anti-Kv10.2 antibody is 
not specific for Kv10.2 detection.  
The Sigma-Aldrich anti-Kv10.2 antibody, targeting the third extracellular loop of Kv10.2, 
recognized a protein compatible with BBS-Kv10.2 of approximately 116 kDa in the HEK293 BBS-
Kv10.2 cell lysate only (Figure 8C). We observed in all samples a non-specific protein band that 
is of slightly lower molecular weight than the protein detected in HEK293 BBS-Kv10.2 cell 
lysate. Using mouse total brain lysate, the antibody recognized a protein with the predicted 
molecular weight of 112 kDa of Kv10.2. Since we observed a non-specific protein band at the 
same molecular weight as Kv10.2 in the HEK293 cells, the antibody seems to be not specific for 
detection of Kv10.2. 
The Abcam C-terminal anti-Kv10.2 antibody recognized a protein with a molecular 
weight of approximately 116 kDa within all HEK293 cell samples (Figure 8D). Interaction with 
this non-specific protein in HEK293 Wt and HEK293 BBS-Kv10.1 cells showed that the Abcam C-
terminal anti-Kv10.2 antibody is not specific to detect Kv10.2.  
The Alomone Biolabs anti-Kv10.2 antibody recognized a protein at approximately 116 




indicates interaction of the anti-Kv10.2 antibody towards Kv10.1, pointing to a non-specific 
detection of Kv10.1 by this antibody. Hence, this anti-Kv10.2 antibody is also not suitable for 
Kv10.2 expression analysis.  
In summary, Western blot analysis showed that all commercially available anti-Kv10.2 
antibodies were either not sensitive to detect Kv10.2 or were cross-reactive with Kv10.1 with 
our protocol. Hence, these antibodies were not acceptable for our aim to unravel the Kv10.2 
protein expression. We approached this issue by generating a novel polyclonal anti-Kv10.2 
antibody. 
4.2 Generation of a novel anti-Kv10.2 polyclonal antibody 
4.2.1 Generation of a C-terminal human Kv10.2 construct  
Since all tested commercially available antibodies analyzed for their ability to detect 
Kv10.2, showed no specificity for Kv10.2, we decided to generate a novel antibody. The aim was 
to generate an antibody that is not only capable of distinguishing between Kv10.1 and Kv10.2, 
but also recognizing both the human and murine form of Kv10.2. Therefore, we choose the 
human C-terminus of Kv10.2 as the antigen. This region of Kv10.2 is characterized by the least 
homology (44 %) towards Kv10.1 in human and human and mouse protein sequence is 94% 
identical (Figure 9).  
The C-terminus of the human Kv10.2 ion channel cloned in the pET16b protein 
expression plasmid was already available in our department. The plasmid contains an IPTG 
inducible T7 promoter and a 10xHis-tag N-terminal of the cloned KCNH5 sequence to allow 
purification of the C-terminus of Kv10.2 by Ni-affinity chromatography. Sequencing of the 
construct confirmed the correct KCNH5 sequence. From here on, the expressed His-tagged C-








Figure 9: Protein sequence alignment of Kv10.2, Kv10.2 C-terminus Kv10.1  
Protein sequence alignment of human Kv10.2 (hKv10.2), C-terminus of human Kv10.2 (hKv10.2-C-




(44 %) with Kv10.1. Mouse and human full-length Kv10.2 protein sequence share a high homology (98 
%), also in the C-terminus (94 %). Sequence homology is colour coded as indicated in lower right panel. 
Asterix indicates start C-terminus expressed for antibody generation. Sequence alignment was 
performed by T-Coffee (Notredame et al., 2000, Di Tommaso et al., 2011). 
4.2.2 Heterologous expression of human His-Kv10.2-CTerm in E.coli 
We transformed E.coli BL21 with the pET16b plasmid containing the His-Kv10.2-CTerm. 
These cells are a common prokaryotic expression system for protein synthesis. Samples were 
collected before IPTG induction and at an interval of 1 h starting 2 h after IPTG induction. 
Different temperatures (30°C and 37°C) as well as different concentrations of IPTG (0.3 mM, 
0.7 mM and 1 mM) were used to optimize the expression conditions (data not shown). 
Analysis of bacterial protein expression was performed by SDS-PAGE. After Coomassie staining 
we found an approximately 46 kDa protein expressed in the IPTG induced samples, but not in 




































Figure 10: Prokaryotic protein expression of the C-terminus of Kv10.2 analyzed by SDS-PAGE and 
Coomassie staining 
A: E.Coli BL21 cells were transfected with the His-Kv10.2-CTerm expression construct and expression was 
induced with IPTG. His-Kv10.2-CTerm expression was detected only in the induced sample at 
approximately 46 kDa (arrow), verified by SDS-PAGE and subsequent Coomassie staining. B: Verification 
of His-Kv10.2-CTerm protein expression by Western blot analysis with anti-His antibody. An 
approximately 50 kDa protein (arrow) was detected only in the induced cell lysate. C: Analysis of soluble 
(periplasmic space) and insoluble (inclusion bodies) fractions and elution after Ni-affinity 
chromatography in Coomassie stained SDS-gel revealed His-Kv10.2-CTerm protein in low amounts in the 




In order to confirm, that this protein is indeed the His-Kv10.2-CTerm, we performed 
Western Blot analysis of non-induced and IPTG induced cells with an anti-His antibody (Figure 
10B). The result that a protein band at approximately 50 kDa was detected by the anti-His 
antibody only in IPTG-induced cell lysate confirmed the expression of the His-Kv10.2-CTerm 
protein. 
Upon overexpression, proteins often form inclusion bodies. Hence, we investigated 
whether the His-Kv10.2-CTerm protein was expressed into the periplasmic space or formed 
inclusion bodies. We observed the protein at 46 kDa in the soluble fraction (periplasmic space), 
but also to a high amount in the insoluble fraction (inclusion bodies) indicating that the 
expressed His-Kv10.2-CTerm protein is packed into inclusion bodies during protein synthesis in 
E.coli (Figure 10C). Therefore, we used a denaturation procedure to solubilize the aggregated 
protein.  
4.2.3 Purification of His-Kv10.2-CTerm protein by Ni-affinity chromatography  
The solubilized protein extract containing the His-Kv10.2-CTerm protein was subjected 
to nickel-affinity purification, based on the His-tag. We tested urea or guanidinium 
hydrochloride (GuHCl) for elution and dialyzation of His-Kv10.2-CTerm. In comparison to urea, 
Figure 11 shows that GuHCl yielded a purer protein and a higher protein concentration. When 
dialyzed overnight against PBS, the protein partially precipitated. Therefore, we maintained 
the protein in 2 M GuHCl in PBS. The GuHCl did not allow for total protein concentration 
measurement by a bicinchoninic acid (BCA) protein assay. Hence, the concentration of the 
protein was analyzed by SDS-PAGE with an albumin as standard and subsequent Coomassie 
staining (Figure 11). The concentration of the protein was adjusted to 2 mg/ml and sent to 
Aldevron (Freiburg) for immunization of two rabbits. 57 days after immunization the animals 
were sacrificed. Sera of two rabbits were pooled and the antibody purified by protein A affinity 
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Figure 11: His-Kv10.2-CTerm protein concentration determination by SDS-PAGE  
3 µg, 5 µg, 10 µg, 15 µg and 20 µg albumin were loaded on a SDS-gel to serve as concentration standard. 
SDS-gel is shown loaded with 10 µl purified His-Kv10.2-CTerm maintained in 2 M guanidinium 
hydrochloride (GuHCl) and 2 M urea together with 1:5 dilutions of each approach. Subsequent 
Coomassie staining revealed a higher purity and protein concentration when eluted and dialyzed with 
GuHCl in comparison to urea.   
4.3 Determination of the specificity of the novel anti-Kv10.2 antibody 
4.3.1 Anti-Kv10.2 antibody recognizes its antigen in indirect ELISA 
Having generated a new antibody against Kv10.2, we first ensured that this antibody is 
specific for detection of its His-Kv10.2-CTerm antigen. In particular, we excluded cross-
reactivity towards Kv10.1. As the antigen was a His-tagged form of the Kv10.2 C-terminus, we 
also ruled out reactivity towards the His-tag. 
The interaction of the newly generated polyclonal IgG antibody towards its antigen 
was determined by indirect enzyme-linked immuno sorbent assay (ELISA) (Figure 12, black 
columns). To investigate cross-reactivity towards Kv10.1, we used H1X, a fusion protein of the 
pore and C-terminus of human Kv10.1 previously generated in our department (Hemmerlein et 
al., 2006). To investigate cross-reactivity of the anti-Kv10.2 antibody towards the His-tag, we 
used a His-tagged Ubiquitin C (UbcH5) protein as antigen. UbcH5 is a fusion protein of a 
member of the Ubiquitin C family with a C-terminal 6xHis-tag, which shares no homology with 
Kv10.2 determined by BLAST analysis (data not shown). All of the antigens were coated directly 




controls included detection of the antigens with either anti-Kv10.2 antibody (Figure 12, grey 































Figure 12: Analysis of binding specificity of anti-Kv10.2 antibody by ELISA 
The anti-Kv10.2 antibody (black columns) recognized the His-Kv10.2-CTerm antigen that was used for 
antibody generation. The antibody was also probed against H1X, a human Kv10.1 fusion protein. The 
affinity of the antibody was approximately 5 times higher to the His-Kv10.2-CTerm antigen than to H1X 
(Kv10.1). UbcH5His protein served as control for investigation of His-tag detection by the anti-Kv10.2 
antibody, which was not observed. Further controls included uncoated (PBS) wells or incubation of 
antigens with HRP labeled secondary anti-rabbit antibody only. Black columns: anti-Kv10.2 antibody and 
secondary HRP conjugated anti-rabbit antibody (anti-Rb). Grey columns: anti-Kv10.2 antibody, only. 
White columns: HRP conjugated anti-rabbit antibody only. Measurements performed in triplicates. *= P 
<0.01. Statistical significances were calculated with the one-way ANOVA and the Post hoc test of 
Tamhane. 
 
As shown in Figure 12, the anti-Kv10.2 antibody recognized the His-Kv10.2-CTerm 
protein applied for antibody generation (high significance, P <0.01) and bound to the H1X 
antigen (high significance, P <0.01). However, the signal obtained was approximately five times 
weaker in the H1X coated wells in comparison to wells coated with the His-Kv10.2-CTerm 
antigen. The anti-Kv10.2 antibody did not bind to the UbcH5 antigen. Since the signal obtained 
from the combination of the anti-Kv10.2 antibody together with the secondary antibody was at 
the same level compared to the controls, it can be concluded that the anti-Kv10.2 antibody did 




In summary, the Kv10.2 antibody binds to the His-Kv10.2-CTerm protein. With the 
indirect ELISA we could demonstrate weak cross-reactivity towards H1X, a Kv10.1 fusion 
protein representing the C-terminus of Kv10.1 and no interaction with the His-tag of the UbcH5 
protein. 
4.3.2 Anti-Kv10.2 antibody detects Kv10.2 in Western blot analysis 
To evaluate the specificity of the anti-Kv10.2 antibody in Western blot, we used cell 
lysates from human HEK293 Wt, HEK293 BBS-Kv10.1 and HEK293 BBS-Kv10.2 cells. 
Furthermore, total mouse brain lysates were applied on SDS-gel to verify recognition of mouse 
Kv10.2 by the newly generated antibody. The lysates derived from HEK293 Wt and HEK293 
BBS-Kv10.1 overexpressing cells served as controls. As shown in Figure 13, the anti-Kv10.2 
antibody detected a protein at the predicted molecular weight of 116 kDa in HEK293 BBS-
Kv10.2 overexpressing cells only. At this particular molecular weight, no protein was recognized 
in the controls (Figure 13, arrow). The anti-Kv10.2 antibody did not bind to BBS-Kv10.1. In total 
mouse brain lysate the antibody recognized a protein at approximately 112 kDa, the predicted 
molecular weight of Wt Kv10.2 (Figure 13). It is noteworthy, that the weight difference of 4 kDa 
between the BBS-Kv10.2 sample and the total brain lysate can be explained by the 27 amino 
acid (aa) sequence containing the α-bungarotoxin binding site in the BBS-Kv10.2 protein. 
Although partial recognition of Kv10.1 (H1X) by the anti-Kv10.2 antibody occurred in ELISA, 
cross-reactivity against Kv10.1 was not observed in Western blot analysis. A representative 
image of the whole Western blot is illustrated in the appendix section. We concluded that the 
anti-Kv10.2 antibody generated by us was sensitive to differentiate between Kv10.1 and Kv10.2 
protein and to detect the human Kv10.2 in samples of overexpressing Kv10.2 cells as well as 













Figure 13: Validation of binding of the newly-generated anti-Kv10.2 polyclonal antibody to Kv10.2 by 
Western blot analysis 
Western blot analysis of protein lysates from human HEK293 Wt, HEK293 BBS-Kv10.1 and HEK293 BBS-
Kv10.2 cells as well as from total mouse brain were performed in combination with anti-Kv10.2 antibody. 
Only in HEK293 BBS-Kv10.2 cell lysate the antibody detected a protein at the predicted molecular weight 
of BBS-Kv10.2, being approximately 116 kDa (arrow). In total brain lysate the antibody detected a 
protein of lower molecular weight (approximately 112 kDa) than in the HEK293 BBS-Kv10.2 sample, due 
to the 27 amino acid insert containing the BBS. Equal protein loading was determined by anti-α-tubulin 
(arrow). 
4.3.3 Anti-Kv10.2 antibody specifically detects Kv10.2 by the use of 
immunocytochemistry 
In order to determine the specificity of the Kv10.2 antibody to recognize human Kv10.2 
in immunostaining procedures, HEK293 Wt, HEK293 BBS-Kv10.1 and HEK293 BBS-Kv10.2 
overexpressing cells were grown on coverslips. Cells were fixed with paraformaldehyde, 
followed by the chromogenic immunocytochemistry (ICC) and counterstaining with 
hematoxylin was performed (Figure 14). Cells used as negative controls were treated without 
primary anti-Kv10.2 antibody (Figure 14G-I). The anti-Kv10.2 antibody only stained HEK293 BBS-
Kv10.2. As shown in Figure 14C and F an intracellular and membranal staining were observed. 
Not all HEK293 BBS-Kv10.2 cells were positive for Kv10.2 since the HEK293 BBS-Kv10.2 cells are 
not derived from a monoclonal cell line. Besides BBS-Kv10.2 overexpressing cells, none of the 





In summary, ICC performed with the novel polyclonal anti-Kv10.2 antibody resulted in 
an intracellular and membrane staining of HEK293 BBS-Kv10.2 cells only. In contrast to the 
result of the ELISA, but consistent with our Western blot data, no cross-reactivity towards 






Figure 14: Immunocytochemistry with anti-Kv10.2 antibody on HEK293 Wt, HEK293 BBS-Kv10.1 and 
HEK293 BBS-Kv10.2 overexpressing cells 
(A,D,G) HEK293 Wt, (B,E,H) HEK293 BBS-Kv10.1, (C,F,I) and HEK293 BBS-Kv10.2 cells were grown on 
coverslips and fixed. (A-F) ICC was performed on the cells by using anti-Kv10.2 antibody, secondary HRP 
conjugated anti-rabbit antibody and DAB substrate (brown) and counterstained with hematoxylin (blue). 
(A,D) HEK293 Wt and (B,E) HEK293 BBS-Kv10.1 cells were negative for Kv10.2. (C,F) Only HEK293 BBS-
Kv10.2 overexpressing cells were positively stained with the anti-Kv10.2 antibody, where Kv10.2 was 
detected in the cytoplasm and in the membrane of HEK293 BBS-Kv10.2 overexpressing cells (arrows). (G) 
Negative control of HEK293 Wt cells, only secondary anti-rabbit HRP conjugated antibody and DAB 
substrate was used where no signal was obtained. (H) Negative control of HEK293 BBS-Kv10.1 cells, only 
secondary anti-rabbit HRP conjugated antibody and DAB substrate was used where no signal was 
obtained. (I) Negative control of HEK293 BBS-Kv10.2 cells, only secondary anti-rabbit HRP conjugated 




4.4 Kv10.2 is virtually ubiquitously expressed in mouse tissues 
4.4.1 Kv10.2 protein is virtually ubiquitously expressed in various mouse tissues and 
brain regions 
Since the anti-Kv10.2 antibody specifically recognized a protein corresponding to Kv10.2 
protein in Western blot analysis using the HEK293 system, we applied the antibody in Western 
blot to analyze the endogenous expression of Kv10.2 in protein lysates from different organs 
(Figure 15B-D) and brain regions (Figure 16B,C) of the adult mouse. Moreover, we analyzed 
lysates of various organs (Figure 15A) and brain regions (Figure 16A) for Kcnh5 mRNA by qRT-
PCR.  
On every SDS-gel, we added protein lysates from the different HEK293 cells as controls 
as already described. Briefly, protein lysates of HEK293 Wt and HEK293 BBS-Kv10.1 served as 
negative controls while protein lysate of HEK293 BBS-Kv10.2 cells was used as positive control. 
The predicted molecular weight of Kv10.2 is 112 kDa. For internal control α-tubulin was 
detected with an anti-α-tubulin antibody. 
Of the tissue analyzed by qRT-PCR, trachea, adrenal gland and testes showed the 
highest mRNA levels of Kcnh5 (Figure 15A). Low or very low Kcnh5 mRNA levels were found in 
uterus, bladder, kidney, stomach, prostate and placenta. Colon, liver, heart and lung did not 
contain detectable levels of Kcnh5 transcripts.  
Since the anti-Kv10.2 antibody recognized a protein corresponding to Kv10.2 protein in 
Western blot analysis using the HEK293 system, we used the antibody to analyze the 
endogenous expression of Kv10.2 protein in protein lysates from different organs (Figure 15B-
D) and brain regions (Figure 16B,C) of the adult mouse in Western blot. As shown in Figure 
15B, protein lysates of pancreas, spleen, liver, kidney, heart and lung from adult mice were 
investigated. All organs were positive; a faint band at the expected molecular weight of Kv10.2 
was observed in the lung sample. Verification of equal protein loading, determined by anti-α-
tubulin antibody, revealed low protein amounts in lysates of pancreas, liver and kidney. 
Although the loading control showed low protein amounts in lysate of kidney, a protein of the 















































Figure 15: Kv10.2 mRNA and protein expression in organs of the adult mouse determined by qRT-PCR 
and Western blot analysis 
A: Kcnh5 mRNA distribution in mouse adrenal gland, testes, prostate, uterus, bladder, colon, heart, 




brain calibrator (expression =1, data not shown). Trachea, adrenal gland, testes had the highest mRNA 
levels of Kcnh5 of the tissue analyzed. Kcnh5 mRNA levels detected in uterus, prostate, placenta,  
bladder, stomach and kidney were low or very low, while qRT-PCR analysis of colon, liver, heart and lung 
and did not result in detectable transcripts of Kcnh5. B: Western blot analysis of spleen, kidney, heart 
and lung of adult mouse with anti-Kv10.2 antibody. Protein of the predicted molecular weight of Kv10.2 
(=112 kDa) was detected in all organs. C: Western blot analysis of bladder, intestine, salivary gland, 
thymus and trachea with anti-Kv10.2 antibody. Protein of the expected molecular weight of Kv10.2 (=112 
kDa) was detected in all organs. D: Western blot analysis of skeletal muscle, mammary gland, ovaries, 
prostate and testes of adult mouse with anti-Kv10.2 antibody. Protein of the predicted molecular weight 
of Kv10.2 (=112 kDa) was detected in all organs, except in testes. B-D: Equal protein loading was 
determined by anti-α-tubulin (arrows). HEK293 Wt and HEK293 BBS-Kv10.1 cell lysates served as 
negative and HEK293 BBS-Kv10.2 as positive controls. A protein of the predicted molecular weight of 
BBS-Kv10.2 (=116 kDa) was detected only in HEK293 BBS-Kv10.2 lysates. Arrows indicate approximate 
weight of BBS-Kv10.2 (=116 kDa) overexpressed in HEK293 BBS-Kv10.2 cells. 
Furthermore, bladder, intestine, stomach, salivary gland, thymus and trachea were 
analyzed (Figure 15C). In all tissues analyzed a band of the molecular weight corresponding to 
Kv10.2 was detected. A strong signal at the expected molecular weight of to Kv10.2 was 
observed in the sample of the thymus, albeit low protein loading was observed. In addition, we 
demonstrated that from the analyzed tissues of skeletal muscle, mammary glands, ovaries, 
prostate and testes, Kv10.2 was detected in the lysates of skeletal muscle, prostate and very 
faintly in the mammary glands and ovaries, while no Kv10.2 was observed in the testes (Figure 
15D).   
Next, we assessed Kv10.2 distribution in different regions of the CNS by qRT-PCR and 
Western blot analysis. As shown in Figure 16, on the mRNA and protein level, we detected a 
ubiquitious expression of Kv10.2 throughout the samples investigated. The qRT-PCR, which was 
normalized against total mouse brain calibrator, was performed on cortex, cerebellum, 
mesencephalon, hippocampus, spinal cord, brainstem, hypothalamus and striatum. Kcnh5 
transcription was most prominent in the cortex and striatum, while the lowest expression was 
found in the cerebellum (Figure 16A). Western blot analysis was performed on lysates of 
cortex, hippocampus, hypothalamus, thalamus and brainstem (Figure 16B), as well as on 
lysates of olfactory bulb, striatum, tectum, pituitary gland, cerebellum and spinal cord (Figure 
16C). All brain regions analyzed by Western blot were positive for Kv10.2 protein. Only in 
pituitary gland the protein was detected at low level, which might correlate to low protein 






































 Figure 16: Kv10.2 mRNA and protein expression in brain regions of the adult mouse by qRT-PCR and 
Western blot analysis 
A: Kcnh5 mRNA levels were analyzed by qRT-PCR in different regions of the mouse brain. All values were 
normalized to the total mouse brain calibrator (expression=1, data not shown). All brain regions 
investigated were positive for Kcnh5. Kcnh5 is abundantly expressed in the cortex and striatum, while 
the cerebellum showed the lowest amount of Kcnh5 transcripts. B: Western blot analysis of adult mouse 
total brain, cortex, hippocampus, hypothalamus, thalamus and brainstem with anti-Kv10.2 antibody. 
Protein corresponding to the predicted molecular weight of Kv10.2 (=112 kDa) was detected in total 
brain and all brain regions investigated. C: Western blot analysis of adult mouse olfactory bulb, striatum, 
tectum, pituitary gland, cerebellum and spinal cord with anti-Kv10.2 antibody. Protein of the expected 
molecular weight of Kv10.2 (=112 kDa) was detected in all brain regions investigated. B,C: Equal protein 
loading was determined by anti-α-tubulin (arrows). HEK293 Wt and HEK293 BBS-Kv10.1 cell lysates 
served as negative and HEK293 BBS-Kv10.2 as positive controls. A protein of the predicted molecular 
weight of BBS-Kv10.2 (=116 kDa) was detected only in HEK293 BBS-Kv10.2 lysates. Arrows indicate 




Taken together, qRT-PCR results indicates varying Kcnh5 transcript levels in different 
mouse organs, while all brain regions analyzed were Kcnh5 mRNA positive. Western blot 
analysis with the anti-Kv10.2 antibody revealed a ubiquitous expression of a protein of the 
predicted molecular weight of Kv10.2 in regions of the CNS such as cortex, hippocampus, 
hypothalamus, thalamus, brainstem, olfactory bulb, striatum, tectum, pituitary gland, 
cerebellum and spinal cord and various organs of mouse such as spleen, kidney, heart, 
bladder, intestine, salivary gland, thymus, trachea, skeletal muscle, mammary gland, ovaries, 
lung and prostate, with the exception of testes. 
4.4.2 Kv10.2 protein is localized to distinct regions in adult mouse brain 
The investigation of protein expression in mouse tissues by Western blot resulted in 
the detection of a protein of the predicted molecular weight of Kv10.2 in virtually all samples. 
We further analyzed the distribution and localization of Kv10.2 with the anti-Kv10.2 antibody by 
the use of immunohistochemistry (IHC) on adult mouse brain sections.  
As control, the tissues were incubated with secondary HRP conjugated anti-rabbit 
antibody and the detection system only. IHC in combination with the anti-Kv10.2 antibody 
resulted in a distinct staining pattern in the adult mouse brain (Figure 17A). Regions containing 
cells that stained positive for Kv10.2 include the mitral cell layer (Figure 18A, MCL) and the 
external plexiform layer of the olfactory bulb (Figure 17A, OB; Figure 18A). In the mitral cell 
layer the Kv10.2 staining suggests a localization of Kv10.2 to cell processes (Figure 18A, arrow) 
Kv10.2 protein in the cortex can be detected in the middle layers (Figure 17A, Cx; Figure 18B). 
Here, the results of the IHC suggested that the ion channel was localized to the membrane. 
Within the hippocampus the cornu ammonis area (CA) 3 and, to a lesser extend, CA2 were 
stained. Additionally the hilus was Kv10.2 positive (Figure 17A, Hil). Within the cerebellum, 
staining was observed in the Purkinje layer (Figure 18C, arrow) and the lateral cerebellar 
dentate nucleus (Figure 17A, Cdn) in the white matter. In the globus pallidus and thalamus, we 
detected Kv10.2 protein localization outside of cytoplasm of the cells (Figure 18D,E). Since the 
regions were intensely stained, a localization to the membrane was not possible. The intense 
staining was also observed in the amygdala, zona inserta, genicular nuclei and partially in the 
cochlear nuclei of the brainstem (Figure 18F). In contrast to the surrounding areas, the capsula 












































Figure 17: IHC analysis with anti-Kv10.2 antibody in adult sagittal mouse brain sections  
A: Kv10.2 protein expression pattern was detected by immunohistochemistry with anti-Kv10.2 antibody 
(NBT/BCIP; blue) on paraffin mouse brain sections with counterstain (NFR; red). Regions stained by IHC 
with the anti-Kv10.2 antibody are: olfactory bulb (OB), cortex (Cx), amygdala (Amg), thalamus (Th), zona 
incerta (ZI), globus pallidus (GP), medial genicular nucleus (MG), lateral geniclar nucleus (LG), brainstem 
(BrSt). The CA3 region of the hippocampus (Hip) and the hilus (Hil) were stained. Inside of the 
cerebellum (Cb) the piriform layer and the lateral cerebellar dentate nucleus (Cdn) were Kv10.2 positive. 
No staining was observed in the caudate putamen (CPu), dentate gyrus (DG) the internal capsula (IC), 
lateral ventricle (LV), olfactory cortex (OCx) and hippocampus (Hpc). B: The negative control, consisting 
of the HRP conjugated secondary anti-rabbit antibody, the detection system and counterstain (NRF; 
red), showed no staining. A,B: Paraffin sections obtained at 7 µm. Scale bar represents 1000 µm. 
IHC analysis of mouse brain performed with the anti-Kv10.2 antibody resulted in 
positive staining of the middle layers of the cortex and the cochlear nuclei of brainstem. 
Furthermore, the olfactory bulb, thalamus, globus pallidus, amygdala, zona inserta, genicular 
nuclei, middle layers of the cortex, CA3, CA2, hilus, choclear nucleus of the brainstem and 












Figure 18: IHC analysis with anti-Kv10.2 antibody in selected brain regions of the adult mouse  
A: Olfactory bulb: in the mitral cell layer (MCL) Kv10.2 was detected at the membrane of cells and in 
cellular processes (arrow). Granular cell layer (GCL) was negative for Kv10.2. B: Cortex: membrane 
staining was observed in a layer of cells that were positive for Kv10.2 (arrows). C: Cerebellum: Purkinje 
layer was Kv10.2 positive (arrow). Molecular layer (ML) and granular layer (GL) were Kv10.2 negative. D: 
Globus pallidus: IHC analysis resulted in neuropil staining, while the cell bodies (arrows) remained 
negative. It is indiscernible, if membranes of the cells were also stained. E: Thalamus: similar to the 
globus pallidus, IHC analysis resulted in neuropil staining, while the bodies of cells (arrows) were not 
stained. F: Brainstem: Cells of the cochlear nucleus were stained (arrow). A-F: IHC performed with anti-
Kv10.2 antibody (NBT/BCIP; blue) in paraffin mouse brain sections with counterstain (NFR; red). Sections 
obtained at 7 µm. Scale bar represents 20 µm. 
4.4.3 Kcnh1 mRNA is ubiquitously expressed in the murine brain 
Since favorable controls like tissue sections of Kv10.2 knockout mice were not available 
and blocking experiments could not be performed, cross-reactivity of the anti-Kv10.2 antibody 
against other proteins cannot be ruled out. 
As another approach, in order to have a further proof of Kv10.2 detection by the anti-
Kv10.2 antibody, we wanted to compare the expression pattern of Kcnh5 in brain slices on 




obtain a specific protocol for the Kcnh5 probe, we first established the Kcnh1 ISH probe. Since 
a Kcnh1 total knockout mouse (Ufartes et al., 2013), was available in our department that 
served as negative control, the Kcnh1 probe was used as a reference. Moreover, Kv10.1 protein 
distribution in rat brain is already published, allowing correlation of protein and mRNA 
distribution. 
Kcnh5 and Kcnh1 ISH riboprobes were designed to fulfill the following criteria: First, 
sequences of the probes were specific for their targets in mouse and rat, which were validated 
by BLAST analysis. Second, probes were designed virtually equal in size and base pair content, 
indicating highly similar ISH parameters required for specific annealing.  
Both probes were digoxigenin labeled mRNA, which were obtained by in vitro 
transcription. The Kcnh1 probe was 66 bases and the Kcnh5 probe 63 bases in length. DNA 
templates were amplified by primers, which were directly linked to T7 promoters on the 5’ end 
of either forward or reverse primers. Sequencing validated amplification products obtained. 
Following in vitro transcription, mRNA probes were analyzed by agarose gel electrophoreses 
(data not shown). To investigate the specificity and cross reactivity of the probes, a dot blot 
assay was performed with the antisense probes (see Appendix section), which resulted in 
specific probe annealing. 
Strong hybridization with the Kcnh1 antisense probe was seen in piriform cortex 
(Figure 19, Pfc), hippocampus (Figure 19, Hip), dentate gyrus (Figure 19, DG) and cerebellum 
(Figure 19A, Cb). Application of Kcnh1 antisense and sense probe resulted in high background 
staining on adult Wt mouse brain sections (Figure 19A,B). The signal obtained with the sense 
probe partially outlined the same brain regions as detected with the antisense probe, but only 
slightly above the background level (Figure 19B). Both ISH probes did not hybridize to any 














Figure 19: mRNA distribution of Kcnh1 in adult mouse brain determined by ISH 
A: In Situ hybridization with the Kcnh1 antisense RNA probe detected Kcnh1 transcripts ubiquitously 
throughout the wild type mouse brain. The strongest expression is detected in the piriform cortex (Pfc), 
hippocampus (Hip), dentate gyrus (DG) and cerebellum (Cb). B: The Kcnh1 sense probe applied on Wild 
type section revealed a high background staining. C: Antisense Kcnh1 RNA probe did not result in any 
signal obtained in the Kcnh1 deficient mouse. D: Sense Kcnh1 RNA probe did not result in any signal 
obtained in the Kcnh1 deficient mouse. A-D: ISH performed with Kcnh1 ISH probes (NBT/BCIP; blue) on 




In order to correlate the mRNA expression pattern with published protein expression 
pattern, we performed ISH on adult rat brain sections. Similar to our observation in the mouse 
brain, we detected Kcnh1 transcripts ubiquitously in the rat brain (Figure 20A). This is in 
perfect accordance to published IHC results for Kv10.1 protein distribution (see Introduction 
section). The strongest expression detected was in the cortex, cerebellum, dentate gyrus, 
hippocampus, olfactory bulb, the olfactory cortex and brainstem. Also a strong signal was 
visible in the olfactory tubercle and in the Purkinje cells and granular layer of cerebellum. The 





Figure 20: Kcnh1 mRNA distribution in adult rat brain determined by ISH 
A: ISH with Kcnh1 antisense probe detected transcripts ubiquitously in the adult rat brain. The highest 
levels of transcripts were observed in the cortex, cerebellum, dentate gyrus, hippocampus, olfactory 
bulb, brainstem and the olfactory cortex. B: Application of the sense probe led to weak background 
staining all over the rat brain. A,B: ISH performed with Kcnh1 ISH probes (NBT/BCIP; blue) on paraffin-
acrolein sagittal rat brain sections obtained at 7 µm. Scale bar represents 1000 µm. 
For Kcnh1 we showed that the detected mRNA distribution correlates with published 
protein distributions in rat. The next step was to establish ISH for Kcnh5 in order to investigate 








Figure 21: Kcnh5 mRNA distribution in mouse brain determined by ISH 
Application of the (A) Kcnh5 antisense and (B) sense probe resulted in similar signals and patterns 
obtained by ISH. The Kcnh5 sense probe, serving as negative control, hybridized in virtually the same 
pattern as the antisense probe. Especially in the piriform cortex application of the antisense and sense 
probes resulted in strong signals (A,B arrow). A,B: ISH performed with Kcnh5 ISH probes (NBT/BCIP; 
blue) on paraffin mouse brain sections obtained at 7 µm and counterstained with NFR (red). Scale bar 
represents 500 µm.  
ISH for Kcnh5 on mouse brain sections was performed with the same protocol established 
for the Kcnh1 probe. Since no Kcnh5 knockout mouse was available, the negative control for 
Kcnh5 antisense probe was the sense probe. The use of the Kcnh5 antisense probe hybridized 
in similar pattern as obtained by to the sense probe (Figure 21A,B). In order to obtain 
specificity of the antisense probe, we:  
1. increased hybridization temperature,  
2. increased temperature of washing steps,   
3. combined 1 and 2, 
4. titrated the probes, 
5. shortened the hybridization time. 
None of these these steps were successful. Temperatures of hybridization and washing 
steps below 56°C resulted in hybridization of the sense probe, while temperatures above 56°C 
did not lead to hybridization signals obtained by the antisense probe. Therefore, 





With the lack of specificity of the Kcnh5 ISH probe, we were not able to investigate the 
cellular Kcnh5 mRNA distribution to correlate it with its protein distribution.  
4.4.4 Kv10.2 protein is expressed during mouse brain development 
So far, we investigated the Kv10.2 protein distribution on the adult mouse by Western 
blot analysis and IHC. Preliminary data of our group indicate an embryonic lethality of the 



















Figure 22: Kv10.2 expression in developing and postnatal mouse brain by Western blot analysis 
A: Western blot analysis of protein lysates of embryonic (E) mouse stages E 8, E 10, E 12, E 13, E 14 and 
E 15 for Kv10.2 protein expression. Protein at the predicted molecular weight of Kv10.2 (=112 kDa) was 
detected in all E stages investigated. B: Western blot analysis of protein lysates of embryonic (E) mouse 
stages E 16, E 17, E 18 and E 19 and postnatal (PN) stages PN 0 and PN 10 for Kv10.2 protein expression. 
Protein at the predicted molecular weight of Kv10.2 (=112 kDa) was detected in all E and PN stages 
investigated. A,B: Equal protein loading was determined by anti-α-tubulin (arrows). HEK293 Wt and 
HEK293 BBS-Kv10.1 cell lysates served as negative and HEK293 BBS-Kv10.2 as positive controls. A protein 
of the expected molecular weight of Kv10.2 was detected only in HEK293 BBS-Kv10.2 lysates. Arrows 




To investigate the temporal expression of Kv10.2 during brain development, total brain lysates 
of embryonic (E) stages E 8, E 10, E 12 until E 19 and postnatal (PN) stages, PN 0 and PN 10, 
were investigated by Western blot analysis with the anti-Kv10.2 antibody. Throughout all 
embryonic stages tested here we could detect a protein of predicted molecular weight of 
Kv10.2 (= 112 kDa) in the developing mouse brain (Figure 22A,B). The same was observed in 
the total brain lysates of PN 0 and PN 10 (Figure 22B). Protein lysates of HEK293 Wt, HEK293 
BBS-Kv10.1 and HEK293 BBS-Kv10.2 cells were used as negative and positive controls, 
respectively and applied on every SDS-gel. 
Concluding, we demonstrated a Kv10.2 expression starting from the earliest time point 
of embryonic tissue investigated, E 8, until postnatal stage PN 10. 
Next, we assessed the spatial distribution of Kv10.2 protein in embryonic mouse stages 
using IHC. According to the Western blot analysis, E 8.5 and later embryonic stages are positive 
for Kv10.2. To analyze not only the embryos but also the maternal supplementing tissue, the 
uteri of E 8.5, E 9.5 and E 11.5 pregnant mice were sectioned and stained for Kv10.2 (Figure 
23A, Figure 24A, Figure 25A). At E 8.5 the primitive ectoderm of the implanted blastocyst has 
generated the germ layers. After the gastrulation, the organogenesis follows when tissues and 















Figure 23: Kv10.2 protein distribution in the embryo and in uterine tissue of mouse embryonic stage 
8.5 determined by IHC 
A: Detection of Kv10.2 protein distribution in embryonic stage (E) 8.5, determined by anti-Kv10.2 
antibody. The embryo (E), placenta (Pl) and visceral yolk sac (VYS) were Kv10.2 positive. The uterus (U) 
remained negative except for a cell layer towards the embryo. B: Negative control of E 8.5 embryo: 
Secondary HRP conjugated anti-rabbit antibody and detection system was applied; no staining was 
observed. A,B: Sections were counterstained with NFR. Paraffin sections obtained at 7 µm. Scale bar 















Figure 24: Kv10.2 protein distribution in the embryo and in uterine tissue of mouse embryonic stage 
9.5 determined by IHC 
A: Detection of Kv10.2 protein distribution in E 9.5, determined by anti-Kv10.2 antibody. The embryo (E), 
visceral yolk sak (VYS), amnion (A) and placenta (Pl) were positive for Kv10.2. The uterus (U) remained 
negative except for a cell layer towards the embryo, possibly the endometrium. B: Negative control of E 
9.5 embryo: Secondary HRP conjugated anti-rabbit antibody and detection system was applied; no 
staining was observed. A,B: Sections were counterstained with NFR. Paraffin sections obtained at 7 µm. 
Scale bar represents 500 µm. 
 
Negative controls were treated without primary anti-Kv10.2 antibody (Figure 23B, 
Figure 24B, Figure 25B). In all three embryonic stages, E 8.5, E 9.5 and E 11.5, the uterus (U) 
was mainly Kv10.2 negative except for a cell layer towards the embryo (Figure 23A, Figure 24A, 
Figure 25A). Furthermore, the placenta (Pl) and the visceral yolk sack (VYS) were Kv10.2 
positive (Figure 23A, Figure 24A, Figure 25A). Also the embryos of all stages investigated, 
ubiquitously express Kv10.2, except for the E 11.5 embryo in which the developing cartilage of 
the spinal cord was negative (Figure 25A). At E 11.5 the parietal yolk sac (PYS) was Kv10.2 
















Figure 25: Kv10.2 protein distribution in the embryo and in uterine tissue of mouse embryonic stage 
11.5 determined by IHC 
A: Detection of Kv10.2 protein distribution in E 11.5, determined by anti-Kv10.2 antibody. The embryo 
(E), placenta (Pl), visceral yolk sac (VYS) and parietal yolk sac (PYS) were positive for Kv10.2. The amnion 
(A) and the uterus (U) remained negative except a region at the rostral side between the placentas. The 
umbilical cord (UC) remained negative. B: Negative control of E 11.5 embryo: Secondary HRP conjugated 
anti-rabbit antibody and detection system was applied; no staining was observed. A,B: Sections were 
counterstained with NFR. Paraffin sections obtained at 7 µm. Scale bar represents 500 µm. 
In summary, Kv10.2 is virtually ubiquitously expressed in the fetal mouse as well as in 




4.4.5 Kv10.2 protein expression is not altered in brain regions of Kcnh1 total 
knockout mice 
The Kcnh1 total knockout mouse was previously generated in the lab. Behavior studies 
of the Kcnh1 total mouse demonstrated a mild hyperactive phenotype (Ufartes et al., 2013). 
We investigated if Kv10.2 expression was regionally altered in the homozygous Kcnh1 total 
knockout mouse compared to Wt mouse. Therefore, we immunoblotted protein derived from 
different brain regions of the homozygous Kcnh1 total knockout mouse to analyze a regional 
differences in Kv10.2 expression. For internal control tubulin was detected with an anti-α-
tubulin antibody (Figure 26A,B). HEK293 BBS-Kv10.1 and HEK293 BBS-Kv10.2 cells served as 
positive and negative controls, respectively. Brain regions investigated included brain stem, 
thalamus, hypothalamus, hippocampus, cortex, olfactory bulb, striatum, tectum, pituitary 
gland, cerebellum and spinal cord (Figure 33A,B).  
To investigate differential regulation of Kv10.2 protein expression in the Kcnh1 total 
knockout mouse, we directly compared protein lysates of the olfactory bulb, cortex, brain 
stem, cerebellum, tectum, and striatum from Kcnh1 total knockout mouse with the 
appropriate Wt mouse brain regions by Western blot analysis (Figure 27A,B). In all analyzed 
brain regions, with the exception of tectum and striatum, no obvious difference in Kv10.2 
protein levels were detected. To further analyze possibly altered protein levels, we performed 
densitometric analysis (Figure 27C) of Kv10.2 expression normalized to detected actin. As a 
result, only in samples of the tectum and striatum a difference was found. In the tectum the 
homozygous Kcnh1 total knockout mouse had lower levels of Kv10.2, while in the striatum it 
was vice versa. It is noteworthy, that the diffuse band of 120 – 150 kDa observed in the tectum 
could have altered the result. The results are only an indicator that no difference in protein 
levels of Kv10.2 in the homozygous Kcnh1 knockout exists, since only one sample of each 























Figure 26: Western blot analysis with anti-Kv10.2 antibody of brain regions of the Kcnh1 complete 
knockout mouse  
A: Western blot analysis with anti-Kv10.2 antibody of adult homozygous Kcnh1 total mouse total brain, 
cortex, hippocampus, hypothalamus, thalamus and brainstem. Protein of the predicted molecular 
weight of Kv10.2 (=112 kDa) was detected in all brain regions investigated. B: Western blot analysis with 
anti-Kv10.2 antibody of adult homozygous Kcnh1 total knockout mouse olfactory bulb, striatum, tectum, 
pituitary gland, cerebellum and spinal cord with anti-Kv10.2 antibody. Protein of the predicted molecular 
weight of Kv10.2 (=112 kDa) was detected in all regions investigated. A,B: Equal protein loading was 
determined by anti-α-tubulin (arrows). HEK293 Wt and HEK293 BBS-Kv10.1 cell lysates served as 
negative and HEK293 BBS-Kv10.2 as positive controls. A protein of the predicted molecular weight of 
BBS-Kv10.2 (=116 kDa) was detected only in HEK293 BBS-Kv10.2 lysates. Arrows indicate approximate 
weight of BBS-Kv10.2 (=116 kDa) overexpressed in HEK293 BBS-Kv10.2 cells. 
In summary, the investigation of the Kv10.2 expression in Kcnh1 total knockout mouse 
did not show a clear upregulation of the protein detected by the anti-Kv10.2 antibody due to 
the loss of Kv10.1. Furthermore, detection by anti-Kv10.2 antibody did not result in a regional 















































Figure 27: Western blot analysis with anti-Kv10.2 antibody of brain regions of the homozygous Kcnh1 
total knockout mouse compared to Wt mouse 
A: Protein lysates of adult mouse olfactory bulb, cortex and brainstem of Wt and homozygous Kcnh1 




) were immunoblotted and analyzed for Kv10.2 expression with the anti-
Kv10.2 antibody. No obvious differences of protein levels of Kv10.2 in Wt and Kv10.1 deficient mouse 








) were immunoblotted and analyzed for Kv10.2 expression 
with the anti-Kv10.2 antibody. No obvious differences of protein levels of Kv10.2 in Wt and Kv10.1 
deficient mouse were found. A,B: Equal protein loading determined by anti-actin revealed no 
differences in protein loading (arrows). HEK293 Wt and HEK293 BBS-Kv10.1 cell lysates served as 
negative and HEK293 BBS-Kv10.2 as positive controls. A protein of the predicted molecular weight of 
BBS-Kv10.2 (=116 kDa) was detected only in HEK293 BBS-Kv10.2 lysates. Arrows indicate approximate 
weight of BBS-Kv10.2 (=116 kDa) overexpressed in HEK293 BBS-Kv10.2 cells. C: Densitometric analysis of 
Kv10.2 protein expression in different regions of adult Wt and Kcnh1 total knockout mouse. Kv10.2 
expression is presented as % of actin. No standard deviation was performed (N=1). Only in the tectum 
and striatum a difference of Kv10.2 protein level between Wt and Kcnh1 total knockout mouse was 
observed.  
4.5 Investigation of a possible physiological function of Kv10.2 
4.5.1 LoxP construct of Kcnh5 conditional knockout mouse was non-functional 
In order to address the physiological function of Kcnh5 and to avoid the embryonic 
lethality, we decided to use a conditional knockout mouse. Therefore, our lab generated a 
floxed Kcnh5 mouse. This mouse possessed loxP sites flanking the exon 7 of Kcnh5. Cross 
breading of this knockout mouse strain with a Cre-recombinase expressing mouse would result 
in excision of exon 7 leading to a truncated protein with no channel conducting properties. A 
Cre-recombinase under the control of the Emx1 promoter was chosen to inactivate Kcnh5 in 
the developing and mature neurons of the cortex. Surprisingly, qRT-PCR analysis of cDNA of 
the adult homozygous Kcnh5 conditional knockout mouse cortex cross-bred with Emx1-Cre in 
comparison to Wt mouse cortex resulted in no change of Kcnh5 expression (Figure 28A). To 
verify the correct loxP construct and the deletion of exon 7, a genomic DNA amplification of 
exon 7 with the floxed loxP sites was performed. In the Wt mouse this would result in an 
amplification product of approximately 950 bp, while a 450 bp amplification product was 
expected in the conditional knockout mouse lacking exon 7. The PCR performed resulted in 
amplification of a 950 bp product in the Wt mouse and the homozygous Kcnh5 conditional 
knockout, indicating no functional loxP construct in the Kcnh5 conditional knockout mouse 
(Figure 28B). Therefore, no conditional Kcnh5 knockout mouse was available for further 
































Figure 28: Kcnh5 mRNA expression the cortex of Wt and homozygous Kcnh5 conditional knockout 
mice determined by qRT-PCR and PCR amplification of the genomic loxP construct of Wt and Kcnh5 
conditional knockout mice 
A: Kcnh5 mRNA levels were analyzed by qRT-PCR in homozygous Kcnh5 conditional knockout mice cross-
bred with Emx1-Cre. No difference in Kcnh5 expression in the homozygous conditional knockout mouse 
in comparison to Wt mouse was detected. All values were normalized to the total mouse brain 
calibrator (expression =1, data not shown). B: PCR analysis of cDNA of mouse Wt cortex and of 
homozygous Kcnh5 conditional knockout mouse cortex cross-bred with Emx1-Cre spanning exon 6 – 8. 
No genomic alteration was detected after 30 cycles of amplification.  
4.5.2 Kcnh5 is expressed in primary astrocyte cultures  
Since no constitutive or conditional Kcnh5 knockout mouse was available to study the 
function of Kv10.2 we tried to identify cell lines expressing Kcnh5 for functional analysis of 
Kv10.2 in vitro. Therefore, we evaluated its mRNA expression in in-house available cell lines 
derived from the CNS. We further assessed Kcnh5 expression in primary astrocytic and 
oligodendrocytic cell cultures prepared from newborn mice.  
We investigated neuronal cell lines like Neuro 2a (N2a), 108CC05 and 108CC15. The 
latter two are clones of a fused mouse neuroblastoma with rat glioma hybrid cell line, which 
mimic neurons for electrophysiological studies (Prof. Hamprecht, personal communication). In 
N2a cells no transcripts of Kcnh1 and Kcnh5 (Figure 29A) were detected. Both clones, 108CC05 
and 108CC15, were also negative for Kcnh5 and had a low expression of Kcnh1 compared to 
our total mouse brain calibrator (Figure 29A). Therefore, we did not find Kcnh5 transcripts in 
mouse cell lines derived from glioblastoma. To investigate if Kcnh5 is expressed in cell lines 
originating from other neural cell populations, cDNA of the immortalized oligodendrocytic 
precursor cell line Oli-neu was analyzed by PCR for Kcnh1 and Kcnh5 expression. PCR analysis 
was performed due to the low quantity of cDNA. After 30 cycles of PCR no amplification 




were successfully amplified in total mouse brain cDNA. Amplification of hypoxanthine 
phosphoribosyltransferase (HPRT) served as an internal control and resulted in comparable 
levels of Oli-neu cDNA to the mouse total brain cDNA (Figure 29B).  
In addition to cell lines, we further obtained two different primary astrocyte cell 
preparations and in vitro differentiated oligodendrocytes from the Cellular Neuroscience 
Group (Max Planck Institute of Exp. Medicine). These cells were prepared from newborn mice 
(PN 0) and had a purity of approximately 95% (Sebastian Schmitt, personal communication) 
and were analyzed by qRT-PCR (Figure 29). We detected a high expression of Kcnh5 in primary 
astrocytic cell cultures (Figure 29C). In differentiated primary oligodendrocyte cell cultures, the 
Kcnh5 expression was low compared to the mouse brain calibrator (Figure 29C). Kcnh1 
transcripts were also detected in both astrocytic cell cultures, but virtually absent in 
oligodendrocytes (Figure 29C).  
In summary, no transcripts of Kcnh5 were detected in all the cell lines investigated. 
Yet, in vitro primary astrocyte cultures express Kcnh5 while differentiated oligodendrocytes 























































Figure 29: mRNA expression of Kcnh5 and Kcnh1 in neural mouse cell lines and in primary astrocytic 
and differentiated oligodendrocytic cell cultures 
A: qRT-PCR analysis of 108CC05 and 108CC15 showed a low Kcnh1 mRNA expression (black columns) 
with no detectable Kcnh5 transcripts (grey columns). N2a cells were negative for both Kcnh channels. All 
values were normalized to the total mouse brain calibrator (expression =1, data not shown). B: Kcnh1 
and Kcnh5 RT-PCR analysis on cDNA from Oli-neu cells resulted in no amplification of either channel. 
HPRT as housekeeping gene indicated equal amount of cDNA in the Oli-neu and control total mouse 
brain probe. Kcnh1 and Kcnh5 were amplified in the control reaction, with total mouse brain cDNA as 
template. C: Two separate astrocyte cell cultures (1 and 2) and differentiated oligodendrocytes were 
analyzed for Kcnh1 (black columns) and Kcnh5 (grey columns) mRNA expression. All values were 
normalized to the total mouse brain calibrator (expression =1, data not shown). In vitro astrocytes 
express Kv10.2 abundantly. Oligodendrocytes cultured are positive for Kv10.2 mRNA, in respect to 
cultured astrocytes and total brain calibrator to a low extend. Kcnh1 expression is low in primary 




4.6 Kv10.2 protein was shown to preferentially localize to neurons in the 
mouse brain  
We demonstrated that in vitro Kcnh5 is expressed on the mRNA level in primary 
cultured astrocytes. Therefore, we further wanted to unravel, if the channel is also expressed 
in astrocytes in the mouse brain. To do so, IHC analysis with anti-Kv10.2 antibody was 
performed on vibratome brain sections of transgenic heterozygous GFEA mice, which have 
human GFAP-driven expression of enhanced green fluorescent protein (eGFP) in astrocytes. In 
the cortex, no overlapping expression of Kv10.2 and eGFP positive cells was observed (Figure 
30A-C). In the cerebellum, Kv10.2 did not co-localize with the majority of eGFP positive cells 
(Figure 30D-F, arrows F). This indicates that Kv10.2 is not expressed in astrocytes of the cortex 
as well as in the majority of astrocytes of the cerebellum of the adult mouse. The negative 
control performed with secondary Alexa-633 conjugated anti-rabbit antibody only resulted in 
no positive signal (Figure 30G-I). 
To further investigate the localization of Kv10.2 to specific cell populations of the brain, 
we used the anti-Kv10.2 antibody in IHC on sagittial vibratome sections of transgenic 
heterozygous TYFF mice, which have thy1-driven expression of enhanced yellow fluorescent 
protein (eYFP) in neurons. There, the IHC showed localization of Kv10.2 to neurons of the 
middle layers of the mouse cortex (Figure 31A-C, arrows). Results obtained from IHC on TYFF 
cerebellar sections suggest a Kv10.2 localization to the soma and cell membrane of the Purkinje 
layer (Figure 31D-F, arrows). Within the hippocampus, results of the IHC analysis indicates that 
Kv10.2 localizes to the soma and to the membrane of eYFP positive neurons (Figure 31G-I, 
arrows). In the analyzed brain regions, especially in the cortex, only few cells were eYFP 
positive, suggesting not all neurons expressed eYFP. The negative control, performed with 
secondary Alexa-633 conjugated anti-rabbit antibody on cortical mouse brain section of eYFP 
positive neurons (Figure 31J-L), resulted in no signal. The negative controls of the hippocampus 
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Figure 30: IHC analysis with anti-Kv10.2 antibody in cortex and cerebellum of transgenic heterozygous 
GFEA mouse brain 
Flourescent IHC analysis of transgenic heterozygous GFEA sagittal vibratome sections of mouse cortex 
and cerebellum performed with anti-Kv10.2 antibody. A-C: Cortex: (A) Staining obtained by anti-Kv10.2 
antibody in (B) cortical section with eGFP positive astrocytes. (C) No co-localization of eGFP positive cells 
and Kv10.2 was observed. D-F: Cerebellum: (D) Kv10.2 staining in (E) cerebellar section with eGFP 
positive astrocytes resulted (F) in a small population of Kv10.2 positive astrocytes. Kv10.2 positive cells 
were detected in the Purkinje layer (F, arrows) and in the granular layer (GL). (ML = molecular layer). G-I: 
Cortex: IHC performed (G) with Alexa-633 conjugated secondary anti-rabbit antibody only, serving as 
negative control, in (H) cortical section with eGFP positive astrocyte mouse brain sections, resulted in (I) 























Figure 31: IHC analysis with anti-Kv10.2 in selected brain regions of transgenic heterozygous TYFF 
mouse  
IHC analysis of heterozygous transgenic TYFF sagittal section of mouse cortex, hippocampus and 
cerebellum performed with anti-Kv10.2 antibody. A-C: Cortex: (A) Staining obtained by anti-Kv10.2 
antibody in (B) section of the cortex with eYFP positive neurons (C, arrows) suggests a localization of 
Kv10.2 to the soma and the membrane of neurons. D-F: Cerebellum: (D) Kv10.2 staining of (E) cerebellar 
section with eYFP positive neurons indicating (F, arrows) a soma and membrane localization of Kv10.2 in 
the Purkinje layer. Few cells were Kv10.2 positive in the molecular layer (ML) and the granular layer (GL) 
(F). G-I: Hippocampus (Hpc): (G) Kv10.2 expressing cells and (E) eYFP positive neurons of the 
hippocampus were co-localizing (I). The staining suggests a localization of Kv10.2 to the soma, 




conjugated secondary anti-rabbit antibody only, serving as negative control, in (H) cortical section with 
eGFP positive astrocyte mouse brain sections, resulted in (I) no specific staining. (L). A-L: Sagittal 
vibratome sections were obtained at 25 µm. Scale bar represents 50 µm. 
In order to further analyze Kv10.2 expression in other cell types of the CNS, we 
performed IHC on transgenic heterozygous CXCR mice, which have CX3CR1-driven expression 
of enhanced green fluorescent protein (eGFP) in microglia. Kv10.2 did not co-localize to 
CX3CR1 positive microglia in the cortex (Figure 32A-C), cerebellum (Figure 32D-F) and the 
hippocampus (Figure 32G-I) of CXCR mice. All Kv10.2 expressing cells were morphologically 
different than eGFP positive microglia. The negative control, performed with secondary 
antibody Alexa-633 on cortical mouse brain section sections of CXCR mice (Figure 32H-J), 
resulted in no specific signal. For negative controls of the hippocampus and the cerebellum 
with secondary Alexa-633 conjugated anti-rabbit antibody only see appendix. 
In summary, Kv10.2 protein was shown to localize preferentially to neurons in cortex, 





A anti-Kv10.2 B CXCR C Merge
D anti-Kv10.2 E CXCR F Merge
G anti-Kv10.2 H CXCR I Merge






Figure 32: IHC analysis with anti-Kv10.2 antibody in selected brain regions of heterozygous transgenic 
CXCR mouse  
IHC analysis of heterozygous transgenic CXCR sagittial mouse sections performed with anti-Kv10.2 
antibody. A-C: Cortex: (A) Staining obtained by anti-Kv10.2 antibody in (B) cortex with eGFP positive 
microglia (C) showed no co-localization. D-F: Cerebellum: (D) Kv10.2 immunoreactive cells and (E) eGFP 
positive microglia of the cerebellum (F) were not co-localization. G-I: Hippocampus (Hpc): (G) Kv10.2 
expressing cells and (H) eGFP positive microglia of the hippocampus showed (I) no co-localization. J-L: 
Cortex: (J) Negative control cortical section with secondary Alexa-633 conjugated anti-rabbit antibody 
only on (K) eGFP positive microglia resulted in no specific staining (L). A-L: Sagittal vibratome sections 




4.7 The anti-Kv10.2 antibody recognized a cilia-like structure 
So far, we were able to show, that the anti-Kv10.2 antibody only labeled neurons in the 
investigated regions of the mouse brain. To further localize the cellular localization of Kv10.2, 
we performed chromogenic IHC analysis of lung and liver sections of the adult mouse. As 
shown in Figure 33, we found only a weak staining of lung epithelial cells. Interestingly, 
staining of cilia-like protrusions of the cells was observed (Figure 33A, arrows). The structure 
recognized by the anti-Kv10.2 antibody had a high similarity with the structures detected when 
applying an anti-acetylated tubulin antibody in IHC (Figure 33C, arrows). The anti-acetylated 
tubulin is reported marker, besides others, of cilia and the primary cilium of every cell (Alieva 





Figure 33: Anti-Kv10.2 antibody recognizes cilia-like cellular protrusion in epithelial cells of mouse lung 
by IHC analysis 
A: Chromogenic IHC analysis of mouse lung sections performed with anti-Kv10.2 antibody (NBT/BCIP, 
blue) resulted in a staining of epithelial cells and of a cilia-like structure (red arrows). B: Negative 
control, consisting of the HRP conjugated secondary anti-rabbit antibody and the detection system, 
showed no staining. C: IHC analysis of mouse lung sections performed with anti-acetylated tubulin 
antibody (NBT/BCIP, blue) resulted in a staining of epithelial cells and a cilia-like structure similar to the 
structure detected by anti-Kv10.2 antibody (red arrows). D: Negative control, consisting of the secondary 
HRP conjugated anti-mouse antibody and the detection system, showed no staining. A-D: Sections were 




After detection of this cilia-like structure in lung sections with the anti-Kv10.2 antibody, 
we wanted to perform further IHC analysis to investigate if the anti-Kv10.2 antibody also 
recognizes the cilia of cells of different tissue. Hence, we analyzed liver sections by IHC. Cells of 
the liver only have one cilium, which is the primary cilium. Again, we observed staining of cilia-
like protrusions of the cells (Figure 34A, arrows), which were similar to the staining obtained 
when using the anti-acetylated tubulin antibody (Figure 34C, arrows). Therefore, this finding 
suggests, that the anti-Kv10.2 antibody might stain in IHC analysis a structure corresponding to 





Figure 34: Anti-Kv10.2 antibody recognizes cilia-like cellular protrusion in mouse liver by IHC analysis 
A: Chromogenic IHC analysis of mouse liver sections performed with anti-Kv10.2 antibody (NBT/BCIP, 
blue) resulted in a staining of a cilia-like structure (arrows). B: Negative control, consisting of the 
secondary HRP conjugated anti-rabbit antibody and the detection system, showed no staining. C: 
Chromogenic IHC analysis of mouse liver sections performed with anti-acetylated tubulin antibody 
(NBT/BCIP, blue) resulted in a staining of a cilia-like structure similar to the structure detected by anti-
Kv10.2 antibody (arrows). D: Negative control, consisting of the secondary HRP conjugated anti-mouse 
antibody and the detection system, showed no staining. A-D: Sections were counterstained with NFR. 
Paraffin sections obtained at 7 µm. Scale bar represents 10 µm.  
Further chromogenic IHC analysis on mouse brain sections resulted in stained cilia-like 
protrusions of the cells in the mouse cortex and cerebellum (Figure 35A,C, arrows). These cilia- 









Figure 35: Anti-Kv10.2 antibody recognizes cilia-like structures in mouse cortex and cerebellum by IHC 
analysis 
A: Chromogenic IHC analysis of mouse cortical section performed with anti-Kv10.2 antibody (NBT/BCIP, 
blue) resulted in a staining of a cilia-like structure (arrows). B: IHC analysis of the cerebellum of mouse 




arrows). C: IHC analysis of mouse cortical section performed with anti-adenylyl cyclase III (ACIII) 
antibody (NBT/BCIP, blue) resulted in a staining of a cilia-like structure similar to the structure detected 
by anti-Kv10.2 antibody (arrows). D: IHC analysis of mouse cortical section performed with anti-ACIII 
antibody (NBT/BCIP, blue) resulted in a staining of a cilia-like structure similar to the structure detected 
by anti-Kv10.2 antibody (arrows). E: Negative control of cortex section, consisting of the secondary HRP 
conjugated anti-rabbit antibody and the detection system, showed no staining. F: Negative control of 
the cerebellum, consisting of the secondary HRP conjugated anti-rabbit antibody and the detection 
system, showed no staining. A-F: Sections were counterstained with NFR. Paraffin sections obtained at 7 
µm. Scale bar represents 10 µm.  
anti-adenylyl cyclase III (ACIII) in IHC analysis of the same regions (Figure 35C,D arrows).  ACIII 
is a known marker for primary cilia of the cells of the brain (Bishop et al., 2007). Comparing the 
staining pattern obtained by the antibody against acetylated tubulin and ACIII with the staining 
obtained by our antibody we found that the anti-Kv10.2 antibody recognizes a similar 
structure. This probably suggests a potential localization of Kv10.2 in cilia and to the primary 





The aim of the present study was to analyze the Kv10.2 protein expression pattern in 
mice, to localize Kv10.2 in different cells of the CNS and to unravel Kv10.2 temporal expression 
during embryogenesis. Due to a lack of commercially available antibodies specific to Kv10.2, we 
generated and evaluated a novel polyclonal antibody directed against Kv10.2. The expression 
pattern of Kv10.2 in mouse tissue detected with the novel anti-Kv10.2 antibody in Western blot 
revealed a virtually ubiquitious Kv10.2 distribution. Studies of Kv10.2 distribution in the mouse 
brain with this antibody by IHC showed an expression of Kv10.2 in specific brain regions and 
indicated localization to neurons. Furthermore, the novel antibody anti-Kv10.2 detected a 
cellular structure similar to a cilium on mouse tissue such as brain, lung and liver. 
5.1 Strategy to generate a novel anti-Kv10.2 antibody  
We successfully generated an anti-Kv10.2 antibody that detected Kv10.2 in Western 
blot and ICC analysis. Since none of the commercially available antibodies were shown to be 
specific for Kv10.2 detection, we applied the best possible strategy to obtain an antibody that 
specifically recognizes Kv10.2. We chose to generate a polyclonal antibody by using a 299 
amino acid (aa) long antigen, which is well in excess of the 12-20 aa needed for a peptide to 
function as an immunogen (Tanaka et al., 1985, Takahashi et al., 2004, Gupta et al., 2007). The 
299 aa long antigen successfully exhibited immunogenicity in rabbits and contained various 
potential epitopes. For antigen synthesis we used prokaryotic expression in E.coli, which is a 
cost and time effective system and a widespread source of immunogens. It has been used for 
expression of either large fragments or full-length proteins (Wojciechowski et al., 2004, 
Lindskog et al., 2005, Nilsson et al., 2005). The optimization of the E.coli protein expression 
necessary to gain sufficient quantities of the antigen for vaccination led to an enrichment of 
the expressed protein in inclusion bodies, which has been reported for other highly expressed 
proteins in E.coli (Kane and Hartley, 1988, Fahnert et al., 2004).  
Polyclonal antibodies are known to be less likely affected by conformational changes of 
epitopes because of the heterogeneity of polyclonal antibodies, which allows them to bind to 
different epitopes (Cooper and Paterson, 2001, Nakazawa et al., 2010). However, as we 




molecular weights, indicating the recognition of different epitopes other than Kv10.2. The 
heterogeneity of the polyclonal anti-Kv10.2 antibody might have increased the sensitivity of 
Kv10.2 detection by recognizing different epitopes of Kv10.2.  
While our strategy resulted in generation of an antibody capable of recognizing a 
protein of the molecular weight of Kv10.2 and of discriminating between Kv10.1 and Kv10.2, all 
commercially available anti-Kv10.2 antibodies that were evaluated showed no specificity for 
Kv10.2. They were either not sensitive enough to recognize a protein of the molecular weight 
of Kv10.2 or they cross reacted with another protein of the same molecular weight, possibly 
Kv10.1. The most plausible cause for their lack of specificity towards Kv10.2 might be the 
selection of the antigen sequence used for immunization, since Kv10.1 and Kv10.2 share an 
extensive homology throughout the entire amino acid sequence. Therefore, we selected a low 
or non-homologous region for the antigen used for immunization. Only two companies, Sigma-
Aldrich and Alomone Labs, provide the peptide sequences that were used as antigens. BLAST 
analysis of these two epitopes, however, did not detect homology with Kv10.1 (data not 
shown). Despite the fact that the amino acid sequences of the antigen did not show homology 
with Kv10.1, they recognized a protein of the same molecular weight as Kv10.1 in lysates of 
Kv10.1 overexpressing cells, but not in the HEK293 Wt sample. Additionally, the Sigma anti-
Kv10.2 antibody was considered “uncertain” by the Human Protein Atlas (Uhlen et al., 2005, 
Uhlen et al., 2010), when used in IHC analysis.  
Therefore, published data obtained with the commercial anti-Kv10.2 antibodies should 
be treated with caution. Some publications exist using the Alomone Labs (Wadhwa et al., 
2009) and Sigma-Aldrich (Huang et al., 2012) antibodies in IHC. Wadhwa and co-workers 
analyzed the Kv10.2 distribution in renal cell carcinoma by IHC, which resulted in the 
observation of aberrant Kv10.2 levels in cancerous tissue. In the context of diseases, Huang and 
colleagues indicated an upregulation of Kv10.2 expression in medullablastomas (Huang et al., 
2012). Jeng and colleagues showed a localization of Kv10.2 in hippocampal neurons, which will 
be discussed later (Jeng et al., 2005). 
5.2 Aspects of antibody evaluation 
The newly generated anti-Kv10.2 antibody recognized Kv10.2 and did not cross react 
with Kv10.1 in Western blot analysis and ICC, which was validated by the use of HEK293 cells 




The evaluation of novel antibodies on overexpressing cell lines is a reasonable 
approach for the investigation of the antibody binding capacity to its antigen. This system has 
already been applied for the evaluation of Eag1.62.mAb, an antibody targeting Kv10.1 
(Hemmerlein et al., 2006). Furthermore, this system allowed us to demonstrate that the novel 
anti-Kv10.2 antibody discriminates between Kv10.2 and Kv10.1. This was important, since 
Kv10.2 and Kv10.1 share a high similarity in their entire amino acid sequence and are therefore 
likely to contain identical epitopes recognizable by antibodies raised against these ion 
channels. Our aim was to analyse Kv10.2 distibution in mouse, therefor the use of a human cell 
system overexpressing the human full-length proteins for antibody evaluation only indicates 
specificity of the antibody to mouse Kv10.2.  
In order to verify the newly generated antibody the indirect ELISA system was used, 
which showed a strong binding to its antigen and a weak cross reactivity with H1X, a Kv10.1 
fusion protein. Despite this low cross reactivity detected by ELISA we further evaluated the 
antibody using the HEK293 system in Western blot and ICC analysis. 
It was not possible to use transgenic Kv10.2 knockout animals to investigate the 
antibody’s specificity because Kv10.2 homozygous total knockout mice are embryonic lethal. 
The transgenic conditional Kv10.2 knockout mouse developed in our department could also not 
be applied since it did not result in genomic deletion of Kcnh5 when crossbred with the Emx1-
Cre-mouse line. By evaluation of the anti-Kv10.2 antibody in tissue samples containing the 
protein (Wt animal) in parallel to tissue where the Kv10.2 is deleted (transgenic knockout 
animal) we would be able to reach the highest certainty about the specificity of the antibody 
as reported for other antibodies (Pereira et al., 1996, Pradidarcheep et al., 2008).  
Blocking experiments are also a useful tool to evaluate the specificity of an antibody. 
However, such experiments were not possible to be performed. The antigen expressed was 
only soluble when buffered in guanidinium hydrochloride (GuHCl), a strong denaturizing agent. 
Since GuHCl is known to inhibit protein activity in low concentrations (West et al., 1997, Ren et 
al., 2009), a preincubation of the antibody with the antigen (antibody blocking) buffered in this 
reagent, prior to immunoassays, would have denatured the antibody. A positive result of the 
blocking experiment, meaning no binding of the antibody is detectable, might be either due to 
a successful blocking of the antibody with its antigen or due to antibody denaturation in the 
presence of GuHCl in the antigen buffer. Therefore, the result would have been ambiguous. 
Evaluation of the antibody specificity by Western blot analysis showed a protein band 




mouse brain, as well as virtually all mouse tissue investigated. Most likely, the antibody reacts 
with Kv10.2. However, it also recognized proteins of different molecular weight, e.g. at 90 kDa 
and at 150 kDa. Since no Kcnh5 transcripts were detected in the HEK293 wt and BBS-Kv10.1 cell 
lines, the proteins of different molecular weight recognized by the anti-Kv10.2 antibody 
indicate either unspecific binding, or could represent splice forms of Kcnh5, which were not 
found by our qRT-PCR analysis. The phenomenon has also been seen for the rabbit polyclonal 
anti-Kv10.1 antibody 9391. Kv10.1 has at least two different splice variants that correspond to 
the 70 and 50 kDa band and were detected by the Kv10.1 antibody (unpublished data). 
Nevertheless, the anti-Kv10.2 antibody proved suitable for our aim of investigating the Kv10.2 
protein distribution, since it did not recognize other proteins at the molecular weight of Kv10.2 
in HEK293 cells, and therefore did not interfere with our analysis. Furthermore, in the mouse 
total brain sample a band at the approximate molecular weight of Kv10.2 was indeed detected, 
indicating its ability to recognize mouse Kv10.2. 
The specificity of the anti-Kv10.2 antibody was demonstrated in ICC studies by the 
intracellular and membrane staining we observed in HEK293 BBS-Kv10.2 cells. This staining 
pattern is consistent with the ICC results of an anti-Kv10.1 antibody in HEK293 BBS-Kv10.1 cells, 
which also showed an intracellular and membrane staining (Kohl et al., 2011). Not all HEK293 
BBS-Kv10.2 cells were Kv10.2 positive due to the properties of the polyclonal stable cell line. In 
contrast, native HEK293 cells and those transfected with BBS-Kv10.1 showed no 
immunoreactivity with the anti-Kv10.2 antibody.  
The Western blot analysis detected proteins of different molecular weight while the 
ICC resulted in immunoreactivity in HEK293 BBS-Kv10.2 only. Therefore, the antibody may be 
considered more specific in ICC procedures than in Western blot analysis. A possible 
explanation for this discrepancy could be the difference between the techniques. Western blot 
analysis is performed with denatured samples, hence more epitopes become accessible to the 
antibody, as reported for other proteins (Garcia-Barreno et al., 2005), while conformation-
dependent epitopes can disappear by denaturation (Morris, 2007). Denatured epitopes did not 
affect the binding of the anti-Kv10.2 antibody to Kv10.2 in Western blotting. In contrast, in ICC 
the proteins retain their native structure and protein complexes are maintained. Furthermore, 




5.3 Distribution of Kv10.2 protein in mouse tissues 
Since expression analysis of Kv10.2 protein has not yet been performed throughout the 
mouse system, this study assessed the distribution of Kcnh5 on the mRNA and protein level in 
order to investigate the region-specific expression. In general, a wide Kv10.2 expression on 
protein level and a more restricted mRNA distribution was observed the organs investigated. 
Furthermore, a possible posttranslational modification was detected in certain brain regions.  
The Kcnh5 mRNA distribution pattern obtained by qRT-PCR with probes from adult 
mouse brain regions is in general accordance with reported data obtained by quantitative ISH 
on mouse brain sections reported in the Allen Brain Atlas (Lein et al., 2007) and by Northern 
blot analysis performed on adult rat brain tissue (Ludwig et al., 2000). The only difference 
occurred in the striatum, where Ludwig and co-workers did not detect transcripts of Kcnh5 in 
rat (Ludwig et al., 2000). In accordance with our results, data of the Allen Brain Atlas also show 
a Kcnh5 expression in the striatum of the mouse. The differences in the results might reflect 
variations between different mRNA detection methods, such as qRT-PCR and ISH.  
It is worth noting, that with the approaches available, we show the antibody’s 
functionality in Western blot and its specificity in ICC. As the most reliable control, i.e. Kv10.2 
knockout tissue, was not available for testing, we can only have a certain degree of confidence 
that the antibody specifically recognizes Kv10.2. The following discussion is based on the 
assumption that the results obtained with the anti-Kv10.2 antibody reflect genuine Kv10.2 
recognition by the anti-Kv10.2 antibody.  
The data we obtained from Western blot analysis of the hypothalamus, thalamus, 
tectum and olfactory bulb using the anti-Kv10.2 antibody differed to the pattern we detected 
with other tissues. In these four samples a diffuse band in the range of 120 – 150 kDa was 
visible. The fact that this diffuse band is larger than the expected molecular weight excludes it 
as a degraded form of Kv10.2. One explanation for this could be unspecific binding of the 
antibody to a protein within this range in these four brain regions. Alternatively, in the case of 
specific binding to Kv10.2, this indicates a possible posttranslational modification of this 
protein in the hypothalamus, thalamus, tectum and olfactory bulb in vivo. In vitro, the human 
Kv10.2 is reported not to be glycosylated (Ju and Wray, 2002). For the homologous Kv10.1 it 
has been shown in vivo that posttranslational modification occurs (Napp et al., 2005). 




glycosylated in vivo. Wether or not Kv10.2 is posttranslationally modified needs to be clarified 
by future experiments.  
While the regional Kv10.2 protein distribution, especially in mouse brain, is in general 
accordance with the Kcnh5 mRNA distribution demonstrated here, inconsistencies were 
observed in some tissues. Examples are the prostate, heart and intestine, where Western blot 
analysis from adult mouse tissues revealed the presence of Kv10.2, whereas only very low or 
no mRNA was detected. The reasons for this divergence are not clear, but such a difference of 
protein and mRNA level has already been shown for Kv10.1. Martin and co-workers 
investigated the protein distribution in rat brain sections (Martin et al., 2008) which did not 
match the patterns obtained by ISH in former publications (Ludwig et al., 2000, Saganich et al., 
2001). One possibility is that the Kv10.1 protein “in vivo half-lives [may be altered] as the result 
of varied protein synthesis and degradation” (Martin et al., 2008), which may apply for Kv10.2. 
The synthesis and degradation of a specific protein might be tissue dependent. Additionally, 
the mRNA in vivo half-life might be differentially regulated within different tissues. A low copy, 
non-degraded mRNA may still lead to protein translation detectable by Western blot analysis. 
Another explanation for the discrepancy of protein and mRNA level might be due to the Kv10.2 
detection methods applied. For our qRT-PCR we applied primers in exon 8 and 9, while our 
anti-Kv10.2 antibody targets the C-terminus, which is encoded by exon 11 in mouse. Although 
the reported alternatively spliced versions of Kv10.2 have a truncated C-terminus (Saganich et 
al., 1999, Ju and Wray, 2002), further isoforms or tissue specific isoforms might exist. For 
Kv10.1, alternatively spliced variants were detected that contain the C-terminus but not the 
pore domain (unpublished data). To resolve the discrepancy of the observed Kcnh5 mRNA and 
protein levels, a future experiment might be to design qRT-PCR primers for the exon 11 of 
mouse, thereby detecting the same exon which encodes the antibody’s epitope. 
The Kv10.2 ubiquitious protein expression in all analyzed tissues of the adult mouse 
does not allow an interpretation of a possible specific physiological function. Since the channel 
is ubiquitously expressed throughout the CNS, it could play a role in many putative processes, 
such as processing of olfaction information (olfactory bulb), emotional information (limbic 
structures), and many functions related to other CNS structures. Furthermore, Kv10.2 protein is 





5.4 Clarifying the regional Kv10.2 expression 
We localized the protein in different nuclei of the brain by IHC, which in general is in 
accordance with known mRNA expression patterns (Ludwig et al., 2000, Saganich et al., 2001). 
Specific immunohistochemical staining was obtained in the olfactory bulb, cortex, amygdala, 
thalamus, zona incerta, globus pallidus, medial genicular nucleus, lateral genicular nucleus, 
cochlear nucleus of the brainstem, within the hippocampus CA3 and CA2 field and the hilus. 
Furthermore, the Purkinje layer and the lateral cerebellar dentate nucleus were stained. ISH 
analysis for Kcnh1 mRNA distribution overlapps with the protein distribution, while a cellular 
detection of Kcnh5 mRNA using ISH failed. 
In the regions analyzed by IHC, different patterns of immunostaining were observed. In 
the cortex, Purkinje layer of the cerebellum, cochlear nucleus of the brainstem, hippocampus 
and the lateral cerebellar dentate nucleus, the staining indicates a localization of Kv10.2 to the 
cell soma. In the mitral cell layer of the olfactory bulb and the hippocampus, the soma of the 
cells, as well as their processes were stained. A neuropil staining was observed in the regions 
of the olfactory bulb, thalamus, globus pallidus and the amygdala. For the olfactory bulb 
(Pinching and Powell, 1971), the globus pallidus (Coulter, 1988) and the thalamus (Peden et al., 
2008) such a neuropil staining has been already reported, while for other regions it has been 
speculated that they contain neuropil elements (Chklovskii et al., 2002).  
Our results of the IHC for Kv10.2 distribution are in general accordance with the 
different ISH performed to date (Ludwig et al., 2000, Saganich et al., 2001). Although the data 
obtained show some incongruences to the two ISH reports, the overlapping results are 
consistent with our results. Differences were found in the cerebellum in the Purkinje layer, 
where we detected a weak staining, while no Kcnh5 mRNA was found by ISH (Ludwig et al., 
2000, Saganich et al., 2001). In the cortical layers, the protein distribution seems to be more 
restricted to the middle layers, which is in accordance with the ISH results by Saganich 
(Saganich et al., 2001). Both ISH approaches (Ludwig et al., 2000, Saganich et al., 2001), did not 
detect protein in the globus pallidus, while we observed an intense staining by IHC. This also 
applies to the Purkinje layer, where we detected a weak Kv10.2 protein expression. In contrast 
to Ludwig and co-workers’ finding, no protein was detected in the dentate gyrus (Ludwig et al., 
2000).   
Possible reasons for the discrepancy in mRNA and protein detection have already been 




While the underlying cause has not been confirmed yet, this might reflect posttranslational or 
–transcriptional mechanisms involved in Kv10.2 regulation.  
To correlate on a cellular level the Kcnh5 mRNA expression with protein distribution 
obtained with our anti-Kv10.2 antibody, we tried to establish ISH for Kcnh5 and Kcnh1 mRNA. 
The ISH probe for Kcnh1, which we successfully established, resulted in a specific staining in 
accordance with the known expression pattern for Kcnh1 in rat on the mRNA (Dr. S. Martin, 
personal communication) and protein level (Martin et al., 2008). However, the application of 
our established protocol for Kcnh1 was not successful for the Kcnh5 probe.  
To deduce a physiological function from the IHC is also not possible. The regions 
detected as Kv10.2 positive are involved in various physiological functions, for example 
processing of emotional information (limbic system), motor behavior (thalamus, globus 
pallidus), cognition (cortex, hippocampus, globus pallidus) and the diverse functions of the 
other regions. 
It is noteworthy that the IHC staining obtained with our anti-Kv10.2 antibody is clearly 
distinguishable from the expression pattern of the Kv10.1 protein, which shows an ubiquitious 
expression in adult rat brain (Martin et al., 2008). This further underlines that our antibody 
does not recognize Kv10.1 in IHC studies.  
One other explanation for the different results we obtained with Western blot analysis 
and the IHC might be that the sample preparation for tissue lysates of the brain regions 
involves a surgical sectioning. Thereby, errors may occur in the sampling of the tissue, 
especially in small brain regions, leading to Kv10.2 positive cells in Kv10.2 negative tissue. 
Furthermore, the IHC only displays a small area of the whole mouse brain, possibly missing 
Kv10.2 positive cells within brain regions. In order to resolve the difference, a future 
experiment may be to perform a serial sectioning of the whole brain with subsequent IHC 
analysis.  
5.5 Neuronal localization of Kv10.2 
Kv10.2 protein preferentially localizes to neurons in the cortex, hippocampus and 
cerebellum of mouse, while a small population of astrocytes in the cerebellum was also 
positive. Kcnh5 mRNA localization to neurons has been previously reported in the mouse 




localization of Kv10.2 in neurons of the adult mouse brain, we used heterozygous TYFF 
(neuron), CXCR (microglia) and GFEA (astrocyte) transgenic mice. These systems do not require 
a double staining of Kv10.2 with specific markers, like GFAP for astrocytes (Sofroniew and 
Vinters, 2010), ßIII-tubulin for neurons (Katsetos et al., 2002) or IbaI for microglias (Ito et al., 
2001). For the cortex, Purkinje layer of the cerebellum and the hippocampus we showed the 
preferenatial localization of Kv10.2 to neurons. In the CA3 region of the hippocampus, Jeng and 
co-workers showed a Kv10.2 localization to neurons as well (Jeng et al., 2005). However, by 
using the Alomone Lab anti-Kv10.2 antibody we did not detect any specificity to Kv10.2 in 
Western blot analysis, which was discussed earlier. In virtually all cells investigated, the results 
obtained suggest a localization of Kv10.2 to the soma of neurons and most likely to the 
membrane of the soma, while stained neural processes were almost invisible. This is in 
accordance with our fluorescence IHC analysis, where Kv10.2 was detected to localize mainly to 
neurons in the Purkinje layer of the cerebellum, hippocampus and cortex. The possible 
membrane localization of Kv10.2 indicates that it may play a role in action potential 
repolarization of the soma. However, future experiments, such as ICC on cultured neurons, are 
necessary to further investigate its subcellular localization in neurons. 
A co-localization of Kv10.2 with endogenously labeled neurons was not evident in all 
cells. The use of transgenic TYFF and GFEA mice has some limitations due to the integration 
site of the construct of the transgenic mice. Hirrlinger and co-workers reported that the 
“transgenes showed a variable percentage of labeled cells not only in different brain regions 
but also among different mouse lines” (Hirrlinger et al., 2005). In our analysis, we did not 
investigate a possible localization to oligodendrocytes, which are important glia cells of the 
CNS. A double staining with an oligodendrocytic marker, such as Olig2 (Yokoo et al., 2004) may 
further support our finding that Kv10.2 is preferentially localized to neurons in the cortex, 
cerebellum ant hippocampus. 
5.6 Loss of function of the Kv10.2 conditional knockout mouse 
In order to address the physiological role of Kv10.2, a conditional Kcnh5 knockout 
mouse was previously generated in our department. The Cre-loxP system, which was applied, 
is a molecular tool for genome modulation by homologous recombination (Nagy, 2000). The 
analysis of the homozygous Kcnh5 conditional knockout mouse cross-bred with homozygous 




or knockdown of Kcnh5 expression in the cortex. Furthermore, no alteration in the genome 
was observed by PCR using primers spanning exon 6 - 8 and the loxP sites. Genotyping of the 5’ 
loxP site was successful (data not shown), indicating that the 3’ loxP site is missing. This 
speculation is according with observations of the International Knockout Mouse Consortium, 
that “the 3’ loxP site is often lost due to recombination events in the homology region 
between the targeting cassette and 3’ loxP site” 
(http://www.knockoutmouse.org/about/targeting-strategies accessed 28.Jan.12 (2007, 
Skarnes et al., 2011)). Therefore, no Kcnh5 conditional knockout was available for further 
analysis of the physiological function of Kv10.2. Moreover, with the Kcnh5 conditional knockout 
mouse (depleted of the Kv10.2 protein) unavailable, the most effective control for our novel 
antibody was missing for Western blot or IHC analysis. 
5.7 Subcellular localization of Kv10.2 
In our chromogenic IHC analysis utilizing the anti-Kv10.2 antibody on brain sections, we 
detected immunoreactivity of a cilia-like structure akin to a cell protrusion detected by type III 
adenylyl cyclase (ACIII) staining on mouse brain sections. Since ACIII is reported to localize to 
the primary cilium in the brain (Bishop et al., 2007), the similarities between the stainings may 
indicate that the anti-Kv10.2 antibody recognizes a structure highly similar to the cilium of 
cells. Furthermore, anti-Kv10.2 antibody detected similar structures on cells in liver and lung 
sections. The structure detected also resembled a staining pattern which we obtained with 
acetylated tubulin-positive cilia staining in the same organs. Acetylated tubulin is widely used 
as a marker for the primary cilium and cilia in general for non-CNS derived tissue (Alieva et al., 
1999).  
Because our antibody seems to recognize a cilia-like structure, it may be possible that 
Kv10.2 is localized in cilia. In this context, Kv10.2 might regulate potassium efflux after Ca
2+ 
influx. However, to really show this localization, it would be necessary to perform a double 
staining with Kv10.2 and a cilia marker such as acetylated tubulin or ACIII.  
5.8 Possible physiological functions of Kv10.2  
Given that no Kv10.2 localization to cortical astrocytes has been found in IHC analysis, 




cultures derived from prefrontal cortex and midbrain, and not in the neuronal cell lines such as 
N2a or Oli neu. The astrocyte cultures derive from PN 0 mice, while we performed Kv10.2 
localization in tissue in adult mouse brain sections. This finding may indicate a certain 
maturation dependent regulation of Kv10.2 expression in astrocytes. A future experiment 
would be to perform laser capture microdissection on PN 0 mouse brain sections and analyze 
the astrocytes for Kv10.2 expression in order to unravel a possible regulation of Kv10.2 during 
maturation. 
None of the other cell lines, 108CC05, 108CC15, Olig2 or N2a, we investigated express 
Kcnh5. While this finding is inconsistent with our IHC observations, where Kv10.2 was 
preferentially localized in neurons, it is possible, that the neuronal cell lines do not mimic 
neurons in vivo since they are either derived from neuroblastoma cells (108CC05, 108CC15 and 
N2a) or need further differentiation (Olig2 and N2a). 
Kv10.2 protein expression is not altered in Kv10.1 deficient mice. The homozygous 
Kcnh1 total knockout mouse displays only a slight hyperactive phenotype and no Kcnh5 mRNA 
upregulation (Ufartes et al., 2013). An increased Kv10.2 protein expression has also not been 
detected. Hence, in the case that Kv10.2 at least partially mimics the physiological function of 
Kv10.1, the endogenous levels of Kv10.2 are enough to compensate for the loss of Kv10.1. 
Another possibility is that Kv10.2 is not involved in rescuing the phenotype of Kv10.1. A 
knockout mouse resulting in no alteration of phenotype has been reported for other ion 
channels (Guo et al., 2005, Nerbonne et al., 2008) and this is possible also for the homozygous 
Kv10.1 total knockout. 
Kv10.2 is expressed during embryogenesis in mice. Besides the Kcnh5 conditional 
knockout, a Kcnh5 total knockout mouse was generated in our department. Data indicate that 
the homozygous Kcnh5 total knockout mouse is embryonically lethal. Interestingly, the 
heterozygous Kcnh5 total knockout does not display an obvious phenotype (data not shown). 
This indicates that expression of Kcnh5 from one Wt allele is enough to rescue the embryonic 
lethality. We demonstrated the continuous expression of Kv10.2 in neuronal development of 
mice during all stages investigated. Furthermore, by IHC analysis, Kv10.2 was detected 
throughout the embryo, partially in the maternal tissue. In the context of the embryonic 
lethality of the homozygous Kcnh5 total knockout, the lack of Kcnh5 expression in maternal 
tissue cannot be the origin of this phenotype, since all embryos, the homozygous Kcnh5 
knockout mice as well as the heterozygous and wt mice would then be affected, which was not 




itself. Further analysis of the temporal and spatial distribution in mouse embryos of earlier 
stages than E 8.5 should be conducted to investigate the stage of embryonic lethality. 
However, the homozygous Kcnh1 total knockout mouse displays only a mild phenotype, while 
the homozygous Kcnh5 knockout causes a severe defect in embryogenesis. It is obvious that a 
lack of Kv10.2 at early embryonic stages is incompatible with life.  
Summary and Conclusion 
121 
 
6 Summary and Conclusions  
Potassium channels are one of the most heterogeneous groups of ion channels that 
are essential for cellular physiology. An alteration of the physiological properties of these 
channels as a cause of genetic mutations or aberrant expression often results in 
channelopathies such as long QT syndrome, congenital hyperinsulinism and seizures. In this 
context, Kv10.1, the first described member of the Kv10 family, has been implicated in cell cycle 
progression and cancer. While Kv10.1 has been extensively studied, the function and 
localization of Kv10.2, a second member of the Kv10 family, has not been well described 
especially due to non-availability of specific tools. One aspect is the lack of specific antibody, 
which is able to discriminate Kv10.2 from Kv10.1 as both proteins share a high amino acid 
homology. In my thesis, we have studied the distribution of Kv10.2 in the mouse tissues and we 
provide the first analyses exploring a possible physiological function of Kv10.2. 
Five commercially available anti-Kv10.2 antibodies tested did not show specificity or 
sensitivity for Kv10.2 in Western blot analysis. Therefore, a novel polyclonal IgG antibody 
directed against the C-terminus of human Kv10.2 was generated. The C-terminus of human 
Kv10.2 shares least homology towards Kv10.1 and this region has a high homology to the 
mouse Kv10.2 protein. By the use of Kv10.2 and Kv10.1 overexpressing HEK293 cells, we 
demonstrated recognition of Kv10.2 in Western blot analysis and immunological staining 
procedures. The generated polyclonal anti-Kv10.2 antibody discriminated Kv10.2 against Kv10.1.  
Kv10.2 protein was found to have a widespread expression pattern in various mouse 
tissues and brain regions using the newly generate antibody in Western blot analysis. This 
finding was supported by overlapping Kcnh5 mRNA distribution in mouse brain regions, while 
tissues were only partially congruous. The analyzed Kv10.2 distribution was clearly distinct 
from reported ubiquitious Kv10.1 protein distribution in the rat brain (Martin et al., 2008), 
further indicating no recognition of Kv10.1 by the anti-Kv10.2 antibody. A preferentially neural 
localization of Kv10.2 in cortex, hippocampus and cerebellum was assessed by IHC performed 
on mouse brain sections of transgenic mice that express yellow fluorescent protein (YFP) 
under the control of neuron-specific Thy1 promoter. No co-localization by IHC was detected in 
mice expressing eGFP under the CX3CR1 promoter (microglia). Furthermore, only a small 
population of cells of the cerebellum was Kv10.2 positive in mice expressing eGFP under the 
control of the GFAP promoter (astrocytes). Moreover, Kv10.2 was detected in the soma of 
neurons in the hippocampus, cortex and cerebellum, while cell processes of the hippocampus 
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and mitral cell layer were also Kv10.2 positive. This indicates an altered subcellular localization 
of Kv10.2 in neurons of different regions of the mouse brain. Additionally, the antibody 
recognized a cilia-like structure on cells of mouse brain, lung and liver tissue in IHC analysis. 
The detected structures were highly similar to cilia that are stained by the established cilia 
markers, adenylyl cyclase III and acetylated tubulin.  
Western blot analysis of Kv10.2 protein levels in the Kv10.1 deficient mice, which shows 
a slightly hyperactive phenotype, suggests no altered Kv10.2 protein levels, which is in line with 
reported mRNA findings. 
An approach to investigate the physiological function of Kv10.2 by a Cre-recombinase 
mediated deletion of Kv10.2 in the homozygous Kcnh5 conditional knockout mouse did not 
result in decreased levels of Kcnh5 mRNA. No genomic alteration of the Kcnh5 gene locus was 
observed, indicating a lack of the required LoxP sites for gene recombination. Therefore, the 
Kcnh5 conditional knockout mouse was not available for further studies or antibody 
evaluation. In contrast to the homozygous Kcnh1 conventional knockout mouse, preliminary 
data of the homozygous Kcnh5 total knockout indicates embryonic lethality, while the 
heterozygous Kcnh5 total knockout mouse did not show any obvious phenotype. The temporal 
expression of Kv10.2 protein in the developing mouse head was detected from embryonic day 
8, the earliest investigated developmental stage, until postnatal stages and in the adult mouse. 
The spatial distribution of Kv10.2 protein showed ubiquitous expression throughout the mouse 
embryo and the placenta.  
In conclusion, we generated a sensitive polyclonal anti-Kv10.2 antibody, which 
discriminates Kv10.2 towards Kv10.1. In future, our generated anti-Kv10.2 antibody might be 
used for investigation of an involvement of Kv10.2 in human diseases. While the Kv10.2 protein 
is widely expressed throughout the adult mouse, further investigation about the onset of the 
expression of this ion channel during embryogenesis has to be conducted. Moreover, the 







7.1 Nomenclature of the members of the Eag family 
Table 1: Overview of the current and previous nomenclature of the Eag family after IUPHAR (Gutman 
et al., 2005) 
Potassium 
channel name 




related), member 1 
Kv10.1a; Kv10.1b; KCNH1a; ether-a-go-go; Kv10.1; 
eag; h-eag; Kv10.1; r-eag; EAG channel 1; ether-a-go-
go potassium channel 1; potassium voltage-gated 
channel subfamily H member 1; voltage-gated 





related), member 5 
Kv10.2; KCNH5; ether-a-go-go potassium channel 2; 
potassium voltage-gated channel subfamily H member 





related), member 2 
ether-à-go-go-related gene; HERG; erg1; hergb; LQT2; 
Kv11.1; ERG-1; RERG; eag-related protein 1; ether-a-
go-go-related gene potassium channel 1; ether-a-go-
go-related protein 1; potassium voltage-gated channel 
subfamily H member 2; r-ERG; voltage-gated 
potassium channel subunit Kv11.1; merg1a; M-erg; 




related), member 6 
erg2; KCNH6; Kv11.2; HERG2; ERG-2; Eag-related gene 
member 2; eag-related protein 2; ether-a-go-go-
related gene potassium channel 2; ether-a-go-go-
related protein 2; potassium voltage-gated channel 








related), member 7 
erg3; KCNH7; Kv11.3; HERG3; ERG-3; eag-related 
protein 3; ether-a-go-go-related gene potassium 
channel 3; ether-a-go-go-related protein 3; potassium 
voltage-gated channel subfamily H member 7; voltage-





related), member 8 
elk1; elk3; Kv12.1; Ets-1; ELK channel 3; ELK1, member 
of ETS oncogene family; ether-a-go-go-like potassium 
channel 1; ether-a-go-go-like potassium channel 3; 
potassium voltage-gated channel subfamily H member 
8; potassium voltage-gated channel, subfamily H, 
member 8; potassium voltage-gated channel, 




related), member 3 
BEC1; Elk2; Kv12.2; BEC1 protein; ELK channel 2; brain-
specific eag-like channel 1; ether-a-go-go-like 
potassium channel 2; potassium voltage-gated 
channel subfamily H member 3; rElk2; voltage-gated 
potassium channel subunit Kv12.2; Melk2; ether a go-




related), member 4 
BEC2; Elk1; Kv12.3; ELK channel 1; brain-specific eag-
like channel 2; ether-a-go-go-like potassium channel 1; 
potassium voltage-gated channel subfamily H member 
4; rElk1; voltage-gated potassium channel subunit 
Kv12.3 
7.2 Anti-Kv10.2 antibody detects Kv10.2 in Western blot analysis 
 Figure 36 illustrates Western blot image processing based on Figure 13.  Images of 
Western blots were obtained in the Chemi-Doc luminescence detection system with no 
illumination for acquisition of Western blot (Figure36, chemiluminescent acquisition) and epi-
white illumination for acquisition of the protein standard (Figure36, epi-white acquisition). For 




with drawn bars to indicate the migration distance of the molecular weight standard in all 
Western blots presented in the results section.  
As already discussed, the anti-Kv10.2 antibody detects a protein of predicted molecular 
weight of BBS-Kv10.2 (=116 kDa) only in the HEK293 BBS-Kv10.2 cell lysate. At this particular 
molecular weight, no signal was obtained in lysates of HEK293 Wt and HEK293 BBS-Kv10.1 
cells. In the total mouse brain sample, a band at the predicted weight of Kv10.2 (=112 kDa) was 
observed. Further proteins at different molecular weight, i.e. at approximately 50 and 70 kDa 























Figure 36: Representation of Western blot image processing based on Figure 13  
Western blot analyses performed with anti-Kv10.2 antibody were acquired in the Chemi-Doc 
luminescence detection system with no illumination for acquisition of Western blot and epi-white 
illumination for acquisition of the protein standard. For better illustration, protein standard was 
removed from the images obtained and replaced with drawn bars to indicate the migration distance of 
the molecular weight standard. Anti-Kv10.2 antibody detected a protein of the predicted molecular 
weight of BBS-Kv10.2 (=116 kDa) in the lysate of HEK293 BBS-Kv10.2 cells. In total mouse brain lysate, a 
protein of the predicted molecular weight of Kv10.2 (=112 kDa) was recognized. At this molecular 
weight, no protein was detected in lysates of HEK293 Wt and HEK293 BBS-Kv10.1 cells. In all samples, 
bands of proteins of different molecular weight were observed, i.e. approximately at 50 kDa and 70 kDa. 
7.3 In Situ hybridization probes are specific in dot blot assay 
To examine the specificity of the in vitro synthesized digoxigenin labeled ribonucleic 
ISH probes, we performed a dot blot assay. For this we amplified the target sequences of both 




a calbindin amplification product that did not have any homology towards either Kcnh1 or 
Kcnh5, these amplification products were blotted on a membrane and incubated with our ISH 
probes. We observed a strong signal at 51°C of the Kcnh1 probe on both Kcnh1 target 
sequences with decreasing signal intensity in lower target concentrations (Figure 37A). 
Although the probe also recognized the highest three Kcnh5 dilutions in this dot blot assay we 
concluded that this was depending on the annealing temperature of the probe. The Kcnh5 
probe specifically bound to the Kcnh5 target sequences at 55°C, while a very weak signal on 
the Kcnh1 target sequence was observed (Figure 37B). The calbindin sequence was not 
recognized by either probe.  
We concluded that our Kcnh1 and Kcnh5 antisense probes specifically bind to their 



















Figure 37: Specificity of Kcnh1 and Kcnh5 ISH RNA riboprobes determined by dot blot assay 
A: Dot blot assay with Kcnh1 antisense RNA probe performed at 51°C. The probe hybridized to Kcnh1 
target sequences with decreasing signal intensity in higher dilutions (dil). Analogous Kcnh5 sequences, 
to verify cross reactivity, were weakly detected. Calbindin sequence serving as a negative control was 
not recognized by the Kcnh1 probe. B: Dot blot assay with Kcnh5 antisense RNA probe performed at 
55°C. The probe detected only Kcnh5 target sequences with decreasing signal intensity at higher 
dilutions (dil). Calbindin sequence serving as a negative control was not recognized by the Kcnh1 probe.  
7.4 Hippocampus and cerebellum negative controls of IHC on TYFF and CXCR mouse 
brain sections 
As shown in Figure 38:, controls performed without primary anti-Kv10.2 antibody 
resulted in no specific staining observed in the hippocampus  (Figure 38A-C) and cerebellum 




Alexa-633 conjugated secondary anti-rabbit antibody. The same control was performed on 
sections of the hippocampus (Figure 39A-C) and cerebellum (Figure 38D-F) of CXCR animals  
which contain endougenous eGFP labeled microglia. In both controls no staining with 
secondary anti-rabbit Alexa-633 antibody was observed (Figure 39A,C,D,F). 
 
A anti-Rb-Alexa 633 B TYFF C Merge
D anti-Rb-Alexa 633 E TYFF F Merge
 
 
Figure 38: IHC negative controls of heterozygous transgenic TYFF mouse hippocampus and cerebellum 
A-C: Hippocampus: (A) Negative control with Alexa-633 conjugated secondary anti-rabbit antibody on 
(B) eYFP expressing neurons resulted in (C) no specific staining. D-F: Cerebellum: (D) Negative control 
with Alexa-633 conjugated secondary anti-rabbit antibody on (E) eYFP expressing neurons resulted in (F) 




A anti-Rb-Alexa 633 B CXCR C Merge
D anti-Rb-Alexa 633 E CXCR F Merge
 
 
Figure 39: IHC negative control of heterozygous transgenic CXCR mouse hippocampus and cerebellum  
A-C: Hippocampus: (A) Negative control with secondary Alexa-633 conjugated anti-rabbit antibody on 
(B) eGFP expressing microglia resulted in no specific staining (C). D-F: Cerebellum: (D) Negative control 
with secondary Alexa-633 conjugated anti-rabbit antibody on (E) eGFP expressing microglia resulted in 
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